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ABSTRACT 
 
Exploring Key Orientations of Small Molecules to Disrupt Protein-protein Interactions. 
(May 2012) 
Eunhwa Ko, B.S., Chungnam National University, the Republic of Korea; 
 M.S., Seoul National University, the Republic of Korea 
Chair of Advisory Committee: Dr. Kevin Burgess 
 
 
Protein-protein interactions (PPIs) are attractive targets because of their 
therapeutic potential.  One approach to design small molecules that can disrupt the PPIs 
is to use structural information of proteins.  With this approach, triazole-based 
peptidomimetics that mimic β-turn hot-spot regions in neurotrophins were synthesized.  
The monovalent mimics were assembled into bivalent mimics via a combinatorial 
method.  Three different bivalent mimics were prepared for different studies.  Bivalent 
mimics with long-linkers bound to TrkA or TrkC receptor and showed partial 
antagonism for the receptors.  Other mimics were conjugated with cytotoxic compounds 
and they were used for TrkC targeted drug delivery.  The last group of bivalent mimics 
previously showed targeted delivery effects for pancreatic cancer cells.  In this study, we 
synthesized Eu-chelated bivalent mimics to perform a competitive binding assay for 
pancreatic cancer cells.  
Previous research in our group focused on design of secondary structures’ 
mimics on rigid scaffolds as “minimalist mimics”.  We sought to establish structural 
design criteria for the minimalist mimics, and we wanted to propose that sets of such 
compounds could mimic local pairs of amino acids in any secondary structures as 
“universal peptidomimetics”.  Thus, we designed five compounds, such as oxazoline-, 
pyrrole-, dyine- “kinked” and “linear” bistrizole-based peptidomimetics, and performed 
molecular modelings, DFT calculations, and QMD for them to validate our hypothesis.   
 iv 
On the concepts of “minimalist mimics” and “universal peptidomimetics”, we 
developed the Cα – Cβ vector matching program to evaluate preferred orientations of 
Cα - Cβ coordinates for secondary structures.  We applied the program to omegatides 
and pyrrolinone-pyrrolidine oligomers.  The compounds matched better with strands 
than for helices.   
We expanded the Cα – Cβ vector matching idea to a method that ranks preferred 
conformations of small molecules on any combination of three interface side-chains in 
all structurally characterized PPIs.  We developed a PDB mining program (explores key 
orientation, EKO) to do this, and EKO applied to pyrrolinone-pyrrolidine oligomers to 
find targets.  EKO found several interesting targets, such as AICAR Tfase, GAPDH, and 
HIV-1 protease.  HIV-1 dimerization inhibition and Zhang-Poorman kinetic assays were 
performed to validate our hypothesis, and the results showed that pyrrolinone-
pyrrolidine derivatives inhibited HIV-1 dimerization. 
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 1 
CHAPTER I 
INTRODUCTION* 
1.1 Design of Small Molecules to Resemble Protein Fragments 
Proteins and peptides play crucial roles in biology, so they are studied as targets 
in medicine.1,2  However, there are several limitations to using them as therapeutic 
agents, including vulnerability to proteolysis and poor cell permeation.  To overcome 
these problems, chemists have developed molecules that can mimic of peptides with less 
of these limitations.  These “peptidomimetics”3 have at least some peptidic parts 
substituted with non-peptide structures.   
Peptide analogs can have unnatural fragments that mimic peptidic main-chains, 
side-chains or both.  To mimic only main-chains in peptides, a peptide backbone can be 
replaced by an ester or thioester (blue circle in Figure 1.1).  However, these compounds 
are uninteresting because they do not have the side-chains that are involved in 
intermolecular interactions.  These structures only form limited H-bonding interaction on 
the backbones.  
 
 
 
 
 
 
____________ 
This dissertation follows the style of the Journal of American Chemical Society. 
*Reprinted in part with permission from “Minimalist and universal peptidomimetics”, 
Eunhwa Ko, Jing Liu and Kevin Burgess, Chem. Soc. Rev., 2011, 40, 4411-4421. 
Copyright 2011 Royal Society of Chemistry.   
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Figure 1.1.  Relationships between peptides and peptidomimetics. 
 
 
Peptide analogs can have unnatural fragments that mimic peptidic main-chains, 
side-chains or both.  To mimic only main-chains in peptides, a peptide backbone can be 
replaced by an ester or thioester (blue circle in Figure 1.1).  However, these compounds 
are uninteresting because they do not have the side-chains that are involved in 
intermolecular interactions.  These structures only form limited H-bonding interaction on 
the backbones.  
Peptidomimetics that mimic both peptidic main-chains and side-chains are more 
common (purple circle in Figure 1.1).  The general strategy is to replace the amide bonds 
with isosteric groups to decrease the limitations described above (Figure 1.2a).  This 
class of compounds is useful in the design of protease inhibitors, but they are 
conformationally flexible, and this decreases their binding selectivities and affinities.4  
One method to overcome this problem is to constrain peptide segments.  Arora’s group 
applied a main-chain hydrogen bond surrogate (HBS) strategy to design helical 
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secondary structure mimics as illustrated in Figure 1.2b.  The HBS α-helix mimics have 
peptide backbones constrained via ring-closing metathesis to give fragments that 
resemble an N-terminal intramolecular hydrogen bond between the peptide i and i + 4 
residues.5  Aube’s group designed β-turn mimics that are formed by dipeptides 
constrained by substituted Aca (6-aminocaproic acid) linkers (Figure 1.2b).6  In this 
case, the non-peptidic part is used to lock the overall conformation of the molecule.  
However, potential applications of these types of compounds as drugs are limited 
because their large size and high polarities mean that they do not tend to permeate into 
cells, hence they are inappropriate for intracellular targets. For this reason, the third type 
of peptidomimetic is intriguing: compounds that mimic only side-chains in analogs (red 
circle in Figure 1.1) and do not contain {polar} amide functionalities.  In our group, we 
refer to such compounds as minimalist mimics. 
 
 
a 
 
Figure 1.2  (a) Examples of peptide isosteres.  (b) Examples of mimics both peptide 
main-chains and amino acids side-chains. 
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Figure 1.2  continued 
 
 
Most minimalist peptidomimetics do not have polyamide backbones, but they 
mimic peptides because of their side-chain compositions and orientations.  This 
approach is legitimate because statistical analyses of structurally characterized protein-
protein interfaces show side-chain substituents account for about 80 % of the 
interactions and main-chain interactions contribute about 11 %.7  According to this 
paradigm, many groups have designed analogs of peptide secondary structures that 
present selected side-chains.  In this case, the peptide backbones are replaced with rigid 
scaffolds.  
Figure 1.3 illustrates some examples of minimalist peptidomimetics.  Hamilton’s 
group has generated many elegant designs of helical mimicry by using terphenyl 
scaffolds to present side-chains in appropriate orientations.8-11  Ahn’s group also has 
designed α-helical mimics based on a bis-benzamide that incorporates four side-
chains.12,13  In β-turn mimicry, Hirschmann and Smith’s group reported a series of 
minimalist β-turn mimics where sugar,14,15 steroid16 or catechol17 backbones were used 
to hold relevant side-chains.  In addition, Arora’s group prepared 
triazolamers as functional β-strand mimetics.18 
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Figure 1.3.  Examples of minimalist mimics. 
 
 
1.2 Methods to Identify Small Molecules that Perturb Predetermined PPIs 
It is important to develop small molecules that can disrupt PPIs for the 
development of pharmacological probes and therapeutics.7  The most common 
approaches to do this are high-throughput screening (HTS), fragment-based drug 
discovery, and computer-aided drug discovery.19  
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1.2.1 High-throughput Screening (HTS) 
Since the late 1980s, HTS has been the most widely used approach to find lead 
molecules for therapeutic applications.19  An example of drug discovered via HTS is 
“maraviroc”, an antiretroviral that acts as a chemokine receptor antagonist and is used in 
the treatment of HIV infection (Figure 1.4).  UK-107,543 was identified as the most 
promising hit after HTS of the Pfizer file collection, and then maraviroc was selected 
from 1,000 analogs via lead optimization processes which included binding potency, 
antiviral activity, absorption, pharmacokinetics and selectivity against human targets.20  
 
 
 
Figure 1.4.  Discovery of maraviroc via high-throughput screening.   
 
 
There are many successful examples of lead compound discovery via HTS.20  
However, HTS has several limitations.  First, the success of HTS has not been uniformly 
distributed among different drug target classes.  HTS has been highly successful for 
traditional targets such as G-protein coupled receptors, ion channels, and enzymes, but 
much less effective for PPI targets.  One of the potential reasons that PPI targets has 
poor hit rates in HTS is perhaps the compounds were designed for traditional targets.  If 
a library is not chemically suitable for the target, HTS will fail to find a hit.  A 
hypothesis of this thesis is that the wealthy structural information about PPIs could be 
used to find more developed probes and therapeutics that the ones are currently 
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emerging from HTS.   
 
1.2.2 Fragment-based Drug Discovery 
In fragment-based drug discovery, small molecular fragments (less than MW 
~200 – 300 Da) are screened for binding against a target.  Fragments that bind to a 
protein are either elaborated or linked to generate hits with higher affinities (Figure 
1.5a).21  Small fragments tend to be synthetically accessible and more water soluble than 
larger organic molecules,22 and less compounds are screened than in classical HTS, so 
the approach tends to be more facile. An example of fragments-based methods leading to 
a hit compound is the one from Hannah’s group for the immunology target inosine 
monophosphate dehydrogenase (IMPDH, Figure 1.5b).23-25  
A problem with HTS that is accentuated in fragment-based approaches based on 
binding is that it tends to be necessary to screen high concentrations of compounds to 
find weak binders.  High concentrations are impractical for many compounds because of 
solubility and quantity considerations.  Moreover, high concentrations often result in 
false positives.22 
 
 
a 
 
Figure 1.5.  Fragment-based lead discovery: (a) basic approach21; and, (b) an example 
applied to an immunology target, inosine monophosphate dehydrogenase. 
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Figure 1.5.  continued. 
 
 
A subset of fragment-based methods is Wells’ “tethering” approach that largely 
overcomes the high concentration issue.  This strategy uses the reversible covalent bond 
formed between a disulfide-linked fragment and a cysteine residue near the binding site 
in a target protein as illustrated in Figure 1.6.22  Thiol-disulfide exchange amplifies the 
affinity of the fragment for the target protein, and it enables use of low concentrations.  
Mutagenesis allows cysteines to be incorporated at specific locations for added control 
over regions where fragments bind the protein. 
 
 
 
Figure 1.6.  Tethering for fragment assembly.22  
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            However, it is impossible exactly to predict the binding affinities of fragments 
for targets.  Other fragment-based approaches to overcome this limitation are to use 
structural methods, NMR spectroscopy26 or X-ray crystallography27.  NMR 
scpectroscopy uses NMR chemical shifts after a ligand binds to a protein, and X-ray 
crystallographic method monitors changes of the electron density map of a complex 
relative to the unbound form.   
 
1.2.3 Computer-aided Drug Discovery 
Computer-aided drug discovery involves simulation of drug-target interactions 
using tools for bioinformatics and databases to filter undesired molecules from libraries, 
even before synthesis,28 reducing expenditure on resources and time.  There are two 
main paradigms in computer-aided methods: structure- and ligand-based approaches. 
Structure-based approaches use target protein structures and docking algorithms 
to place computer-generated representations of a small molecule;29 this method has been 
particularly successful for enzyme active sites (Figure 1.7a).30  The word “pose” 
describes each docking mode.  Poses are evaluated (“scored”) based on the ability of the 
small molecule to complement the target physicochemical properties (e.g. shape and 
electrostatics).  This process is repeated for all molecules in the library, and the results 
are rank-ordered by scores to select compounds for further investigation (Figure 1.7b).29   
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b 
 
Figure 1.7.  (a) Identification of binding sites on a target protein30; and, (b) docking and 
scoring.  R = a receptor protein, A, B, and C = small molecules to be docked in the 
receptor.29  
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Computer-aided drug design relies on high-resolution protein structure and good 
justification for focusing on certain narrowly defined regions where the small molecules 
can bind.19  PPI interfaces between proteins are relatively extensive and there can be 
many thermodynamically preferred sites for binding a small molecule, including ones 
that are not at the interface.  Consequently, even if the thermodynamically significant 
interface regions (hot-spots) for binding the other protein are known (and in most cases 
they are not), then it is perfectly possible that a small molecule would bind at another 
site on the proteins, if it binds at all.  For these reasons computer-aided drug design is 
not ideal for finding small molecules that perturb protein-protein interactions. 
Ligand-based methods use known ligands as templates to discover new binding 
molecules.19,31  Figure 1.830 indicates how known active ligands are classified according 
to their physicochemical properties (molecular weight, logP, polar surface area, H-bond 
donor and acceptor counts); parameters such as 2D (scaffold, substructure, fingerprints) 
or 3D (pharmacophore) descriptors are stored in a database, and then screening is 
performed via quantitative structure-activity relationship (QSAR) analyses, machine 
learning (Bayesian classification, support vector machines) or pharmacophore searches.  
New potential ligands are then conceived and screen in silico to identify ones that match 
the physicochemical properties of the reference compounds.32  Obviously, this approach 
requires good known ligands;33 it cannot be applied to de novo discovery of unexplored 
PPIs. 
 
 
 12 
 
Figure 1.8.  Ligand-based computational methods for drug discovery.30  
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1.3     Conclusion 
PPIs are important targets because of their roles in cell signaling and their 
therapeutic potential.  There is abundant, detailed structural information about interfaces 
between proteins, but state-of-the-art methods for finding small molecules that impact 
PPIs cannot use this very effectively.  Many of those methods consider only general 
trends in the structural information, e.g. prevalence and “druggability” of helical 
regions.5  Concepts like “minimalist peptidomimetics” are interesting, but at the onset of 
our studies there was no way to relate them accurately to specific structural data; crude 
overlay procedures onto known ligands marks an intellectual boundary in this work.  
Moreover, both types of computer-aided drug discovery methods, structure- and ligand-
based, are not well suited to PPIs.  Experimental fragment-based procedures that feature 
NMR or X-ray use structural information about pre-selected targets, but fragment-based 
methods based on binding assays do not.  Consequently, there is much structural data 
available that cannot be used in fragment-based methods.  For example, there are severe 
restrictions on NMR methods to be used with huge proteins, and X-ray approaches 
cannot be used if crystals of a protein are not amenable to, or available for, soaking 
experiments.  Conventional HTS is probably the crudest approach; it does not make use 
of structural information at all. 
My Ph D research began by focusing on very specific protein-protein interactions 
(neurotrophin-Trk), then gradually turned towards closer consideration the salient 
features of minimalist mimics.  Finally, this led us to focus on the question with the 
broadest impact in this field, specifically, are there better ways to use protein-protein 
interaction structural data to identify small molecule pharmacological probes and 
pharmaceutical leads.  
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CHAPTER II 
DESIGN OF TRIAZOLE-BASED MIMICS TO TARGET                  
Trk RECEPTORS 
2.1 Introduction 
Neurotrophins are a family of growth factors that play key roles in the 
development and maintenance of the peripheral and central nervous systems (PNS and 
CNS).34,35  The family includes nerve growth factor (NGF), brain-derived neurotrophinc 
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4).  These proteins bind 
to the tropomyosin-receptor-kinase (Trk) receptors, (TrkA, TrkB, and TrkC) and the 
pan-neurotrophin receptor p75 with different binding affinities.  The high affinity 
binding interactions are for NGF with TrkA, BDNF and NT-4 with TrkB, and NT-3 with 
TrkC; somewhat lower affinity, non-selective, binding is observed for all ligands with 
p75 (Figure 1a).36,37  Binding of neurotrophins to Trk receptors leads to activation of 
tyrosine kinases, receptor dimerization, phosphorylation, and downstream signaling 
{phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen activated protein kinase (MAPK), 
and phospholipase C-γ1 (PLCγ) pathways}.  Neurotrophins signaling through Trk 
receptors regulates cell survival, proliferation, growth, regulation of channel functions, 
and assembly of cytoskeleta (Figure 1b).34,37   
The p75 receptor is a member of the tumor necrosis factor (TNF) receptor 
superfamily.  Its functions are less clearly understood than they are for Trk receptors.  
Binding of neurotrophins to p75 receptor can lead to apoptosis or survival depending on 
the cells used and the stage that they are at their life cycles (Figure 1b).34   
Activation of Trk and p75 receptors can lead to opposite effects on cells, e.g. 
growth/differentiation and apoptosis,35 thus a major barrier to using neurotrophins as 
drugs is the fact that they can activate both receptors.  On the other hand, small 
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molecules that only bind and activate Trk receptors could be extremely useful as drugs 
and pharmacological probes. 
 
 
a 
 
b 
 
Figure 2.1.  (a) Affinities of neurotrophins for Trk and p75 receptors.  (b) Neurotrophin 
receptors signaling. 
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Neurotrophins and Trk receptors are validated targets to treat a variety of 
pathologies ranging from neurodegenerative diseases to cancers.35,38-40  In most cells, 
activation of Trk receptors by neurotrophins results in survival and neurite outgrowth 
responses.37  NGF supports dorsal root ganglion (DRG) neurons during development and 
small fiber nocieptors in the adult.  NT-3 promotes survival of adult proprioceptive DRG 
neurons and cholinergic neurons, and BDNF supports large fiber DRG neurons and 
cholinergic neurons.41  These critical roles of neurotrophins during development and in 
the adult nervous system mean that agonists for Trk receptors might be useful for the 
treatment for neurodegenerative diseases and stroke.  For example, gambogic amide 
(Figure 2.2a) selectively binds to TrkA, induces receptor dimerization, tyrosine 
phosphorylation, and Akt and MAPK signaling and it is therefore a potentially useful 
probe.42  This compound acts as a TrkA agonist and prevents neuronal apoptosis 
initiated by kainic acid (KA; a compound that induces neuronal cell death in caspase-
dependent and caspase-independent pathways).   
On the other hand, Trk receptors are activated in a broad range of cancers, where 
they modulate tumor growth and motility.39  Antagonists for Trk receptors might provide 
effective treatments for cancers.  For instance, K252a in Figure 2.2b is an alkaloid 
isolated from Nacardiopisis sp. Siol fungi.  It blocks neuronal differentiation of rat 
pheochromocytoma PC12 cells induced by NGF.  Moreover, it is a potent inhibitor of 
the tyrosine protein kinase activity of the NGF receptor, gp 140trk that is the product of 
the trk protooncogene.43 
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a                                                                          b 
 
Figure 2.2.  (a) Gambogic amide, a selective agonist for TrkA.  (b) K252a, a selective 
inhibitor for Trk receptors. 
 
 
Neurotrophins are noncovalent homodimers of ca 120 amino acid protein units. 
Each monomer has three solvent-exposed β-turn regions35 that seem to be “hot-spots” 
for interaction between neurotrophins and Trk receptors.36  Table 2.1 is a summary of 
the hot-spot residues in β-turn regions of neurotrophins.  In small molecules that mimic 
neurotrophins, selectivities for TrkA, B and C might be achieved by amino acid side-
chains in β-turn regions of each neurotrophins.  
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Table 2.1.  Summary of “Hot-spot” Residues in Neurotrophins. 
proteins source β-turn sequence 
     
  30-33 44-47 93-96 
NGF murine DIKG INNS DEKQ 
 human DIKG INNS DGKQ 
 bovine DIKG INNS DNKQ 
 guinea pig DIKG VNNN DGKQ 
  30-33 44-47 93-96 
BDNF pig DMSG VSKG DSKK 
 human DMSG VSKG DSKK 
  29-32 42-45 92-95 
NT-3 mouse DIRG KTGN ENNK 
 human DIRG KTGN ENNK 
a i+1-i+2 sequences that are highlited with red were chosen for syntheses in this study. 
 
 
Our group has designed and synthesized small molecules that can mimic the β-
turn hot-spots.44-49  The first generation structures are cyclic peptidomimetics, such as 
D3.44-46  This compound was designed to mimic i+1 and i+2 of the β-turn in NGF 
through “ring fused C10-motif” as Figure 2.3a and b.45  D3 is a partial agonist for TrkA; 
the compound induced cell survival, neurite outgrowth, and tyrosine phosphorylation in 
vitro assays.50  In addition, the small molecule caused recovery of loss of memory 
function in an in vivo an “aged rat model”.51   
 
 
 
 19 
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Figure 2.3.  β-Turn cyclic peptidomimetics with ring-fused C10 motif. 
 
 
Second generation structures developed by our group are small molecules, 
“minimalist mimics”, that express only side-chains of the β-turn part and have no 
molecular fragments to resemble the main-chain.52  For the structure in Figure 2.4a, a 
heterocyclic scaffold is used instead of peptide backbone.  The scaffold gives rigidity to 
limit the degrees of freedom for bond rotations but, ideally, without excluding 
conformations that correspond the targeted secondary structures.  The first minimalist 
mimics in our group were built on triazole-based scaffolds (Figure 2.4b).47  The triazole 
core was obtained by click chemistry between azido amino acids and alkyes having side-
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chains of amino acids (Figure 2.4c).  The triazole-based β-turn mimics have piperazine 
linkers to build bivalent peptidomimetics that are obtained by SNAr reactions on triazines.  
Combinatorial methods shown in Figure 2.4d were used to combine two different 
monovalent units to give bivalent mimics (hetero- or homo-).  This combinatorial 
method has several advantages.  First, combination of n monovalent compounds gives 
n(n+1)/2 bivalent compounds; a lot of bivalent mimcs can be made from relatively few 
monovalent ones.  Second, the products can be formed without using any protecting 
group on monovalent components.  Third, the third site in triazine core can be used to 
support tags for biological assays, e.g. dyes, biotin, and, as described in the next chapter, 
cytotoxic compounds.  Before I began this effort, Dr Yu Angell, a preceeding student in 
our group, had prepared 78 bivalent peptidomimetics with fluorescein tags and had them 
tested for selective binding to Trk receptors (in fluorescence-activated cell sourting, 
FACS, assays).  Four of the peptidomimetics she made (Figure 2.4e) showed preferential 
binding to TrkA-expressing cells.  
 
 
a 
 
Figure 2.4.  (a) Design of minimalist peptidomimetics with triazole scaffolds.  (b) 
Overlay of triazole-based mimic with type I β-turn.  (c) Strategy to build triazole-based 
β-turn mimics.  (d) A general scheme to prepare bivalent mimics.  (e) Structures of 
compounds that bind to TrkA. 
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Figure 2.4.  continued. 
 
N N
NR
1
O
R2
1
2 3
4 5 6
5.4 Å
i + 1 i + 2
triazole-based
β-turn mimic
overlay
with type l β-turn
N
NN
R1 R2
O
N
triazole-based
β−turn mimic
3
4 5 6
i + 2i + 1
1 2
5.4 Å
N3R1 N
O
+
R2
NP
NP
N N
N
tag
ClN
N
unprotected
monomer 1
N N
N
tag
ClCl
N NBoc
(i) 50% TFA/CH2Cl2
25 oC, 4 h
(ii) K2CO3, THF, 25 oC
8 h
protected
monomer 1
 22 
 
 
 
Figure 2.4.  continued. 
 
 
The results described above proved that the triazole-based compounds can bind 
TrkA expressing cells just as NFG does, but their activities in cellular assays was weak.  
My role was to discover related compounds to improve binding to Trk receptors and the 
activities of these compounds in cellular assays.  In particular, we were interested to use 
long-linkers between triazole core and triazine core in bivalent mimics to provide more 
distance variation for separation of the monovalent units on binding.  Distances between 
hot-spots in neurotrophins are from 10 Å to 43 Å (Figure 2.5a).  Consequently, we 
reasoned that if each monovalent mimic were connected to flexible chains of about 15 Å 
length, the total separation would be about 41 Å maximum, and the warhead regions 
could orient like any pair of turns in NGF (Figure 2.5b).  This strategy might especially 
increase the chances for mimicry of β-turns that are far from each other.  
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Figure 2.5.  (a) Distances between hot-spots in NT-3.  (b) Structures of triazole-based β-
turn mimics with long linkers, and lengths of triazine core and linker.  (c) Strategy to 
build bivalent mimics with different orientation sequences in triazole core. 
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Figure 2.5.  continued. 
 
 
Another new line of investigation for my studies was to use side-chains on the 
peptidomimetics that correspond exactly to the i+1 and i+2 residues in the neurotrophins 
turn regions (Table 2.1, red highlight).  Dr Yu Angell had not done this thoroughly; the 
residues that she used tended to be selected because they were commonly found at hot-
spot interactions in general.  Thus, in my work, seven dipeptide sequences were targeted; 
IK, EK, and GK from NGF, MS and SK from BDNF, and IR and TG from NT-3. 
A third aspect that our group had not previously considered carefully the 
orientation of the side-chains in the mimics as illustrated in Figure 2.5c.  Monovalent 
mimics with the long linkers, 1 were prepared in two different orientations (“forward 
sequence”; R1R2 and R3R4 = i+1-i+2, e.g. TG, “opposite” sequence; R1R2 and R3R4 = 
i+2-i+1, e.g. GT), and bivalent mimics by combination of the monovalent mimics were 
prepared in three different sets (forward only; R1R2 and R3R4 = i+1-i+2 and i+1-i+2, e.g. 
TG-TG, opposite only; R1R2 and R3R4 = i+2-i+1 and i+2-i+1, e.g. GT-GT, and forward-
opposite; R1R2 and R3R4 = i+1-i+2 and i+2-i+1, e.g. TG-GT) as Figure 2.5c. 
 
2.2 Syntheses of Triazole-based Monovalent Mimics with Long Linker 
The triazole-based peptidomimetics have amino acid side-chains corresponding 
to i+1-i+2 of β-turn regions in neurotrophins.  Alkynes with the amino acid side-chains 
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were prepared as Scheme 2.1a.  Alkynes 2 corresponding to Glu, Gly, and Ser are 
commercial available, and those corresponding to Met, Ile, and Thr were obtained by 
SN2 reaction (Scheme 2.1.a).53-55  Azido amino acids 3 for Arg, Gly, Lys, and Ser were 
prepared via azo-transfer reactions (Scheme 2.1.b).56  To prepare a long alkyl chain 
linker, Boc-piperazine was connected to bromoundeconoic acid through amide coupling, 
and then the primary amine 6 was prepared via Gabriel synthesis.57  Azido amino acid 3 
was connected to the linker through amide coupling, and then triazole core 8 was 
obtained with the azide 7 and alkyne 2 via Cu(I)-mediated Click reaction.58 
 
 
Scheme 2.1.  Preparation of Monovalent Mimics with Long Linkers.   
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Scheme 2.1.  continued. 
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Scheme 2.1.  continued. 
 
 
 
Characteristics of the seven triazole-base monovalent mimics 8 with orientation 
of R1R2 = i+1-i+2 were summarized in Table 2.2.  Seven monovalent mimics with 
corresponding but opposite orientations (R1R2 = i+2-i+1) were prepared by Dr Andrey 
Malakhov. 
 
 
Table 2.2.  Monovalent Peptidomimetics 8a - f. 
 
 
compounds  R1’ R2’ yield (%) 
    
8a 
 
H 61 
8b   60 
8c   83 
8d   86 
R1
Cu powder, 1N CuSO4
THF/H2O (5:1)
25 oC, 24 - 48 h
N
H
N
NBoc
O
5
N
O
R2
NN
R1
8, 60-86%
2
R1R2 = IK, EK, GK, MS, SK, IR, TG
             KI, KE, KG, SM, KS, RI, GT
NBoc
NN
H
N
OO
R2
NN
R1
8
OH
S OH
CO2H NHBoc
NHBoc
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Table 2.2.  continued. 
compounds  R1’ R2’ yield (%) 
8e   65 
8f 
  
81 
8g 
  
60 
 
 
2.3 Syntheses of Bivalent Mimics 
A library of 120 bivalent compounds 1 with TEG and six bivalent compounds 
with biotin were prepared from 14 monovalent compounds and morpholine using a 
similar procedure to the triazole-based bivalent mimics prepared by Dr Yu Angell 
(Scheme 2.2).47  The monovalent mimics 8 were deprotected with TFA, and then the 
deprotected compounds were added to solution of equimolar amounts of cyanuric 
chloride with TEG or biotin tag and excess K2CO3 in THF.  The reactions were 
monitored by analytical HPLC.  After the reactions were done, THF was removed, and 
then the second deprotected monovalent mimic was added to the intermediates 9 in 
DMSO, and excess K2CO3.  The solution was stirred at 25 or 50 °C for more than 10 d to 
get the bivalent mimics 1.  After monitoring the reaction in HPLC, the crude compounds 
were lyophilized to remove DMSO, and then purified with RP-preparative HPLC to 
obtain the final bivalent mimics.  Purities of 77 bivalent mimics 1, seven bivalent 
mimics with morpholine cap like 10 and 11, and seven deprotected monovalent mimics 
(NH2) were summarized in Figure 2.6.  Full detail of analyses materials is given in 
Appendix B. 
 
 
 
OH NHBoc
NHBoc
N
H
NBoc
NHBoc
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Scheme 2.2.  Preparation of The Tagged Bivalent Peptidomimetics 1. 
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a. 
8aa 88              
8b 97 100             
8c 98 91 90            
8d 93 100 89 100       UV  
8e 98 95 99 98 98      purities (%)  
8f 100 93 94 98 94 98      90 and above  
8g 100 99 99 87 98 100 100    Below 90  
capb 91 100 98 95 91 100 95      
NH2c 94 100 99 99 97 90 96        
 8a 8b 8c 8d 8e 8f 8g        
 
b. 
8aa 100              
8b 100 100             
8c 100 95 99            
8d 100 100 90 100       SEDEX  
8e 100 100 100 95 99      purities (%)  
8f 100 100 100 99 99 100     90 and above  
8g 100 100 98 96 100 100 100      
capb 96 100 100 100 100 97 100      
NH2c 100 100 100 100 99 100 100        
 8a 8b 8c 8d 8e 8f 8g        
 
Figure 2.6.  Purities of the library of compounds 1.  (a) UV detection; and (b) SEDEX 
detection after purification for a natural orientation library.  (c) SEDEX detection after 
purification for a mix orientation library. a Deprotected forms of 8, b Cap=morpholine, c 
Deprotected monovalent mimics’ purities. 
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c. 
8a 100 100 100 100 100 100 100        
8b 100 96 100 100 100 100 100        
8c 87 100 100 99 100 100 99    SEDEX  
8d 100 100 100 100 100 100 100    purities (%)  
8e 100 99 100 97 100 100 100    90 and above  
8f 100 100 100 100 100 100 100    Below 90  
8g 100 100 100 100 100 100 100      
 8a 8b 8c 8d 8e 8f 8g        
 
Figure 2.6.  continued. 
 
 
2.4 Biological Assays 
Biological assays were conducted by Dr Uri Saragovi and his coworkers at 
McGill University in Canada.  Cell survival assays,59 and signal transduction assays60 
were carried out for the TEG-labeled bivalent mimics and deprotected monovalent 
mimics.  A direct binding assay61 was carried out for biotin-labeled bivalent mimics.  
For the assays, NIH-3T3 cells were transfected with each Trk receptor; NIH-TrkC cells 
express ~100,000 TkrC receptors/cell, NIH-TrkA cells express ~200,000 TrkA 
receptors/cell, and NIH-IGF-1R cells express ~100,000 IGF-1R receptors/cell.  Parental 
NIH-3T3 cells are mouse fibroblasts that do not express any neurotrophin receptors.  
Neuronal PC12 cells express TrkA and p75 neurotrophin receptors and respond to NGF, 
and nnr5-TrkC cells are variant of PC12 that lack TrkA and into which human TrkC 
cDNA was stably transfected and respond to NT-3.  The 4-3.6 cells are B104 rat 
neuroblastoma stably transfected with human TrkA cDNA and express equal levels of 
p75 and TrkA.62   
 
 
 32 
2.4.1 Cell Survival Assays 
A library of 120 bivalent compounds including morpholine cap control 
compounds and 14 deprotected monovalent compounds were tested for cell survival to 
transfected Trk receptor cells.  The cell survival was measured quantitatively by the 
MTT assay in 96-well plates.  The peptidomimetics were tested at non-cytotoxic doses 
for their effect on NGF or NT-3 mediated survival.  From the screening, six compounds 
1ef, 1gf, 1f’e’, 1a’c, 1g’a, and 1b’d in Figure 2.7 reduce the survival of NIH-TrkC cells 
responding to NT-3 (Figure 2.8a).  Two of them 1ef, and 1gf block the survival of TrkA 
induced by NGF, as well (Figure 2.8b).  In control tests, none of the compounds showed 
any significant survival effect for NIH-IGF-1R cells.  Similar results were observed in 
p75 co-expressing cells, nnr5TrkC cells, and PC 12 cells (Figure 2.8c).  p75 co-
expression does not interface in the antagonism of survival by the compounds.   
 
 
 
Figure 2.7.  Structures of antagonists for TrkC or TrkA.  Prime on labels indicated the 
opposite sequences (i+2-i+1) of sequences in Table 2.2. 
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Figure 2.7.  continued. 
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Figure 2.7.  continued. 
 
 
a 
 
Figure 2.8.  Selective antagonism of cell survival (a) NIH-3T3 cells expressing TrkC 
were cultured in SFM supplemented with the indicated peptidomimetic (10 µM) with 
suboptimal (0.2 nM) or optimal (4 nM) concentrations of NT-3; and, (b) NIH-3T3 cells 
expressing TrkA were cultured in SFM supplemented with the indicated peptidomimetic 
(10 µM) with suboptimal (0.2 nM) or optimal (10 nM) concentrations of NGF; and, (c) 
neuronal nnr5-TrkC cells expressing TrkC and p75 and 4-3.6 cells expressing TrkA and 
p75 were cultured in SFM supplemented with the indicated peptidomimetic (10 µM) 
with suboptimal (0.2 nM) concentrations of NGF or optimal (4 nM) concentrations of 
NT-3.   
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b 
 
c 
 
Figure 2.8.  continued.  
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2.4.2 Signal Transduction Assays 
The six active compounds 1ef, 1gf, 1f’e’, 1a’c, 1g’a, and 1b’d from survival 
assay were tested in signal transduction assays to confirm the antagonistic effects for 
TrkA or TrkC.  The tyrosine phosphorylation of the receptors, phosphorylations of Akt, 
and MAPK were studied in Western blots of cell lysates prepared after stimulation of 
cells with the appropriate growth factor with or without compounds (Figure 2.9).  In 
NIH-TrkC cells, NT-3 induces strongly TrkC-pTyr, and the phosphorylation of Akt and 
MAPK.  1ef, 1gf, 1f’e’, 1a’c, 1g’a, and 1b’d decrease these signals in both NIH-TrkC 
cells, and nnr5TrkC cells.  Compounds 1ef, and 1gf also reduced NGF signals in TrkA-
pTyr.  None of the compounds affected the activating signals of IGF-1. 
The biochemical data indicate that the peptidomimetics can inhibit NT-3 or 
NGF-dependent activation, tyrosine phosphorylation of TrkC or TrkA, and downstream 
signals of the receptors.   
 
 
 
Figure 2.9.  Inhibition of TrkC and TrkA receptor phosphorylation and signaling 
pathways.  NIH-TrkC cells were exposed to the indicated peptidomimetics (10 µM) and 
NT-3 (0.2 nM) for 20 min.  Detergent lysates were analyzed by Western blotting with 
anti-pTyr mAb 4G10 or anti-phospho-MAPK or anti-phospho-Akt.  After stripping, 
membrane was reprobed with anti-actin to standardize loading.  Blots were quantified by 
densitometry. 
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2.4.3 Binding Assays with Biotin-labeled Mimics 
For binding assays, 1ef, 1gf, 1f’e’, 1a’c, 1g’a, and 1b’d were tagged with biotin 
instead of TEG.  FACS binding assays indicated that the six compounds bind 
preferentially to the TrkC receptor.  Compounds 1ef and 1gf were shown to be 
antagonist for TrkA and C in the cell survival assays described above; however, in the 
FACS binding data shown in Figure 2.10 does not show that these compounds bind to 
the TrkC expressing cells with much more affinity than other compounds 1f’e’, 1a’c, 
1g’a, and 1b’d.  
 
 
 
Figure 2.10.  FACS binding of selected biotinylated peptidomimetics.  Cell expressing 
the indicted receptors were first bound at 4 oC with the test ligand (20 µM), followed by 
fluorescein-avidin.  After washing, cells were analyzed by FACScan/CellQuest.  The 
background MCFs of NIH-IGF-1R were substracted to analyze the specific MCF 
binding to test cells.   
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2.5 Conclusion 
In previous work, triazole-based β-turn bivalent mimics showed that four 
compounds selectively bind to TrkA.  To improve the binding affinity and selectivity, 
we attached long alkyl chain linkers between triazole core and triazine core, focused the 
side-chains on i+1 and i+2 sequences in β-turn regions of neurotrophins, and gave a 
variation at the sequence orientation.   
The 120 bivalent peptidomimetics were synthesized, and tested for 
overexpressed TrkA, TrkC, and IGF-1R cells.  1f’e’, 1a’c, 1g’a, and 1b’d showed a 
selective antagonism for TrkC.  1ef, and 1gf act as antagonists for both TrkA and TrkC.  
These compounds bind to the receptors, TrkA or TrkC, but not IGF-1R.  The biology 
data showed the compounds are competitive antagonists for NGF or NT-3.  That is, the 
compounds block the binding of natural ligand to the receptors.  The fact that the 
compounds do not reduce the receptor-mediated activities without NGF or NT-3, and 
they do not affect neuritogenic differentiation, mean the compounds act as partial 
antagonists for the receptors, and the antagonisms are limited to ligand-depentant cell 
survival.   
In previous miminalist mimics, four bivalent mimics selectively bind to TrkA.  
However, in the new library, four compounds 1f’e’, 1a’c, 1g’a, and 1b’d selectively 
bind to TrkC, and two compounds 1ef, and 1gf bind to both TrkC and TrkA.  We 
hypothesized that amino acid side-chains corresponding to β-turn in neurotrophins might 
give selectivity of the compounds for Trk receptors.  Comparison between sequences of 
active compounds and neurotrophins were summarized in Table 2.3.  1gf that binds to 
both TrkA and TrkC has dipeptide sequences corresponding to NGF and NT-3 turn 
regions, but 1ef has a dipeptide that corresponds to turns in NT-3 but does not have ones 
found in the NGF.  1a’c and 1g’a that selectively bind to TrkC have sequences 
corresponding to NT-3, but 1f’e and 1b’d that also bind to TrkC selectively have 
sequences for in turns of NGF and BDNF.  Consequently it is hard to explain the 
selectivities of these compounds.  However, one observation may be relevant for this; 
Table 2.3 shows bivalent mimics with N-to-C orientations that correspond to i+1-i+2 in 
 39 
NGF and NT-3 bind to TrkA and TrkC, but bivalent mimics with the opposite, C- to N-, 
allignment selectively bind to TrkC. 
 
 
Table 2.3.  Comparison between Sequences of Antagonists and Neurotrophins.a 
compound 1ef 1gf 1f’e’ 1a’c 1g’a 1b’d 
 TrkA and C antagonists TrkC antagonists 
       
R1R2-R3R4 SK-IK IR-IK KI-KS GT-EK RI-TG SM-GK 
a Red color in sequences corresponds to sequences in NGF, pink corresponds to 
BDNF, and blue corresponds to NT-3.  
 
 
Overall, these results show that the changes of linker length, sequences, and 
sequences orientation in small molecules can give changes of binding selectivity for Trk 
receptors.  In the next project, we want to develop application of the compounds into the 
selective binding for target cells.  
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CHAPTER III 
TRIAZOLE-BASED MIMICS WITH CYTOTOXIC COMPOUND 
AS TUMOR TARGETING LIGANDS 
3.1 Introduction 
All the FDA-approved drugs for chemotherapy for neuroblastoma, pancreatic 
cancer, and non-small cell lung carcinoma are poisons (Figure 3.1).  These cytotoxic 
drugs have therapeutic indices that favor cancer cell death over destruction of healthy 
tissue, but, nevertheless, they are very toxic substances.  It is alarming that development 
of small molecule chemotherapies has never broken out of this particular paradigm.   
Existing “smart”, targeted cytotoxic agents mostly feature antibodies directed to 
cell surface receptors.63,64  Such protein-based targeting agents are expensive to produce 
on-scale, and are vulnerable to proteolytic degradation in vivo.  Consequently, it is 
highly desirable to substitute antibodies with conveniently accessible small molecules.  
Like antibody conjugates, these agents could be injected.  Many small molecules that 
bind cell-surface receptors can be imported into cells as the activated receptor 
internalizes, perhaps more easily than antibodies can.  Finally, unlike large proteins, 
most small molecules are not degraded by proteases and are not immunogenic. 
Despite the attributes of organic targeting agents, there are relatively few for 
over-expressed tumor cell surface receptors; this limits design and innovation.  A reason 
for this situation is that there is no approach to facilitate discovery and production of 
small molecule non-peptidic targeting probes that parallels the convenience and 
reproducibility of antibody production in animals. 
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Figure 3.1.  Examples of FAD-approved drugs for pancreatic cancer, lung cancer, and 
neuroblastoma.   
 
 
Our group designed triazole-based bivalent mimics that target the TrkC 
receptor.48   Compounds KB1341-1349 in Figure 3.2 selectively bind overexpressed 
TrkC cells; some showed partial agonist effects for TrkC, and others induced neurogenic 
differentiation.  TrkC receptors are overexpressed in cancers such as prostate, 
medulloblastoma, neuroblastoma, malignant melanoma, and pancreatic cancer.39  Thus, 
we thought KB1341-1349 and related materials could deliver cytotoxic compounds or 
imaging probes to cancers expressing the TrkC receptor. 
KB1341-1349 (corresponding to these resideus, R1R2-R3R4: IY-LW, IY-LW, IY-
IY) were conjugated with cytotoxic agents (specifically, 6-mercaptopurine and a 
rosamine) via click reactions, then their relative cell-killing effects were tested for both 
NIH-3T3 cells stably transfected with the TrkC receptor (TrkC+ cells), and the 
corresponding wild-type (TrkC- cells or WT).  These experiments were designed to test 
for selective delivery to TrkC+ cells but not to TrkC-  
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Figure 3.2.  Bivalent mimics designed to selectively target the TrkC receptor.   
 
 
6-Mercaptopurine (6-MP; Figure 3.3) has been used as an anti-cancer drug to 
treat leukemia, pediatric non-Hodgkin’s lymphoma, and inflammatory bowel disease.65-
67  It inhibits purine nucleotide synthesis and metabolism.  In our work, N-9 of the 
compound was alkylated to enable it to be connected (via an ethylene glycol linker, in 
fact), and to add azide functionality for the click reaction.   
Our group reported rosamine analogs that have anti-proliferatic activity against 
leukemia and solid tumors.68  One of these (Figure 3.3) showed an IC50 of 0.09 µM for 
the promyelocytic leukemia cell line, HL-60.  This compound is very cytotoxic, water 
soluble, and it can be used for cell imaging.  To do this, we changed the iodine group to 
azide facilitating click reactions. 
The monovalent mimics (scaffolds with two amino acid side chains) used to 
make 4 were synthesized by Dr Dianjun Chen in our laboratory.48  Rosamine azide 6 
were prepared by Dr Liangxing Wu69, and Anyanee Kamkaew, and BODIPY azide 8 
was prepared by Anyanee Kamkaew.  TrkC overexpressed NIH-3T3 cells were kindly 
provided by Dr David Kaplan at University of Toronto in Canada, and wild-type NIH-
3T3 cells provided by Dr Jean-Philippe Pellois at Texas A&M University.  
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Figure 3.3.  6-Mercaptopurine (6-MP) and rosamine analog (Ros).   
 
 
3.2       Syntheses and Biological Data of Bivalent Mimics with 6-Mercaptopurine 
The 6-MP containing bivalent mimics 5 were “clicked” with an alkyne-modified 
TEG tag as previously described by our group.47  Protection of the thiocarbonyl group of 
6-MP with bromodiphenylmethane was used to obtain compound 1.70  2-[2-(2-
Chloroethyoxy)-ethoxy]ethanol was added, then modified to an azide via tosylation then 
treatment with sodium azide (Scheme 3.1a).    Click functionalization using CuSO4 and 
sodium ascorbate at 25 oC did not give the desired product 5.  Consequently, we 
increased the reaction temperature to 50 oC, and, in a separate experiment, added 
catalytic TBTA at 25 °C; both these sets of conditions worked well.  Purification of the 
crude products from these reactions was achieved via RP-preparative HPLC.  
Deprotection of diphenylmethyl group from thione was performed with 50% 
TFA/CH2Cl2 and 3 equimolar phenol at 25 oC, and then the mixture was purified with 
RP-preparative HPLC.  The final products 5 were lyophilized three times in 1.0 % acetic 
acid to remove TFA.  Table 3.1 shows a summary of side-chain structures of bivalent 
mimics with 6-mercaptopurine. 
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Scheme 3.1.  Preparation of Bivalent Mimics containing 6-Mercaptopurine 5.   
a 
 
 
 
 
b 
 
 
 
 
 
N
N
H
N
H
N
S Br
Ph
Ph
K2CO3
DMF, 25 oC, 4 h
N
N NH
N
S
Ph
Ph Cl
O O OH
K2CO3
DMF, 25 to 80 oC, 28 h
1, 67 %
N
N N
N
S
Ph
Ph
O OH
(i) TsCl, DMAP, TEA
CH2Cl2, 0 to 25 oC, 14h
(ii) NaN3, MeCN
reflux, 25 h
2
N
N N
N
S
Ph
Ph
O N3
2
2, 82 % 3, 81 %
N N
N
HN
N
O
N
NN
O
R2
N
N
NN NN
R4
H2N
R1 R3
NH2
O O O
(i)  3
CuSO4, Na ascorbate
TBTA, DMSO:H2O (5:1)
25 oC, 24 h
(ii) 50 % TFA/CH2Cl2
Phenol, 25 oC, 16 h
4
R1R2-R3R4 : IY-IY, IY-IW, IY-LW, 2mol
N N
N NN
HN
NN
O
N N
O ONN NN
R2 R4
N N
N
O N N
HN
N
3 2
S
R3
NH2H2N
R1
5
R1R2-R3R4 : IY-IY, IY-IW, IY-LW, 2mor
 45 
Table 3.1.  Side-chain Structures of Bivalent Mimics with 6-Mercaptopurine 5. 
com’ds sequence R1 R2 R3 R4 
      
a IY-IY 
    
b IY-IW 
    
c IY-LW 
    
d 2mor 
  
 
 
Four bivalent mimics with 6-MP (5a-d) and four with TEG tags (4a-d) were 
tested to investigate targeted cytotoxicity.  TEG labelled compounds 4a-d were used as 
controls lacking the toxic part, 6-MP, and “morpholine capped” agents 5d and 4d were 
used to control for peptide parts.  An antiproliferative assay was used to test 5a-d on 
TrkC+ cells (TrkC) and TrkC- cells (WT; Figure 3.4a).  It emerged that 5a is more 
cytotoxic in TrkC+ cells than TrkC- cells.  Further evidence for targeted delivery of 5a 
was obtained via comparisons with the control compounds mentioned above (Figure 
3.4b); these controls did not show meaningful cytotoxicities for TrkC cells or WT cells.  
Water solubility issues prevented determination of IC50 values for 5a, 5b and 5d (for 
instance, at concentrations >140 µM 5a precipitated in the medium).  
It is known that the cytotoxicity of 6-MP is reduced when it is alkylated in the N9 
position, as in 5a-d.65,71  For TrkC+ cells, we determined 6-MP was has a cytotoxicity of 
10 - 20 µM, but derivatives with an alkyl group to connect the ligands had cytotoxicities 
that were much less; thus 5a-d had cytotoxicities that are significantly less  than parent 
6-MP; this was the main reason we decided to use another cytotoxic compound, the 
rosamine mentioned above.  
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Figure 3.4.  (a) Antiproliferative assay comparison for the compound with 
mercaptopurine 5a (IY-IY-6MP) in MTT assays featuring TrkC-overexpressed NIH-3T3 
cells (TrkC) and wild-type NIH-3T3 cells (WT).  (b) Antiproliferative assay comparison 
for 5a (IY-IY-6MP), 5d (2mor-6MP), and 4a (IY-IY-TEG) in MTT assays using TrkC 
and WT.   
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3.3       Syntheses and Biological Data of Bivalent Mimics with Rosamine, and 
BODIPY 
Previous work from these labs led to fluorescent, water-soluble rosamine 
derivatives with high cytotoxicities.68  Thus, we used one of these rosamines in place of 
6-MP to give fluorescent, water-soluble analogs.  Conjugations were performed for the 
rosamine 6 with 4 (Scheme 3.2a; conditions as for 5a - d), and for BODIPY to 4a to 
obtain 9a.  That non-cytotoxic BODIPY was used for intracellular imaging; its solubility 
in the desired “click-solvent”, 5:1 DMSO:H2O, was low so only DMSO was used. 
 
 
Scheme 3.2.  Preparation of Rosamine Bivalent Mimics 7a - d and The BODIPY One 
9a.  
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Scheme 3.2.  continued. 
b 
 
 
 
 
 
Biological assays and cell imaging experiments for this work were conducted by 
Anyanee Kamkaew in our labs.  All the series 7a - d were tested in an antiproliferative 
assay on TrkC+ cells (TrkC) and TrkC- cells (WT).  Figure 3.5 shows only the data for 
7a on the two key cell types, but Table 3.2 shows a summary of IC50 values for all 
compounds 7a - d.  The best result came from compound 7a; (IC50 15.80 µM for TkrC+ 
cells, and 27.58 µM for TrkC- cells).  Overall the rosamine labeled compounds 7a - c 
were shown to be more cytotoxic for TrkC+ cells than for TrkC- cells, although only 
small IC50 differences were observed for 7b and 7c on the two different cells.  
Significantly, the morpholine control compound 7d did not show any cytotoxicity 
difference for two cells.  
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Figure 3.5.  Antiproliferative assay comparison for the compound with mercaptopurine 
7a (IY-IY-Ros) in MTT assays featuring TrkC+ cells (TrkC) and TrkC- cells (WT).   
 
 
Table 3.2.  IC50 Values Summary of Rosamine-labelled Compounds 7a-d for TrkC+ 
Cells and TrkC- Cells. 
com’d sequence IC50 (µM) for TrkC+ cells 
IC50 (µM) 
for TrkC- cells 
    
7a IY-IY 15.80 ± 0.18 27.58 ± 1.38 
7b IY-IW 13.62 ± 1.09 19.00 ± 0.25 
7c IY-LW 14.08 ± 1.07 17.84 ± 0.94 
7d 2mor 14.11 ± 0.71 14.99 ± 0.34 
 
 
To prove that the rosamine-labeled compound binds to the TrkC receptor, we 
tried to do competitive cytotoxicity test with NT-3 (known natural ligand for TrkC 
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receptor), and IY-IY-TEG 4a (a partial agonist for TrkC receptor)48.  This assay used 3.5 
nM of NT-3, and 20 µM of 4a; the concentrations are sub-optimal doses that are 
obtained from cell-survival assays (data not shown).  In TrkC cells, cytotoxicities by 7a 
were reduced under existence of NT-3 and 4a (Figure 3.6a).  However, the ligands did 
not affect cytotoxicities by 7a in WT cells (Figure 3.6b).  That is, 7a competed with NT-
3 and 4a in TrkC cell, but not in WT cells.   
 
 
a 
 
Figure 3.6.  (a) Competitive cytotoxicity of 7a (IY-IY-Ros), 7a with NT-3 (IY-IY-
Ros+NT-3), and 7a with 4a (IY-IY-Ros+IY-IY-TEG) in TrkC cells; and, (b) in WT 
cells.   
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Figure 3.6.  continued.   
 
 
Next, we took fluorescence from rosamine or BODIPY to investigate if the 
compounds with dyes are internalized into the cells and if so, where the compounds are 
located.  Previous work reported rosamine anolog itself is localized in the 
mitochondria.68  However, rosamine-labeled compounds 7a - c were localized in the 
lysosome, but not the mitochondria (Figure 3.7a).  We confirmed this result with 
BODIPY-labeled compound 9a, because co-localization of rosamine-labeled compounds 
with Lyso-Tracker gave weak signals (Figure 3.7a and 3.7b).  On the other hand, 
“morpholine cap” compound 7d, a negative control without any peptide, accumulated in 
the mitochondria like rosamine analog alone.  The results correspond to Bartheld’s 
report about subcellular pathways of NT-3 that is a known ligand for TrkC.72  Bartheld’s 
group examed subcellular pathways and accumulation of internalized radiolabeled 
neurotrophins in retinal ganglion cells (RGCs).  They reported two possible pathways of 
internalized NT-3; lysosome pathway and Golgi pathway.  In the lysosome pathway, 
NT-3 that bound to TrkC is degraded in the lysosomes.  Moreover, a research for 
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labelling densities (LD) in organelles of RGCs after intraocular injection of NT-3 in 
chick embryos showed LD in lysosomes (LD 7.73) was much higher than other 
organelles, and LD in mitochondria (LD 0.06) was very low compared to other 
organells.  Our cell imaging data, in light of Bartherld’s observation, allow us to 
conclude that our compounds 7a - c follow the pathway of NT-3.   
 
 
a 
 
 
b 
 
Figure 3.7.  (a) Fluorescence of compound 7a and Lyso-Tracker in TrkC cells; (b) 
compound 9a and Lyso-Tracker; and, (c) compound 7d and Mito-Tracker.   
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c 
 
Figure 3.7.  continued   
 
 
3.4 Conclusion 
It is important to develop accessable small molecules that selectively target 
cancer cells, because this would allow the small molecule to deliver anti-cancer drugs to 
the cancer effectively and decrease damage to healthy cells.  With information about a 
type of cancer, such as expressed receptors or structure, targeting molecules can be 
designed.  Previously, our group developed triazole-based bivalent peptidomimetics that 
mimic β-turn hot-spots of NT-3, and selectively bind to the TrkC receptor which is 
overexpressed at various cancers such as medulloblastoma, and neuroblastoma.  To 
confirm the TrkC targeted delivery by the compounds, we synthesized 5a - d, 7a - d, and 
9d conjugated with cytotoxic compounds, 6-mercaptopurine (6-MP), and rosamine 
analog (Ros), and tested the antiproliferative assay for TrkC overexpressed NIH-3T3 
cells, and wild-type NIH-3T3 cells.  Overall data showed the bivalent peptidomimetics 
with cytotoxic compounds were more cytotoxic for TrkC cells than for WT cells.  In 
addition, a competitive assay with NT-3 and IY-IY-TEG proved the bivalent 
peptidomimetics competed with the known ligands for TrkC.  These results show that 
the triazole-based bivalent mimics deliver anti-cancer drugs to a target cancer cell 
selectively.  We developed the targeting compound for TrkC overexpressed cells in 
 54 
vitro, and, in next study, the compounds will be tested for targeting neuroblastoma 
which has overexpressed TrkC receptors in an in vivo assay.   
In this study, we used information that some cancer cells have overexpressed 
TrkC receptors, to develop a targeting compound.  However, rapidly proliferating cancer 
cells express many surface receptors that are not usually found on the surface of healthy 
cells.  The functions and structures of most of these receptors are unknown.  The next 
chapter describes the identification of small molecule ligands for unknown targeting 
cancer cells.   
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CHAPTER IV 
TRIAZOLE-BASED BIVALENT MIMICS THAT TARGET 
PANCREATIC CANCER, PREPARED WITH LUMINESCENT 
EUROPIUM(III) CHELATES TO QUANTITATE BINDING 
4.1 Introduction 
Cancer cells express a complicated set of cell surface receptors, and even the 
corresponding healthy cells have largely uncharacterized surface complexions.  Thus, we 
regard each cell, healthy or tumor, as a living combinatorial library of receptors that may 
be targeted for small molecules.   
Triazole-based bivalent mimics like Figure 4.1a are pairs of “monovalent” 
secondary structure units each expressing two side-chains, as described in Chapter 2.  In 
a previous study from our group, 15 homodimeric and 135 heterodimeric bivalent 
mimics were prepared for “The Luciferase Assay” (Figure 4.1b).73  Liposomes bearing 
the compounds were expected to target undetermined cell surface features in tumor cells.  
Each compound had a hydrocarbon tail to allow them to be anchored into liposomes 
with an entrapped luciferase reporter-gene-cargo, simply by mixing and incubation 
overnight; this was done in a one-per-well format.  Incubation of the functionalized 
liposomes with cells resulted in a background rate of delivery of the luciferase gene, and 
bioluminescence (on lysis and treatment with appropriate reagents).  If the bivalent 
ligand expressed on the surface of the liposome targets a cell surface receptor, then more 
cargo is delivered and bioluminescence is enhanced.  
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a 
 
 
b 
 
Figure 4.1.  (a) Triazole-based bivalent mimics prepared for the luciferase assay.  (b) 
The luciferase assay for identifying small molecules on liposomes that target tumor cells.   
 
 
Tumor cells cultured on their own behave differently to ones “sub-cultured” in 
healthy cells (human umbilival vein endothelial cells, HUVEC) where the cell’s 
receptors adapt to facilitate angiogenesis.  Consequently, in this work, homogeneous 
tumor cells and those in subculture were screened to target both the tumors and the 
vasculature.  Figure 4.2 shows that KB1005 targeted homogeneous PANC-1 cells, 
whereas KB1023 was shown to bind a subculture containing the pancreatic tumor cells 
PANC-1, and KB1061 targeted human H1299 non-small-cell lung carcinoma in 
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subculture.  Neither KB1023 nor KB1061 targeted homogeneous PANC-1 or H1299 
cells.   
 
 
a 
 
b 
 
c 
 
Figure 4.2.  (a) KB1023 targets PANC-1 subculture cells, but not PANC-1 alone.  (b) 
KB1061 targets H1299 subculture cells, but not H1299 alone.  (c) KB1005 targets only 
PANC-1 cells.   
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This chapter describes how a derivative of KB1005 was prepared to enable a 
homogeneous time resolved fluorescence (HTRF) assay to be used to determine a 
binding constant of the compound interacting with PANC-1 cells.  Lanthanide-based 
assays are superior to ones based on radioactive isotopes, and normal fluorescent labels 
because the lanthanide lifetimes are longer than lifetimes of the background fluorescence 
from reagents or specimens (0.2 - 1.5 msec compared to ps - µs).  Long lifetimes 
facilitate delayed measurements of emission signals at intervals when background 
fluorescence has completely decayed.  Additionally, the large Stokes shifts of lanthanide 
complexes facilitate greater sensitivities, and their sharp emission peaks allow tight 
limits to be set on the excitation filters.  For these reasons lanthanide-based fluorescent 
methods can have much higher sensitivities than those based on other dyes.74,75   
Many groups have reported comparisons between traditional and lanthanide 
assays for ligand-receptor interactions.76-79  For instance, Gillies compared a 125I binding 
assay and the dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) for 
binding of NDP-α-MSH to the human melanocortin-4 receptor (hMC4R).77  They 
synthesized Eu-DTPA-NDP-α-MSH (Figure 4.3) and compared its binding with that for 
the compound with 125I-NDP-α-MSH, and NDP-α-MSH for hMC4R; the two 
competitive binding assays showed similar IC50 values (13 nM vs 23 nM), but the 
lanthanide assay showed higher sensitivity.  
 
 
 
Figure 4.3.  Eu-DTPA-NDP-α-MSH.   
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We followed Gillies’ approach to establish HTRF for KB1005 modified with a 
Eu-chelate (Eu-PCTA, 1; Figure 4.4).  Simple TEG-labeled compounds were used for 
binding competition experiments.  Four compounds, similar to KB1005 but with 
different side-chains, were synthesiged as controls to confirm the targeting for pancreatic 
cancer (in fact, they target other cancer cell types). 
 
 
 
Figure 4.4.  Bivalent mimics 1 with Eu(III)-chelate (Eu-PCTA) or TEG tag.   
 
 
4.2 Syntheses of Bivalent Mimics with Luminescent Europium(III) Chelates 
For the lanthanide-based assay, five bivalent peptidomimetics with Eu(III) 
chelates, and five bivalent peptidomimetics with TEG tag were synthesized.  The TEG-
labeled compounds were synthesized by the method described in Chapter 2.3.  
Monovalent mimics 4 were synthesized by Dr Yu Angell.47  
Our group developed a method to conjugate monovalent mimics to bivalent 
mimics on triazine core as was described in Chapter 2.  The general procedure is to 
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attach a tag first at cyanuric chloride via SNAr reaction, and then add one monovalent 
mimic to the core at a time using solvent effects e.g. THF vs DMSO.47,80  First, we tried 
the method illustrated in Scheme 4.1.  Modified chelate 3 was successfully added on the 
core in the first step; all reactions were monitored by analytical HPLC, and MALDI-MS.  
However, product 7 could not be made under these conditions.  Analytical HPLC 
showed the starting material 6 was consumed completely, but compound 7 did not form.  
Our initial thought was that several carboxylic groups in the chelate might be interfering 
with the SNAr reaction.  Thus, we tried to introduce Eu to chelate 2 first, and then to do 
the SNAr reaction with a monovalent mimic 5.  However, we also failed to obtain 7; 
product was a mixture of several compounds by HPLC, and MALDI-MS for the crude 
reaction mixture did not show anything corresponding to 7. 
 
 
Scheme 4.1.  First Attempted Syntheses of Preparing Eu-chelated Bivalent Mimics 1.   
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Scheme 4.1.  continued. 
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We believed that the chelate part was inhibiting the SNAr reaction.  Thus, we 
decided to add monovalent mimics first, and then the chelate in the last step.  The 
synthesis was modified slightly, as shown in Scheme 4.2a.  Boc-piperazine was added to 
cyanuric chloride first as a linker for the chelate, and then the bivalent mimics 9 were 
introduced via the previous method.  Boc deprotection and addition of p-SCN-Bn-PCTA 
gave compound 10.  Finally, we obtained bivalent mimics with the chelate, PCTA, 10a 
and 10e.  However, this method could not be used to make bivalent mimics with Lys 
side-chain 10b - d (SY-KY, KG-SG, and TG-KI).  These compounds after Boc-
deprotection have two different amines, a secondary amine from piperazine and a 
primary amine from the Lys side-chain which can react with p-SCN-Bn-PCTA under the 
reaction condition.  Thus, we modified the method again as shown in Scheme 4.2b; first, 
the monovalent mimics were added to cyanuric chloride via SNAr reaction.  In this case, 
it is also important that the monovalent mimic 3 without a Lys side-chain such as SY, 
SG, and TG is added to cyanuric chloride first.  This is because the primary amine in Lys 
also reacts with cyanuric chloride via SNAr reaction.  Products 10b - d were obtained by 
addition of the modified PCTA 3 to 12.  All compounds 10a - e were purified with RP-
preparative HPLC. 
 
 
Scheme 4.2.  Two Methods for Preparing The Bivalent Mimics 10a - e.   
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Scheme 4.2.  continued. 
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Scheme 4.2.  continued. 
 
 
 
 
 
Europium was bound to compound 10 with an acetate buffer condition at pH 5.5.  
After the reaction, the product mixture was purified by RP-preparative HPLC, and 
compound 1 was obtained as a TFA salt.  It is necessary to remove TFA for biology 
assays.  Generally, the TFA salt form was lyophilized in 1.0 % acetic acid solution three 
times to replace the trifluoroacetate to acetate.  However, analytical HPLC after using 
1.0 % acetic acid showed some Eu escaped from the PCTA-chelate, reforming 
compound 10 under the acidic condition.  Addition of Eu again after lyophilization gave 
one product, as indicated by analytical HPLC.  However, we did not want to leave extra 
Eu in the compound.  Thus, several other conditions were tried to solve this problem, 
such as 0.5 % or 0.1 % acetic acid, 50 nM ammonium acetate, 20 nM HCl and addition 
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of Eu again after lyophilization.  Treatment of 1.0 % and 0.5 % acetic acid, 50 nM 
ammonium acetate, or 20 nM HCl gave split peaks after lyophilization. The best result 
was obtained by 0.1 % acetic acid.  Therefore, lyophilization three times from 0.1 % 
acetic acid was used to remove the TFA.  Table 4.1 shows a summary of side-chain 
structures of the prepared Eu-chelated bivalent mimics. 
 
 
Scheme 4.3.  Synthesis of Eu-labeled Bivalent Mimics 1a - e.   
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Table 4.1.  Side-chain Structures of The Bivalent Mimics. 
com’d sequence R1 R2 R3 R4 
      
a RI-RI 
    
b SY-KT  
 
  
c KG-SG  H  H 
d TG-KI 
 
H   
e 2mor 
  
  
 
 
4.3 Biology Assay 
Total ten compounds including five Eu-labeled bivalent mimics and five TEG-
labeled bivalent mimics were prepared for HTRF competitive binding assay.  The assay 
was conducted by our collaborator, Dr Nancy Smyth Templeton and her coworkers at 
Gradalis Inc..  Figure 4.5 shows the structures of Eu-PCTA compound 1a and TEG-
labeled compound corresponding to KB1005 that targets pancreatic cancer selectively. 
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Figure 4.5.  (a) Structure of Eu-PCTA compound 1a; and, (b) TEG-labeled compound 
corresponding to KB1005 that targets pancreatic cancer.  
 
 
The competitive binding assay used Eu-PCTA 1a-e at a fixed concentration, 0.63 
nM.  The optimized concentration was determined by testing a range of 0.08 to 5.06 nM 
Eu-PCTA 1.  The unlabeled, non-fluorescent compound (TEG-labeled compound) was 
added to the wells of a 96-well dish in concentrations ranging from 1 to 50 nM to 
generate displacement curves.  The binding constant was determined by using a 
nonlinear regression (Figure 4.6).  The binding constant was Ka= 1.1 x 109 M-1.  Binding 
constants of 108 M-1 and greater are associated with small molecules that promote 
expression in the transfection-based assay.  Ligands that meet the criteria for an 
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appropriate binding constant could be used for a personalized, targeted therapeutic in the 
clinic. 
 
 
 
Figure 4.6.  Competitive binding assay curve using Eu-PCTA compound 1a and TEG-
labeled compound.   
 
 
4.4 Conclusion 
It is important to develop small molecules that target only cancer cells, because 
the molecule can deliver anti-cancer drugs to the targeted cells effectively without 
damaging for healthy cells.  In cases where we do not have much information about a 
target, a target can be found by screening with many compounds.  In this strategy, our 
group found a small molecule KB1005 that targets pancreatic cancer, although we do not 
know how KB1005 interacts with the target yet.  Next, we wanted to apply the 
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compound to advanced cancer environment, such as fresh surgical specimens of 
pancreatic cancer, and we wanted to establish a confirmatory homogeneous time 
resolved fluorescence assay (HTRF) to determine a binding constant for the cell.  Thus, 
five Eu-labeled compounds 1a - e and five TEG-labeled compounds were prepared for 
HTRF assay.  The lanthanide-based assay was chosen to avoid background fluorescence 
from specimen.  From the competitive binding assay, we found 1a bound to the cell with 
Ka= 1.1 × 109 M-1.  This value can promote expression in the transfection-based assay.  
Originally, the triazole-based peptidomimetics like KB1005 were designed as β-
turn mimic for neurotrophins hot-spot regions, and showed some activities for TrkA in 
previous work.47  We described these compound as “minimalist mimics”, because the 
compounds mimic only side-chains of peptide secondary structures on a rigid core, e.g. 
triazole core, instead of a peptide back bone.  At the same time, we proposed that sets of 
these types of compounds could mimic local pairs of amino acids in any secondary 
structures as “universal peptidomimetics”.  In our hypothesis, the compounds’ library 
would be very useful for high-throughput assay against various targets because the 
compounds can mimic a range of secondary structures in known or unknown targets.  As 
our hypothesis, KB1005 was found as an active compound for pancreatic cancer cells 
through high-throughput screening, and we followed up on this lead with more advanced 
studies.  Next chapter describes the definition and validation of the minimalist mimics 
and universal peptidomimetics, and propose new scaffolds for them.   
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CHAPTER V 
UNIVERSAL PEPTIDOMIMETICS* 
5.1 Introduction 
“Minimalist mimics” are compounds that mimic only side-chains of peptide 
secondary structures.52  Scaffolds in the minimalist mimics do not exist as a single 
conformation in solution; they equilibrate between forms representing local minima in 
Boltsman distributions of energy states, so there is no reason that their global minimum 
should correspond to the target secondary structure.  Instead, it is sufficient that the 
pertinent conformations for mimicry have energies similar to the global minima so that 
they are populated and the transition-state energy barriers to arrive at them can be 
overcome at ambient temperatures, that is, there are no insurmountable thermodynamic 
or kinetic obstacles to attaining the target conformations.  Identification of 
conformations in equilibrating ensembles that are both kinetically and 
thermodynamically accessible can be done only by comparing with similar systems that 
have been studied experimentally or via computational method.  Spectroscopic 
techniques like NMR cannot detect a preferred solution state conformer of mimic at 
room temperature, because there is none.  Coupling constants and NOE measurements 
for the scaffolds would reflect conformational averaging.  In addition, useful minimalist 
mimic cannot be totally flexible because their scaffolds must have limited degrees of 
freedom to avoid significant entropic penalites on adopting the target secondary structure 
conformations. 
 
 
 
____________ 
*Reprinted in part with permission from “Univeral Peptidomimetics”, Eunhwa Ko, Jing 
Liu, Lisa M. Perez, Genliang Lu, Amber Schaefer, and Kevin Burgess, J. Am. Chem. 
Soc., 2011, 133,  462-477. Copyright 2010 American Chemical Society.  *Reprinted in 
part with permission from “Pyrrole-Based Scaffolds for Turn Mimics”, Eunhwa Ko, and 
Kevin Burgess, Org. Lett., 2011, 13,  980-983. Copyright 2011 American Chemical 
Society. 
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Criteria for design of minimalist mimics have never been specifically delineated 
before.  Thus, we propose the flowing four structural design criteria for minimalist 
mimics: 
 
• facile syntheses with most amino acids side chains 
• kinetically and thermodynamically accessible conformations for induced fit (i.e. 
not too rigid) 
• only moderate loss of entropy on docking (i.e. only a few significant degrees of 
freedom that influence the side-chain orientations) 
• appropriate Cα - Cβ coordinates of an accessible conformation of the mimic 
matching those of the secondary structure. 
 
These are key parameters on the structural basis for designing minimalist 
mimics.  Other considerations, such as water solubilities, toxicities, cell permeability and 
self-life are also important to design peptidomimetics.  However, if the structural basis is 
not satisfied first, other concerns about the physical and pharmacological characteristics 
of the compounds might be inconsequential.  
In the first criteria, Trp, Arg, Tyr, Lys and Glu are amino acids side-chains that 
are found frequently at hot-spots in protein-protein interactions.7  Thus, if mimics cannot 
easily make with the amino acids, but they can be prepared with only simple alkyl 
chains, they are not good mimics.  The second and third criteria are relating to the 
kinetic and thermodynamic accessibilities and the significant degrees of freedom.  
The fourth parameter is about Cα - Cβ vector.  Previously, our group proposed 
that Cβ - Cβ separations are critical in the design of minimalist β-turn mimics.47,48,81  
This is because the Cβ positions represent the last atoms along the side chains that are 
held with some rigidity in these secondary structures.  Compounds A and 1 in Figure 
5.1b were designed and synthesized as β-turn mimics for neurotrophins on this criteria, 
and the verification was proved with biological data; compounds A bind to TrkA, and 
compounds 1 are partial agonists for TrkC.47,48  Cβ - Cβ distances are useful as a “rough 
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cut” to gauge the fit of a proposed minimalist mimic to secondary structures.  A more 
sophisticated standard for minimalist mimics is side-chain Cα - Cβ bond vectors, 
because the parameter reveals how the side-chain projects into space as well as Cβ - Cβ 
distances.  Matching Cα - Cβ bond vectors to secondary structures gives more realistic 
sense of the validity of the mimic.  However, disadvantage for Cα - Cβ bond vector 
consideration is that computational work is required; it is less convenient that the 
intuitive approach based on Cβ - Cβ distances alone. 
 
 
a 
 
 
b 
 
Figure 5.1.  (a) A β-turn and general scaffolds of minimalist mimic.  (b) Minimalist 
mimics A and 1 that were prepared by our group. 
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Minimalist mimics do not have fixed Cβ - Cβ separations (βs values).  For 
example, compounds 1 have several different minimal energy conformations that 
correspond to preferred orientation for the two side-chains (Figure 5.2).  Energy barriers 
for interconversion between the most contracted conformer and the most extended 
conformer are likely to be relatively insignificant, so this particular type of 
peptidomimetics could access a range of βs values.  The extension factor is defined as ef 
= βse/βsc, to calibrate the capacity of a minimalist mimic to span different Cβ - Cβ 
distances.  Peptidomimetics with small extension factors can mimic a limited range of 
Cβ - Cβ separations, while mimics with large extension factors correspond to side-chain 
separations in more secondary structures.  However, large extension factors are not 
always ideal in designs, because they might also represent excessive flexibility in the 
scaffold.  Therefore, ef values are predictors of scope rather than quality.   
 
 
 
 
Figure 5.2.  Definition of extension factor. 
 
 
Six templates 1 - 6 were designed and synthesized using the structural criteria 
listed for minimalist mimics.48,52,82  1, 2, 5, and 6 have piperidine or piperazine linker to 
facilitate assembly of these molecules into heterobivalent mimics.  
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Figure 5.3.  Scaffolds for universal peptidomimetics 1 - 6.   
 
 
Table 5.1 shows the extension factors deduced for mimics A, and 1 - 6.  
Peptidomimetics 3 and 4 have the smallest ef, and 5 have the largest ef in this series.  
Scaffold 1 allows R1 and R2 side-chains to approach more closely than any other in the 
series of compounds.  However, the βs value of 1 is intermediate in the series, that is, the 
extension factor for this mimic is not the smallest of theses compounds.  
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Table 5.1.  Extension Factors for Peptidomimetics A and 1 - 6.   
compounds  βsc (Å) βse (Å) ef 
    
A 5.5 6.2 1.2 
1 5.5 7.1 1.3 
2 5.2 7.2 1.4 
3 5.4 6.2 1.1 
4 7.5 8.1 1.1 
5 7.4 14.1 1.9 
6 12.1 15.0 1.2 
 
 
Table 5.2 shows data from modeling experiments that we performed to assess 
Cβ - Cβ separations for the common elements of secondary structure.  It reveals 
considerable overlap between βs values for different residues in different secondary 
structures with the range of βs values accessible by each mimic.  For instance, the i to 
i+3 βs in a type I β-turn is about equal to that for the i to i+2 in an inverse γ-turn (ca. 5.4 
Å), so a scaffold that can access this βs can mimic those side-chains in both secondary 
structures.  Indeed, the extent of Cβ - Cβ separation overlap in Table 5.2 indicates that 
almost all the side-chain Cβ - Cβ separations could be mimicked with relatively few 
peptidomimetics.  In other word, small sets of such scaffolds can be designed to 
analogue local pairs of amino acids including noncontiguous ones in any secondary 
structures; they are “universal peptidomimetics”. 
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Table 5.2.  Cβ - Cβ Distances for Mimics A and 1 - 6 with Secondary Structures.  
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5.2 Analyses of Universal Peptidomimetics 2, 5, and 6 
For peptidomimetics 2 - 6, density functional theory (DFT) calculations and 
quantum molecular dynamics (QMD) were performed.  DFT calculation was used to 
investigate kinetic accessibility for compounds.  In these calculation, Gaussian 03 was 
used at the B3LYP level of theory with a 6-31+G(d’) basis set and a polarized 
continuum solvation model with a dielectric of 80. 83,84     
The DFT method facilitates calculation of transition-state energies and relative 
energies of resting conformations, but it does not show the all conformations that can be 
formed and rank their relative energies, thermodynamic accessibility.  To do this, QMD 
was used.  In this technique, a molecule is minimized and then subjected to a molecular 
dynamics run at high temperature (1000 K) for a short time (600 ps); 600 conformational 
states are recorded during this run (i.e. every 1 ps) and minimized via molecular 
mechanics.85-88  The lowest energy structures below a user-defined cutoff are selected 
and then clustered into families on the basis of root-mean-square (rms) deviations from 
user-defined atoms.   
Peptidomimetics 2 were synthesized by Dr Jing Liu, peptidomimetics 5 by Dr 
Genliang Lu, and peptidomimetics 6 by Dr Amber Schaefer and Shuhei Shimizu.52 
 
5.2.1 Analyses of 1,3,4-Oxadiazole-based Peptidomimetics 2 
Pharmaceuticals including oxadiazoles scaffold have been shown to have a range 
of bioactivites and applications, including bactericidal, fungicidal, analgesic, anti-
inflammatory, antiproteolytic, anticonvulsant, nervous system depressant, sedative and 
local anesthetic.89-92  As triazole-based peptidomimetics, A and 1, 1,3,4-oxadiazole-
based mimics 2 have a compact five-membered heterocycle that might be ideal for the 
formation of universal peptidomimetics.   
Compounds 2 have two significant degrees of freedom that separate the key 
Cβ−atoms (Figure 5.4a).  Cβ - Cβ separations of 2 are between 5.2 Å and 7.2 Å (Figure 
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5.4b).  In the Table 5.2, the compounds can become mimics of most secondary structures 
with the Cβ - Cβ separations. 
 
 
a 
 
 
b 
 
Figure 5.4.  (a) Degrees of freedom for mimic 2.  (b) Conformations corresponding to 
the βsc and βse of mimic 2 (piperidine ring omitted). 
 
 
In DFT calculation for 2, the global minimum energy structure that was 
identified was set to 0 kcal/mol, and is shown on the left side of Figure 5.5a.  Conformer 
on the right side of Figure 5.5a is gotten by rotation of the bonds.  The conformer is only 
0.41 kcal/mol above the global minima, and the highest energy barrier to arrive at the 
conformer from the global minima is 2.43 kcal/mol.  The energy barrier can be easily 
surmounted at room temperature.  The conformer overlays with the i-i+3 residues in an 
2
H2N
N N
O
HN O
H
N
R1 R
2
rotation about only 
these bonds alter
the Cβ - Cβ 
separations
5.2 Å
7.2 Å
 79 
α-helix as Figure 5.5b.  It corresponds to the results from Cβ - Cβ separations in Table 
5.2; the scaffold 2 can have Cβ - Cβ separations corresponding to the i-i+3 residues in an 
α-helix. 
 
 
a 
 
b 
 
Figure 5.5.  (a) Transposition of the global minima of 2 into a conformation that mimics 
the i and i+3 residues in an α-helix by rotation around one of the significant bonds and 
then the other (ΔG° in kcal/mol).  (b) Overlay of the latter conformation on an ideal α -
helix. 
0.00
2.43
0.11
1.31
0.41
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In QMD techniques for 2, application of a 0.45 kcal/mol energy cutoff gave 180 
minimized conformations.  These 180 structures were clustered by overlay of the 
Cα and  Cβ atoms within 0.3 Å RMSD.  This process gave seven families of 
conformations (Table 5.3).  Family 3 has the most structures that overlaid, and the 
minimum energy structure in this family was only 0.15 kcal/mol above the overall 
minimum energy conformation.  Conformations within this family overlay well with the 
i-i+3 side-chains of an ideal α-helix conformation.  This is the same conclusion that was 
reached using the DFT method (Figure 5.5b).  Other structure in this family also overlay 
the i-i+2 side-chains of an ideal inverse γ-turn (Figure 5.6a).  Moreover, structures in 
family 5 overlay with an ideal type I β-turn at the i+1-i+2 side-chains (Figure 5.6b). 
 
 
Table 5.3.  QMD Analysis of 2.   
 F1 F2 F3 F4 F5 F6 F7 
        
population 66 21 72 11 7 1 2 
ΔE (kcal/mol)a 0.00 0.12 0.15 0.26 0.28 0.34 0.40 
minimum Cβ-Cβ 6.32 6.07 5.91 5.93 5.65 6.50 6.92 
maximum Cβ-Cβ 6.93 6.32 6.48 6.53 5.92 6.50 6.92 
corresponds tob   
α-helix 
γ-turn 
 β-turn   
a Energy differences from lowest energy conformer.   bRepresentative structures in the 
families highlighted overlays with the secondary structures as represented in the figures 
accompanying this table. 
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Table 5.3.  continued.   
 
 
 
The QMD method illustrates how conformations of peptidomimetics 1 can 
mimic three different secondary structures.  QMD facilitates sampling of conformation 
space, and the DFT approaches can be used to reveal if the desired conformations are 
kinetically accessible. 
 
 
a 
 
Figure 5.6.  QMD data for compound 2.  (a) Data from family 3 illustrating overlay with 
an inverse γ-turn (overlay with an α-helix is shown in Figure 5.8).  (b) Data from family 
5 illustrating overlay with a type I β-turn. 
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b 
 
 
 
Figure 5.6.  contiuned. 
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5.2.2 Analyses of “Kinked” Bistriazole-based Peptidomimetics 5 
Peptidomimetics 5 have four significant degrees of freedom separating the key 
Cβ - Cβ separations.  The compounds’ Cβ - Cβ separations are between 7.4 Å and 14.1 
Å.  The ef, (ca. 1.9) is the largest value in the series.  From the separations, Table 5.2 
shows the compounds can mimic α-helix, β-turn, β-sheet (parallel and anti-parallel), and 
classic γ-turn.   
 
 
a 
 
 
b 
 
Figure 5.7.  (a) Four significant degrees of freedom for compounds 5.  (b) 
Conformations corresponding to the βsc and βse of mimic 5. 
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In DFT analysis for compounds 5, a conformer (right side in Figure 5.8b) above 
0.07 kcal/mol of the global minimum conformation (left side in Figure 5.8a) overlays 
with “cross strand” i-i’+3 residues of anti-parallel β-sheet.  The energy barrier to reach 
the β-sheet mimic conformer is only 4.04 kcal/mol that can be surmounted at room 
temperature.    
 
 
a 
 
Figure 5.8.  (a) Transposition of the global minima of 5 into a conformation that mimics 
the i and i’+3 residues in an anti-parallel β-sheet (ΔG° in kcal/mol).  (b) Overlay of the 
latter conformation on an anti-parallel β-sheet. 
 
 
 
0.00 0.07
4.04
 85 
b 
 
Figure 5.8.  continued. 
 
 
The QMD analysis of compounds 5 with the abbreviated structure shows the 
scaffold has total 15 families within 0.3 kcal/mol energy cutoff, and conformers in 
family 3, 4, and 7 can become mimics for α-helix, and β-sheets (Table 5.4).  
 
 
 
 
 
 
 
 
 
 
 
overlay of minimum energy confromaiton with anti-parallel β-sheet
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Table 5.4.  QMD Analysis of 5.a   
 
 F1 F2 F3 F4 F5 F6 F7 F8 
         
population 18 17 13 8 4 11 2 7 
ΔE (kcal/mol) 
from lowest energy 
conformer overall 
0.00 0.01 0.03 0.07 0.08 0.09 0.13 0.15 
minimum Cβ-Cβ 13.36 12.00 12.79 12.38 11.43 11.04 11.33 9.51 
maximum Cβ-Cβ 13.77 12.60 13.65 12.92 11.84 11.73 11.39 10.17 
corresponds tob   
α-
helix 
β-
sheetc 
  
β-
sheetd 
 
a Total 15 families were identified, but F9 - 15 were omitted because F9 and F12 - 15 
have only one structure, and F10 and F11 have four and five structures. b Representative 
structures in the families highlighted overlays with the secondary structures as 
represented in the figures accompanying this table. c Antiparallel form. d Parallel form. 
 
 
The conformer overlaid for anti-parallel β-sheet in DFT calculation is included in 
family 4.  Conformer in family 3 can mimic i-i+8 residues in α-helix, and another 
conformer in family 7 overlays with i-i+4 residues of a parallel β -sheet.  
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b 
 
Figure 5.9.  QMD data for compound 5.  (a) Family 3 overlaid with an α-helix.  (b) 
Family 4 overlaid with an anti-parallel β-sheet.  (c) Family 7 overlaid with a parallel β-
sheet.  
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c 
 
Figure 5.9.  continued. 
 
 
5.2.3 Analyses of “Linear” Bistriazole-based Peptidomimetics 6 
Peptidomimetics 5 feature a 1,3-disubstituted benzene as the central ring.  An 
analog 1,4-disubstituted benzene system 6 gives a greater possible span between the two 
pertinent side-chains up to 15 Å.  However, the extension factor (ef 1.2) of compounds 6 
is smaller than compounds 5 (ef 1.9).  The compounds 6 can mimic distal side-chains of 
α-helix, parallel and anti-parallel β-sheets in Table 5.2. 
 
 
 
 
 
 
 
 
 
clustered 
conformations
conformer with
minimum energy
 in family
overlay of minimum energy 
conformaiton with parallel β-sheet
 89 
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b 
 
Figure 5.10.  (a) Four significant degrees of freedom for compounds 6.  (b) 
Conformations corresponding to the βsc and βse of mimic 6. 
 
 
DFT calculation shows a conformer that has 0.46 kcal/mol higher energy than a 
global energy minima overlays with the i and i+4 residues in a parallel β-sheet.  The 
energy barrier to arrive at the β-sheet mimic conformer is only 3.80 kcal/mol that can be 
surmounted at room temperature.    
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a 
 
b 
 
Figure 5.11.  (a) Transposition of the global minima of 6 into a conformation that 
mimics the i and i+4 residues in a parallel β-sheet (ΔG° in kcal/mol).  (b) Overlay of the 
latter conformation on a parallel β-sheet. 
0.00
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In QMD analysis, compounds 6 have 10 families within 1.0 kcal/mol energy 
cutoff (Table 5.5).  Conformers in families 2 and 5 can be overlaid with α-helix and 
parallel β-sheet.   
 
 
Table 5.5.  QMD Analysis of 6.a   
 
 F1 F2 F3 F4 F5 F6 F7 
        
population 25 19 16 13 17 5 6 
ΔE (kcal/mol) 
from lowest energy 
conformer overall 
0.00 0.03 0.16 0.24 0.33 0.50 0.85 
minimum Cβ-Cβ 13.92 13.18 14.10 13.63 12.62 13.35 13.78 
maximum Cβ-Cβ 14.48 13.56 14.32 14.24 13.13 13.44 14.11 
corresponds tob  β-sheetc   α-helix   
a Total 10 families were identified, but F8 - 10 were omitted because F8 and F10 have 
only one structure, and F9 has three structures. b Representative structures in the families 
highlighted overlays with the secondary structures as represented in the figures 
accompanying this table. c Parallel form. 
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Conformer in family 2 overlaid well with a parallel β-sheet, placing the i-i+4 at 
appropriate distances (Figure 5.11 and 5.12) like the result of DFT.  In addition, 
conformer in family 5 can also mimic the i-i+8 residues of α-helix.  
 
 
a 
 
Figure 5.12.  QMD data for compound 6.  (a) Family 2 overlaid with a parallel β-sheet 
as in figure 5.11,  (b) Family 5 overlaid with an α-helix. 
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Figure 5.12.  continued. 
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5.3 Syntheses and Analyses of 1,3-Butadiyne-based Peptidomimetics 4 
Over 1000 compounds with two or more conjugated acetylene have been isolated 
from Nature.  These compounds show interesting biological activities in a wide area, 
such as antibacterial, antimicrobial, antifungal, antitumor, anticancer, anti-HIV, and 
pesticidal properties.93  For example, “panazytriol” containing diyne is an important 
contributor to the activity of Red Ginseng.  It shows inhibitory activity against MK-1 
expressing tumor cells, and the cytotoxicity of mitomycin C against human gastric 
adenocarcinoma cell lines.94   
1,3-Butadiyne-based compound is a suitable scaffold for minimalist 
peptidomimetics, because the template can be easily obtained from amino acids.  
Conversion of N-Boc amino acids into the corresponding alkyes 8a - h was achieved via 
the Ohira-Bestmann modification.95,96  The optimized condition to get the heterodiynes 
10a - f was a coupling between 1-bormo alkynes 9a - c and the parent alkynes 8b, d - f, 
h via Cadiot-Chodkiewicz condition.94,97   
 
 
Scheme 5.1.  Preparation of 1,3-Butadiyne-based Peptidomimetics 4a - f.   
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Scheme 5.1.  continued. 
 
 
 
 
 
 
 
1,3-Butadiyne-base pepditomimetics 10a - f and 4a - f with various side-chains 
including Leu, Phe, Trp, Ile, Lys, Tyr, Arg, and Ser were synthesized and summarized in 
Table 5.6.  The final compounds 4a - f were obtained as TFA salt forms after Boc-
deprotection. 
 
 
 
 
 
 
 
 
 
BocHN
R1
Br2, nBuLi
THF, -78 oC, 2 h
BocHN
R1
Br
9a-c8a, c, h
NHBoc
R2
BocHN
R1
Br +
CuCl, EtNH2
 NH2OH HCl
MeOH/THF 
0 oC, 3 h
BocHN
R1 R2
NHBoc
10a - f9a - c 8b, d - g
50 % TFA
CH2Cl2
0 oC, 3-5 h
H2N
R1 R2
NH2
4a-f
87 - 100 %
 96 
Table 5.6.  Summary of 1,3-Butadiyne-based Peptidomimetics 10a - f and 4a - f.   
 
compounds R1 R2 
10 
(%) 
4 
(%)a 
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94 90 
b 
 
 
84 87 
c 
  
71 100 
d 
  
74 93 
e 
  
95 93 
f 
  73 90 
a TFA salt forms of 4.   
 
 
There is only one significant degree of freedom involved in moving the two 
Cβ atoms close to or farther away from each other and simultaneously adjusting the 
orientation of the Cα - Cβ vectors (Figure 5.13a).  These compounds 4 are very 
constrained; the Cβ - Cβ separations are between 7.5 Å and 8.1 Å, and the extension 
factor is ef=1.1 (Figure 5.13b, and Table 5.1).  Nevertheless, the peptidomimetics 4 can 
become mimics for β-turn, β-sheets, and γ-turn in limited residue sets (Table 5.2).  
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Figure 5.13c shows the overlay of the compound with the i-i+2 side-chains of a classical 
γ-turn. 
The Cα−alkyne and alkyne-alkyne bonds in compounds 4 are essentially free to 
rotate.  DFT calculations revealed that the energy maximum between the two 
conformations in Figure 5.13b was less than 0.01 kcal/mol, that is, the conformations 
were essentially equal in energy.  Similarly, QMD calculations indicate that every 
possible conformation has almost the same energy and is equally populated.  These data 
show that this peptidomimetics would surrender very little entropy on induced fit that 
sets its Cβ atoms between these ranges. 
 
 
a 
 
b 
 
Figure 5.13.  (a) Compound 4 has only one significant degree of freedom.  (b) 
Conformations corresponding to the βsc and βse.  (c) Overlay of one conformation of 4 
with the i and i+2 side-chains of a classical γ-turn. 
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Figure 5.13.  continued. 
 
 
5.4 Syntheses and Analyses of Pyrrole-based Peptidomimetics 3 and 13 
Pyrrole derivatives are important heterocyclic templates because they can be 
found in various natural products, and most compounds have biological activities.  For 
examples, the pyrrole units are included in several natural pigments, such as heme, 
chlorophyll, bile pigments, and enzymes like cytochromes.98  Thus, many synthetic 
approaches have been developed for construction of pyrrole building block, such as 
Hantsch procedure, Knorr reaction, Paal-Knorr reaction, and various metal-mediated 
cycloadditions.99-101   
As amino acid surrogates, placement of a carbonyl group at the 2- or 5- position 
of a pyrrole arranges the CO and heterocyclic N- in a 1,3-disposition, just like the CO 
and N of amino acids.102-104  There are some groups to use amino acids as starting 
materials for syntheses of pyrroles with peptide-like side chains.105-108  However, none of 
these strategies have used two amino acids to give pyrrole derivatives with two amino 
acid derived side-chains.  
1H-Pyrrolo[1,2-c]imidazole derivatives that can be synthesized from pyrrole 
scaffolds are also interesting ring system.  The templates have shown interesting 
biological properties as herbicidal, anti-inflammatory and anti-pyretic or as a part of 
 99 
highly antimicrobial active compounds.109-111  These pyrrole derivatives from amino 
acids can be universal peptidomimetics that mimic type I β-turn and inverse γ-turn. 
 
5.4.1 Syntheses of Pyrrole-based and 1H-pyrroleo[1,2-c]imidazole-3(2H)-ones-
based Peptidomimetics  
Scheme 5.2 shows overall route to synthesize pyrrole-based and 1H-
pyrroleo[1,2-c]imidazole-3(2H)-ones-based peptidomimetics.  The syntheses of the 
compounds 13 began with Weinreb amides of Boc-protected amino acids.112,113  The 
Weinreb amides were reduced to the corresponding aldehydes without isolation, and 
then immediately reacted with Boc-protected alkynes derived from amino acids in order 
to give propargylic (2-pyridyl)alcohols 11.114  
 
 
Scheme 5.2.  Scheme of The Pyrrole-based Peptidomimetics 13.   
 
 
 
 
 
Sarpong group reported Pt(II)-mediated cyclization of propargylic (2-
pyridyl)alcohols as an initial paradigm for formation of pyrrole in this work in 2007.115  
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The cyclization of 11a in the similar reaction condition with Sarpong’s work gave 
desired compound 12a and elimination by-product 14a of the NHBoc group (Scheme 
5.3a).  To investigate an origin of the by-product 14a, 14a was exposed in the same 
cyclization condition except using a microwave.  As the results in Scheme 5.3b, the by-
product 14a was drived from 12a 
 
 
Scheme 5.3.  Hydroamination to build a Pyrrole Scaffold 12.   
a 
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Scheme 5.3.  continued. 
 
 
 
Figure 5.14a reiterates the mechanistic hypothesis outlined by Sarpong et al. for 
their transformation.  The experimental data in Scheme 5.3b gave a possible mechanism 
for the elimination of NHBoc group as Figure 5.14b.    
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Figure 5.14.  (a) Mechanism of Pt(II)-catalyzed hydroamination.  (b) A possible 
mechanism of elimination of the NHBoc group. 
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The elimination of the NHBoc group on the newly formed pyrrole side-chains 
becomes a problem for pyrrole formation.  Thus, a series of microwave-mediated trial 
reactions were run to optimize the conversion and 12:14 product ratio.  Attempts to use 
other catalysts did not give better results.  Similarly, acidic or basic additives, or 
phosphine ligands did not give benefits.  However, changing the solvent from toluene to 
1,4-dioxane increased the conversion, although it gave approximately the same product 
selectivity (Table 5.7).   
 
 
Table 5.7.  Pt(II)-catalyzed Pyrrole Formation through Hydroamination in Solvent 
Effect.   
 
 
 
 
 
 
 
 
 
 
BocHN
OH
NHBoc
N
Boc
NHBoc
N
Boc
0.05 PtCl2
solvent, MW 110 oC, 1 h
+
11a
12a 14a
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Table 5.7.  continued. 
entry solvent 12a:14a 
conversion 
yield  (%) 
    
1 benzene 4.0:1.0 85 
2 1,4-dioxane 4.3:1.0 80 
3 THF 2.4:1.0 61 
4 1,2-dichloroethane 2.1:1.0 50 
5 toluene 4.8:1.0 46 
6 EtOH 1.1:1.0 21 
 
 
Table 5.8 shows data for a series of substrates 12 with the various amino acids 
side-chains, such as Ile, Leu, Val, Tyr, Met, Thr, and Gly.  An adjustment had to be 
made for the glycine-containing substrate 11f, because very little product was formed in 
this situation.  Product was formed when the bis-Boc protected compound 11f’ was used, 
but the product yield was still low.   
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Table 5.8.  Summary of Pt(II)-catalyzed Pyrrole Formation through Hydroamination.   
 
compounds R1 R2 12 (%) 14 (%)a 
     
a 
  
82 12 
b 
  
72 3 
c 
 
 
21 10 
d 
  
61 17 
e  
 
30 trace 
fa 
 
H 13 trace 
a Substrate for 11f was used for this reaction 
 
 
 
Compounds 12 have two different Boc protecting groups.  Attempts to remove 
the two Boc groups at once failed, but the Boc protecting group on the side-chain could 
be selectively deprotected in TMSOTf and 2,6-lutidine (Scheme 5.4a).116  Removal of 
R1
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BocHN
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the pyrrole-N protecting group under basic conditions led to simultaneous cyclization to 
the 1H-pyrrolo[1,2-c]imidazole-3(2H)-one scaffolds 13 as in Scheme 5.4b.  
 
 
Scheme 5.4.  Deprotection of Boc-protecting Groups, and Cyclization to The β-Turn 
Mimics.   
a 
 
 
b 
 
 
 
5.4.2 Analyses of Pyrrole-based Peptidomimetics 
Peptidomimetics 3 have only one significant degree of freedom.  Cβ - Cβ 
separations of compounds 3 are between 5.4 Å and 6.2 Å, and the extension factor is 
ef=1.1 (Table 5.1).  It is the same values to compound 4.  Although the value is the 
shortest value in this series, the mimic 3 can mimic α-helix, β-turn, β-sheets, and γ-turns 
in Table 5.2.  DFT calculation shows that the maximum energy barrier as the bond 
rotation is 3.12 kcal/mol, that is, all conformers exist at room temperature (Figure 5.15).   
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Figure  5.15.  Global minimum, intermediate, and transition state structures and energy 
changes as the bond rotation in DFT calculation (ΔG° in kcal/mol, d=Cβ - Cβ distance).  
 
 
The global minimum conformer of pyrrole-based mimics overlaid with i+1-i+2 
residues of type I β-turn (Figure 5.16a).  However, pyrroloimidazolone-based 
peptidomimetics 13 show better matching with the i+1-i+2 residues of type I β-turn 
(Figure 5.16b).  Moreover, the compounds 13 also overlaid with the i+1-i+2 residues of 
an inverse γ-turn. 
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a 
                            
 
b 
 
 
c 
 
Figure 5.16.  (a) Overlay of pyrrol-based peptidomimetics 3 with type I β-turn.  (b) 
Overlay of pyrroloimidazolone-based peptidomimetics 13 with type I β-turn; and, (c) 
with an inverse γ-turn. 
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5.5 Validation of Universal Peptidomimetics 
Scaffolds A and 1 were originally designed to mimic β-turn in neurotrophins.  
FACS assay of compounds A for Trk and p75 receptors showed the compounds 
selectively bind to TrkA.47  Compounds 1 are known as partial agonists for TrkC 
through binding, survival and neurotogenic, and signal transduction assays.48  
 Compounds A, 1, 2, and 5 were submitted to the NIH Molecular Libraries Small 
Molecule Repository (MLSMR) for screening.  In an assay for the protein-protein 
interactions involving the Bcl-2 family proteins Mcl-1 and Bid, peptidomimetics 2 and 5 
shows some activities.  In addition, scaffold A mimics Bim protein in Bcl-XL/Bim 
interaction.  In inhibition assays for PB1-domain interaction of MEK with either native 
or a Lys-Ala mutant of MEKK2, peptidomimetics 1 and 5 showed activities for the 
native MEKK2 protein.52   
These results are very interesting, because Bcl-2 family has helical conformation 
in the protein-protein interactions,117 and the interface of PB1-domain interaction of 
MEK has β-sheet118.  As we expected from Table 5.1, calculations and modelings, the 
biology data proved that scaffold A, 1, and 5 can become mimics for β-turn, α-helix or 
β-sheet, that is, they are universal peptidomimetics.  
 
5.6 Conclusion 
Peptidomimetics 1 - 6 were designed and synthesized as minimalist mimics.  
Combinations of the compounds based on minimalist mimics with complementary βs 
and ef values can correspond to pairs of amino acids in any secondary structure 
conformation.  The sets of compounds call universal peptidomimetics.  To prove this 
hypothesis, DFT calculation, QMD method, and modeling for ideal secondary structures 
were performed.  The analysis data showed that 1,3,4-oxazoline-based peptidomimetics 
2 can mimic α-helix, β-turn, and γ-turn without any significant energy barriers as the 
results by Cβ - Cβ separations in Table 5.1.  Similarly, pyrrole-based peptidomimetics 3, 
and 1,3-butadiyne peptidomimetics 4 with the smallest ef values in this series can mimic 
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close side-chains of β-turn, and γ-turn.  “Kinked” and “Linear” bistrizole-based 
peptidomimetis 5 and 6 with large Cβ - Cβ separations are able to mimic relatively distal 
side-chains in α-helix and β-sheets.  In addition, biophysical data also validated the 
hypothesis; some peptidomimetics showed significant activities for several targets with 
various secondary structures in targeted assays and high-throughput screening against 
diverse targets.   
With these results, universal peptidomimetics are likely to be useful for targets 
where exact binding conformations are unknown, and the peptidomimetics libraries are 
also useful for high-throughput screening against various targets.  These are because the 
compounds can mimic a range of secondary structures, and present any protein amino 
acid side-chains corresponding to hot-spots in protein-protein interactions.   
In this stage, we mostly use Cβ - Cβ separations and ef values to design 
minimalist mimics because proper distances between Cβ atoms are necessary for the 
design.  However, it is a “rough cut” to fit mimics to secondary structures.  To do more 
accurate fitting, consideration of coordinates of the Cα - Cβ bond vectors in side-chains 
might be required as well as Cβ - Cβ distances.  Matching Cα - Cβ bond vectors for 
secondary structures can be achieved with computational work.  Thus, it is necessary to 
develop a program that can do it.  In addition, so far, the designed minimalist 
peptidomimtics are compounds having two side-chains.  However, many literatures have 
indicated that motifs with three side-chains play important roles in biology.119  Increased 
number of side-chains or lengths may give better affinities and selectivities in protein-
protein interaction.  Of course, longer compounds are also important, but it would not be 
easy to synthesize them effectively.  Therefore, in next stage, it is necessary to design 
universal peptidomimetics with three side-chains. 
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CHAPTER VI 
UNIVERSAL PEPTIDOMIMETICS WITH THREE SIDE-
CHAINS: DEVELOPMENT OF A Cα  - Cβ  VECTOR 
MATCHING ALGORITHM *
6.1      Introduction 
Protein-protein interactions (PPIs) mediate many essential cellular processes.   
Misregulation of these interactions is the cause of a range of diseases,120 hence PPIs are 
important for development of pharmacological probes and pharmaceuticals.  Protein-
protein interfaces are huge, so it is not easy to target them, 7 but it is possible, 
particularly by targeting “hot-spot” residues at the interface that dominate the binding 
free energy.7,120-122   
Secondary structures, such as helices and strands, are the prevalent at protein-
protein interfaces (Figure 6.1).  For example, 40 % of secondary structures in 
homodimeric interfaces are helical, 19 % in these are β-sheets,123 and the remainder 
include turns, loops, and other.  In heterocomplexes, the percentages are a little different 
(helices and strands 26 % and 24 %, respectively). Consequently, secondary structures in 
PPIs are attractive targets since hot-spots in proteins are often associated with them.   
 
 
 
 
 
____________ 
*Reprinted in part with permission from “Omegatides: Constrained Analogs of Peptide 
Primary Sequence”, Dmytro Fedoseyenko, Arjun Raghuraman, Eunhwa Ko, and Kevin 
Burgess, Org. Biomol. Chem., 2012, 10, 921-924. Copyright 2011 Royal Society of 
Chemistry.  *Reprinted in part with permission from “Pyrrolinone-Pyrrolidine 
Oligomers as Universal Peptidomimetics”, Arjun Raghuraman, Eunhwa Ko, Lisa M. 
Perez, Thomas R. Ioerger, and Kevin Burgess, J. Am. Chem. Soc., 2011, 133,  12350-
12353. Copyright 2011 American Chemical Society. 
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a                                                                     b 
 
Figure 6.1.  Protein-protein interface involving (a) helix-helix (PDB ID 1t02); and, (b) 
strand-strand (PDB ID 1jl0) interactions. 
 
 
Previous chapters in this thesis have explained why our group is interested in 
mimicry of side-chains in secondary structures, and compounds that we call 
“minimalist”, and “universal” mimics.52,82  In that work, we used Cβ - Cβ separations to 
give a “rough cut” to fit mimics to secondary structures.  However, Cα - Cβ bond 
vectors are a more sophisticated standard because they depict how the side-chains 
project.  Computational methods are required to match Cα - Cβ bond vectors for mimics 
and ideal secondary structures.  This chapter describes how we developed such a 
computational method and applied it to analyze the value of structures we call 
“omegatides” and “pyrrolinone-pyrrolidine oligomers”, as new universal 
peptidomimetics (Figure 6.2).  
 
 
 
Figure 6.2.  (a) Omegatides.  (b) Pyrrolinone-pyrrolidine oligomers. 
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Omegatides and pyrrolinone-pyrrolidine oligomers have several attributes 
compared with our “first generation mimics” that were discussed in Chapter 5.  Notably, 
they can express three side-chains and not two as before thereby giving the potential to 
increase affinity and selectivity of binding.  Scaffolds with three side-chains roughly 
correspond to tripeptides; strands of three amino acids have been recognized minimal 
motifs for effective molecular interactions.119  For example, Reynold’s group reported 
that good ligand affinities are obtained from 30 heavy atoms and noted the average 
number of heavy atoms in three natural amino acids is 25.124  Moreover, using an 
informatics method DILIMOT (Discovery of Linear MOTifs), Russell’s group reported 
small segments of 3-10 residues play critical roles in protein interactions.125  Thus we 
reasoned it was important to develop a method to compare preferred conformations of 
peptidomimetics with three side-chains with ideal secondary structures in terms of Cα - 
Cβ bond vectors.  Here we illustrate this procedure and data obtained for omegatides 1 
(synthesized by Dr Dmytro Fedoseyenko), and pyrrolinone-pyrrolidine oligomers 2 
(prepared by Dr Arjun Raghuraman). 
 
6.2       Development Of A Cα  - Cβ Vector Matching Algorithm  
Quenched molecular dynamics (QMD), described in Chapter 5, provides a 
method to identify and cluster preferred peptidomimetic conformations.  Critically, we 
elected to use the Cα and Cβ coordinates as a basis for the clustering routine.  A cut-off 
of 0.5 Å RMSD based on Cα and Cβ coordinates was used to identify conformers that 
belong in the same family (or cluster).  A cluster that contained conformers within 3.0 
kcal/mol of the global minimum was considered for matching with the secondary 
structures.  This part of the procedure was developed in collaboration with Dr Lisa M. 
Perez as mentioned.  However, an algorithm to compare these conformations with ideal 
secondary strucutres also had to be developed to fulfill our goal.  That algorithm was 
developed in conjuction with Dr Thomas Ioeger of the Computer Science Department at 
Texas A&M University. 
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Figure 6.3.  (a) Three Cα - Cβ vectors A on a preferred conformer to be evaluated for 
goodness of fit on side-chain residues of a secondary structure B.  (b) Mismatched 
residue sets are disregarded.  (c) Matched residue sets are evaluated in terms of RMSD 
and score. 
 
 
The “matching algorithm” first identifies all combinations of three amino acids 
on inputted secondary structures.  It then superposes each conformer of a mimic onto 
each combination of three amino acid side-chains based on Cα - Cβ vectors (Figure 6.3).  
Each superposition in the matching procees is scored for goodness of fit based on RMSD 
of Cα and Cβ atoms: this is a valuable metric because RMSD scores are widely 
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appreciated in science.  Another metric used here is a “score” system we developed 
based on work of others.126  Here the “score” is a weighted combination of distance 
similarities between Cα’s in the two structures, and the angles between of the Cα - Cβ; 
like RMSD, a lower score means a better fit, but, unlike RMSD values, scores do not 
have units.   
This program was applied to omegatides 1 and pyrrolinone-pyrrolidine oligomers 
2 with three side chains (six Cα and Cβ coordinates) to evaluate fit of preferred 
secondary structures on ideal secondary structures.   It can also be applied to compounds 
with two side-chains, in which case it uses four coordinates from two Cα - Cβ vectors. 
 
6.3       Analyses of Omegatides as Analogs of Peptide Primary Sequence and 
Application of The Cα  - Cβ Vector Matching Algorithm to Omegatides 
Our group designed contiguous constrained amino acid surrogates that have side 
chains to reflect the primary sequence di- and tri-peptides; we call this design 
“omegatides”.127  This oligomer is based on tetramic acid building blocks wherein φ and 
ψ angles are locked, and rotation about the ω-bond is less constrained, opposite to 
peptides where the ω-vector is more constrained than φ and ψ.   
 
 
 
Figure 6.4.  Omegatides as analogs of peptide primary sequence.  
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QMD and DFT calculations were performed to assess the conformational biases 
1 (R1 = R2 = R3 = Me).  QMD for 3 showed an overwhelming preference for two 
conformations shown in Figure 6.5a; 594 of the 600 structures existed as these two 
conformers to within 3.0 kcal/mol, and RMSD 0.5 Å.  Members of this family present 
the two methyl side-chains on the same side of the molecules, so we refer to this as syn-
3, and the other preferred family as anti-3 because the side-chains are approximately on 
opposite faces.  DFT calculations on 3 indicated the energy difference between the syn 
and anti conformers was only 0.42 kcal/mol and the energy barrier that must be 
surmounted to interconvert them was only 9.58 kcal/mol.  That is, most conformers exist 
at room temperature. 
 
 
a 
 
Figure 6.5.  (a) Preferred conformations for QMD.  (b) Low-energy conformers and 
energy barrier for interconversion from DFT calculations for compound 3.  All energy 
shown is free energy (∆G°) in kcal/mol. 
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Figure 6.5.  continued. 
 
 
Next, we generated a Ramachandran plot for 600 conformers of different 
stereomers 3a - d (LL, LD, DL, and DD; Figure 6.6).  Dihedral angles of all omegatide 
stereomers were analyzed; most had conformations corresponding to β-sheet regions but 
with φ and ψ angle variances that are much less than in peptides.  Full detail of analyses 
materials and methods is given in Appendix F. 
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Figure 6.6.  Ramachandran plot for diastereomers of 3.  Red (3a, LL), green highlighted 
with black arrow (3b, DL), pink (3c, LD), and blue (3d, DD). 
 
 
Finally, we ran the Cα - Cβ vector matching program with 1a - c, and 3a - b for 
six different ideal secondary structures: 310-helix, α-helix, π-helix, β-strand, parallel β-
sheet, and sheet-turn-sheet (ie an anti-parallel β-sheet with type II β-turn).  In our 
experience, RMSD of 0.3 Å or less is a good fit for structures based on two side-chains.  
On the basis of this standard, data for mimics with two side-chains 3a - b showed these 
compounds have better fits for strands than for helices, and the L,D-isomer 3b is a better 
mimic for the strands than the L,L-isomer 3a (Table 6.1); 3b overlays especially well on 
a β-strand (RMSD 0.3 Å, score 7.8) and parallel β-sheet (RMSD 0.23 Å, score 4.3).   
It is harder to fit six coordinates than four, so matches of the mimics involving 
three side-chains would have higher RMSD.  To fit these structures, we used a standard 
of RMSD of 0.5 Å or less.  As was seen in the mimics with two side-chains, the mimics 
with three side-chains 1a - c showed better matching for strands than for helices.  
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Interestingly, the L,D,L-form 1b, and the L,D,D-form 1c, gave a better fit strands than the 
L,L,L-form 1a. 
 
 
Table 6.1.  Evaluation of Preferred Conformers of Mimics 3a - b and 1a - c on 
Secondary Structures. 
 
 
 
com’
d 310-helix α-helix π-helix β-strand 
parallel 
β-sheet 
sheet/turn-
sheet 
 Ra Sb R S R S R S R S R S 
             
3a 0.52 21.8 0.49 22.5 0.55 26.7 0.52 12.6 0.39 14.2 0.49 14.2 
3b 0.51 22.8 -c - 0.66 33.6 0.3 7.8 0.23 4.3 0.31 5.0 
1a 1.08 44.3 1.04 61.4 0.90 47.1 0.72 28.7 0.72 24.5 0.73 21.8 
1b 1.00 29.1 0.88 42.2 0.82 54.7 0.43 17.5 0.41 15.4 0.49 16.4 
1c 1.14 40.8 0.95 51.1 0.82 40.5 0.64 19.2 0.58 27.6 0.69 17.4 
a R means RMSD (Å). b S means score. c Matching values of 3b for α-helix were not 
obtained. 
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Figure 6.7 shows overlays of 1a and 1b on a parallel β-sheet.  1a overlays on a 
parallel β-steet with an RMSD of 0.72 Å and a score of 24.5, and the conformer overlaid 
is 1.33 kcal/mol above the lowest energy structure obtained in the QMD experiment for 
1a.  The L,D,L-isomer 1b is matched for parallel β-sheet with RMSD 0.41 Å and a score 
15.4.  The conformer overlaid has 0.67 kcal/mol higher energy than the lowest energy 
structure.  Overall, omegatides show better fits for strands than for helices, and this is 
supported by their populations in the Ramachandran plot in Figure 6.6.   
 
 
a 
 
Figure 6.7.  Overlays of preferred conformations of 1a and 1b on an ideal parallel β-
sheet.   
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Figure 6.7.  continued. 
 
 
6.4      Analyses of Pyrrolinone-pyrrolidine Oligomers as Universal Peptidomimetics 
and Application of The Cα  - Cβ Vector Matching Algorithm to Pyrrolinone-
pyrrolidine Oligomers 
Pyrrolinone-pyrrolidine oligomer 2 is a non-contiguous analog of omegatides 1 
(Figure 6.8).128  The templates have a variety of attributes for pharmacological probes 
and pharmaceutical leads.  Two of their four significant degrees of freedom involve 
vinylogous urea bonds that are somewhat rigid due to π-N conjugation.  None of the 
nitrogen atoms are basic, so the molecules are not polycationic under physiological 
conditions.  The scaffold has some intrinsic water solubility modulated by R1, R3, R5, RC 
and RN.  Variation of RC and RN will not significantly affect the preferred template 
conformations.   
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Figure 6.8.  Pyrrolinone-pyrrolidine oligomer as close analogs of peptides.   
 
 
We checked the kinetic accessibility of conformers via DFT calculations.  The 
calculation gave three major intermediates, and their energies are slightly different 
(Figure 6.9a and b, E = the lowest energy structure, ∆Gº of F = 0.64 kcal/mol, ∆Gº of G 
= 1.20 kcal/mol).  The maximum energy barrier is 5.10 kcal/mol; this can be surmounted 
at ambient temperature to interconvert the conformers.  The free energy differences from 
the DFT calculations predict that relative populations of the three conformers (E, F, and 
G) exist in the ratio 1.00:0.34:0.12.  Application of the QMD method to check 
thermodynamical accessibilities gave the three families, H, I, and J, shown in Figure 
6.9c; 581 of the 600 structures existed as these three conformers to within 3.0 kcal/mol 
and RMSD 0.5 Å.  The structure populations for each family are H=380, I=78, and 
J=123.   
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b 
 
Figure 6.9.  (a) Structures and parameters used for DFT and QMD analyses.  (b) Low-
energy conformers and energy barriers for interconversion from DFT calculations, and 
all energies shown are free energies (∆Gº) in kcal/mol.  (c) Preferred conformers from 
QMD calculations. 
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Figure 6.9.  continued. 
 
 
Our Cα - Cβ vector matching program run on compounds 5, 6, and 2a - h in the 
pyrrolinone-pyrrolidine oligomer series (Table 6.2) revelaed 5 and 3a in the omegatide 
series matched very similarly on the ideal secondary structures; this is unsurprising 
because both these compounds present amino acid side chains corresponding to 
contiguous amino acids.  However, compound 6 that mimics non-contiguous amino 
acids is a much better mimic for secondary structures than contiguous templates 3, and 
5.  Preferred conformations of 6 have RMSDs less than 0.3 Å for all secondary 
structures; i.e. 6 is an excellent universal peptidomimetic.  Figure 6.10a shows the best 
matching of 6 on α-helix i-i+3 residues (RMSD 0.14 Å, score 5.4).  The conformer 
shown is only 0.83 kcal/mol higher in energy than the lowest energy conformer.  
Moreover, a preferred conformer of 6 overlays extremely well on sheet-turn-sheet i+1-i’ 
residues (RMSD 0.08 Å, score 2.5; Figure 6.10b).  The conformer is only 0.59 kcal/mol 
higher in energy than the lowest energy conformer.  Procedure for overlays and overlays 
of preferred conformations of 6 on the remainder of secondary structures are given in 
Appendix F.     
 
 
H JI
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Table 6.2.  Evaluation of Preferred Conformers of Mimics 5, 6 and 2a - h Overlaid on 
Secondary Structures. 
 
 
com’
d 310-helix α-helix π-helix β-strand 
parallel 
β-sheet 
sheet-turn-
sheet 
 Ra Sb R S R S R S R S R S 
             
5 0.55 22.0 0.50 22.1 0.54 25.7 0.46 10.3 0.39 8.7 0.56 8.3 
6 0.22 9.9 0.14 5.4 0.14 6.8 0.19 7.5 0.10 4.2 0.08 2.5 
2a 0.58 35.1 0.78 33.8 0.63 18.9 0.73 32.2 0.42 23.9 0.46 27.3 
2b 0.62 26.2 0.67 24.4 0.67 45.6 0.57 23.6 0.42 22.9 0.34 20.0 
2c 0.70 41.5 0.64 31.9 0.54 21.3 0.44 21.0 0.47 25.0 0.34 20.1 
2d 0.87 53.1 0.81 49.9 0.83 43.9 0.61 21.5 0.46 16.6 0.36 16.7 
2e 0.83 30.8 0.76 31.8 0.64 40.0 0.47 25.6 0.33 21.3 0.36 18.6 
2f 0.51 30.5 0.60 26.4 0.64 35.5 0.48 26.1 0.32 10.5 0.34 15.0 
2g 0.69 42.9 0.62 33.8 0.59 24.9 0.46 22.5 0.35 18.1 0.33 18.8 
2h 0.72 37.2 0.65 30.5 0.57 29.8 0.68 28.8 0.54 22.7 0.44 29.1 
a R means RMSD (Å). b S means score. 
 
 
 
 
N
O
Me
HN
O
Me
N OMeN
O
Me
HN OMe
Me
L LL
L
5 6
N
O
Me
HN
O
Me
N N N
O
OMe
Me
2a (LLL), 2b (DLL), 2c (LDL), 2d (LLD)
2e (LDD), 2f (DLD), 2g (DDL), 2h (DDD)
* * *
 125 
a 
 
 
b 
 
Figure 6.10.  Overlays of preferred conformations of 6 on (a) an ideal α-helix i-i+3 
residues; and (b) an ideal parallel β-sheet i+1-i’ residues.   
 
 
In the structures with three side-chains (pentamers), non-contiguous compound 2 
(RMSD 0.32 – 0.87 Å, score 10.5 – 53.1) has preferred secondary structures that overlay 
better than contiguous compound 1 (RMSD 0.41 – 1.14 Å, score 15.4 – 61.4) on all the 
featured secondary structures.  Analyses for the eight stereomers 2a - h indicate that this 
type of structure is a better mimic for strands than for helices; almost all RMSDs for 
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strands including β-strand, parallel β-sheet, and sheet-turn-sheet are less than 0.5 Å (blue 
highlights in Table 6.2).  Stereomers 2f (D,L,L) and 2g (L,D,D) also show good fits for 
helices compared with other stereomers.  Figure 6.11a shows the best match (2f, RMSD 
0.32 Å, score 10.5, ∆Gº= 1.28 kcal/mol) in this series on parallel β-sheet.  Interestingly, 
the three side chains of 2a can overlay well with an ideal sheet-turn-sheet (RMSD 0.46 
Å; score= 27.3, ∆Gº= 1.93 kcal/mol, Figure 6.11b), and we found one example of 
protein-protein interaction between monomers in the Rad52 undecamer where 2a 
matched three side-chains with an RMSD of only 0.14 Å (Figure 6.11c).   
 
 
a 
 
Figure 6.11.  (a) Overlay of 2f on parallel β-sheet motif.  (b) Overlay of 2a on sheet-
turn-sheet motif.  (c) Matching of 2a with a monomer of Rad52.  
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Figure 6.11.  continued.  
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6.5       Conclusion 
Secondary structures mimics have traditionally been studied because of their 
relevance to drug design.  Our group suggested four structural criteria for design of 
effective minimalist mimics of secondary structures: (i) facile syntheses with most 
amino acid side-chains; (ii) kinetically and thermodynamically accessible conformations 
for induced fit; (iii) only moderate loss of entropy on docking; and (iv) appropriate Cα - 
Cβ coordinates of an accessible conformation of the mimic matching to the secondary 
structures.  However, prior to the work described here, there was not a clearly defined 
computational method to evaluate preferred orientations of Cα - Cβ coordinates via 
molecular modeling.  We developed the Cα - Cβ vector matching program to do this, 
and applied it to new templates including ones with three amino acid side-chains.  
Omegatides 1, and pyrrolinone-pyrrolidine oligomers 2 showed better matches for strand 
structures than for helices.  Interestingly, non-contiguous structures 2 gave better fits for 
all secondary structures than contiguous structures 1.  Increased degrees of freedom from 
the pyrrolidine linker in 2 give more flexibility and more appropriate spacing for good 
fits to secondary structures.   
At this stage of the research we realized a much higher goal is possible: Cα - Cβ 
vector matching to evaluate goodness of fit of small molecule preferred conformations 
on any combination of three interface side-chains in all structurally characterized 
protein-protein interactions (PPI).  This motivated us to develop programs to do this; 
specifically, we created a matching program for selected structurally characterized PPIs 
(eKO), and a PDB mining program (EKO).  The next chapter describes how these 
programs were developed and applied.   
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CHAPTER VII 
THE MATCHING ALGORITHM                                    
“EXPLORING KEY ORIENTATIONS (EKO)” 
7.1 Introduction 
Protein-protein interactions (PPIs) are involved in most of the essential processes 
that occur in living organisms, so there have been many attempts to discover small 
“druggable” molecules that can perturb these.129  Discovery strategies in this field 
include high-throughput screening (HTS), fragment-based methods, and computer-aided 
drug discovery.19  HTS typically features hundreds of thousands of compounds, but the 
“hit rates” obtained for PPIs are far less than for traditional targets like enzymes and G-
coupled protein receptors.129,130  Fragment-based methods use small libraries of 
molecular fragments screened for binding against a target.  However, the fragments 
almost invariably have low binding affinities, so it is necessary to use high compound 
concentrations and these may give spurious results in biochemical assays.   
Peptide-centered approaches are distinct from those featuring small molecules.  
Peptides are powerful tools to target proteins, but peptide leads have poor 
pharmacokinetics properties including low cell membrane permeability, and metabolic 
degradation.  Consequently, we do not discuss them further here.   
Computer-aided drug discovery is fast, and requires less resource than other 
methods.  There are at least three approaches in the computer-aided drug discovery 
methods for PPIs: structure-based (featuring docking), complete ligand-based, and 
ligand fragment (corresponding to experimental fragment-based methods, e.g. NMR or 
X-ray).  All these methods use protein structure data and/or compound databases to find 
lead molecules.  However, docking approaches for shallow clefts at PP-interfaces are 
unreliable, as are methods to match the physiochemical properties of small molecules 
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with those of the protein surfaces.  In fact, we hypothesize there are several major 
problems with this approach in general: 
 
• desirable chemotypes of small molecules for interfering with PPIs have not been 
defined; 
• protein conformations may adjust when a small molecule interacts, and the 
conformation of the molecule may similarly change;  
• selectivity issues; and, 
• there is no obvious way to relate the structures of molecules found in HTS libraries 
to the protein ligands that bind to the protein of interest. 
 
Of course, these problem are accentuated for PPIs that are not structurally 
characterized.33  
Here we suggest a set of desirable chemotypes for small molecules that may 
perturb PPIs.  Observers may justifiably question if these chemotypes are ideal, but their 
acceptance as a working hypothesis means that all the other issues outlined above 
become solvable for structurally characterized PPIs.  The genesis of our thinking arose 
from aspects of the work already discussed in this thesis, as outlined below. 
First, we expanded the Cα - Cβ vector matching idea to include any combination 
of at least three side-chains on one protein at a PPI-interface regardless of the secondary 
structures involved.  Justification for the importance of this idea is as follows.  The 
majority (over about 80 %) of hot-spots for PPIs feature only side-chain interactions.7  
Hot-spots are small sets of cooperative contact residues that complement similar ones on 
the other interface and account for much of the binding energy.121  There is no method, 
computational or otherwise, that definitively shows which residues combine to give hot-
spots, so it is impossible to reliably identify hot-spots, particularly for PPIs that have not 
been studied in biophysical experiments.  All hot-spots occur at PPI interfaces, so 
instead of targeting hot-spots, we set out to find interface-mimics instead, and present 
researchers with the opportunities to decide whether or not to follow the ideas generated.  
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We supposed that users of our approach would routinely consult the literature regarding 
the hit PPIs to see what residues have been implicated in hot-spots (if any).  In any case, 
compounds that perturb an interface, but not at hot-spots, are perfectly valid candidates 
to modulate protein-protein interactions via allosteric effects.  In summary, identification 
of interface-mimics is likely to give good pharmacological probes.  Conversely, nobody 
knows how to definitively identify hot-spots, and it would be unnecessarily exclusive to 
focus on hot-spot mimics alone.  
Much research on molecules closely related to peptides has focused on mimicry 
of secondary structures as a way to perturb PPIs.  However, hot-spots in protein-protein 
interfaces are not limited to secondary structures; they may take side-chains from several 
secondary structure types or from poorly defined folds.  For instance, the putative hot-
spot residues of epidermal growth factor (EGF, a growth hormone that interacts with 
epidermal growth factor receptor 1, EGFR1;ErbB-1;HER1) are Tyr13, Leu15, Met21, 
Ile23, Leu26, Arg41, and Leu47 (Figure 7.1).131  These hot-spot residues are not 
confined to defined secondary structures.  Finally, it is reasonable to question the 
justification for broadly analyzing all side chains at PPI-interfaces rather than restricting 
considerations to hot-spots.  Hot-spots are small sets of cooperative contact residues that 
complement similar ones on the other interface and account for much of the binding 
energy.25  There is no method, computational or otherwise, that definitively shows which 
residues combine to give hot-spots.  Thus we set out to find interface-mimics, and 
present users with the opportunity to decide whether or not to follow this virtual hit.  
Users should routinely consult the literature regarding the hit PPIs to see what residues 
have been implicated in hot-spots (if any).  In any case, compounds that perturb an 
interface, but not at hot-spots, are perfectly valid candidates to modulate protein-protein 
interactions via allosteric effects.   In summary, identification of interface-mimics is 
likely to give good pharmacological probes.  Conversely, nobody knows how to 
definitively identify hot-spots, and it would be unnecessarily exclusive to focus on hot-
spot mimics alone. Therefore, we wanted to expand our focus from secondary structures 
to whole interfaces in protein-protein interfaces.   
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Figure 7.1.  Protein interface between EGF and EGFR (PDB 1ivo).132  Residues shown 
on EGF are putative hot-spots.   
 
 
The approach we formulated to find interface mimics is illustrated in Figure 7.2a.  
Thermodynamically preferred conformations (from QMD) of small molecule scaffolds 
conforming to our chemotypes are systematically overlaid on any combination of three 
side-chains at PPI-interfaces, and then scored for “goodness of fit”.  Just as with our 
previous work on matching small molecules to secondary structures, this approach is 
based on Cα - Cβ vectors; Cγ - Cδ orientations and those of more distal bonds in side 
chains are less important because they are relatively free to rotate.  Moreover, as 
described in Chapter 6, we focus on sets of three side-chains because this is 
computationally manageable, and simultaneously, we hypothesize that three side-chains 
are enough to give good affinities and selectivities.  Sets of six coordinates each 
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corresponding to three side-chain Cα - Cβ vectors characterize and differentiate special 
orientations of side-chains in the preferred conformations (Figure 7.2b).  I wish to stress 
that use of all thermodynamically accessible conformations of molecules (as obtained by 
QMD) rather than single conformations is important because it reflects the fact that 
small molecules conforming to our chemotypes do not adopt one single conformation.   
We model only compounds with all three side-chains set as methyl (Ala-Ala-Ala 
derivative) since our approach only relies on Cα - Cβ coordinates.  It is not necessary to 
mine using full side-chains that correspond to each PPI target because the orientations of 
the side-chains are largely determined by the Cα - Cβ coordinates of the first side-chain 
bond in the preferred conformations, and they correspond to these coordinates in the 
structural data too. 
In our method, preferred conformations of the small molecule are simulated in a 
featureless medium of dielectric 80 (corresponding to water).  We hypothesize that 
preferred conformations of a molecule with three methyl side-chains in this medium will 
be even more preferred for corresponding compounds with fully functionalized side-
chains bound to a protein-binding partner.  Perturbations to the preferred conformations 
of the scaffold with other side-chains in the absence of the protein are inconsequential. 
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Figure 7.2.  (a) EKO matches key side-chains in PPIs with preferred conformations of 
rationally designed molecule.  (b) Six Cα - Cβ coordinates in a small molecule define 
the side-chains’ projection in space. 
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In the key step of our matching algorithm, all accessible conformations from 
QMD are paired on all relevant areas of PPI-interfaces.  That is, our system screens 
accessible conformations from our molecule against all combinations of three side-
chains at all the distinct interfaces in structurally characterized PPIs.  This mining 
procedure is achieved in one analysis that takes about 6 h on the TAMU supercomputer 
system.  
The issue outlined above about protein and small molecule conformations 
adjusting in interaction, is circumvented when matching preferred conformations of 
small molecules to conformations of side chains at structurally characterized PPI-
interfaces.  This is because it is known that the PPI-interface regions preferentially 
crystallize in these structures, and the conformations of the small molecule that match 
them are also preferred.  In other words, concerns based on the small molecule and the 
PPI interface adjusting to each other are insignificant because the orientations of side 
chains in both components are known to be favorable. 
Our proposed solution to the selectivity issue outlined above relies on the fact 
that our molecules are based on any combination of side-chains expressed on the 
scaffold with any relative stereochemistry.  Just as peptides have different diverse 
functions based on the composition and orientations of their side-chains, compounds 
based on our chemotypes will gain affinity and selectivity as a result of the same factors.  
In summary, our method is outlined in Figure 7.2a may be regarded as “virtual 
affinity chromatography” where all structurally characterized PPIs are passed through an 
affinity column bearing the featured small molecule bait, free to adopt any of its 
preferred conformations.  We think this approach is novel.  It is unique to mine preferred 
conformations of a small molecule on PPI-interfaces.  The closest method may be 
Bartlett’s CAVEAT program.  This can use Cα - Cβ vectors to pair preferred 
conformations of small molecules to a structurally characterized substrate-enzyme 
complex to facilitate design of inhibitors.133  The key differences are that CAVEAT: (i) 
only considers one preferred conformation of the small molecule rather than the holistic 
approach that QMD provides; (ii) matches those single preferred conformations of small 
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molecules on enzyme substrate fragments that bind in active sites (not on protein side-
chains at PPI-interfaces); and, (iii) has not been used for mining huge structural 
databases featuring proteins.  DOCK is another well known algorithm that is similar to 
CAVEAT.134  This operates by calculation low energy binding of interactions of small 
molecules in active sites of a macromolecule.  DOCK does not focus of Cα - Cβ 
coordinates, it does not use data from protein side-chains at PPI-interfaces, and it has 
never been used for mining huge structural databases of PPIs.   
 
7.2 Development of The EKO Algorithm 
To achieve the goals we had identified above we needed a mining algorithm.  
The one that is now developed we call Exploring Key Orientations (EKO).  It would not 
have been possible to create EKO without considerable help from experts in the writing 
and implementation of computational algorithms; consequently, we are indebted to Dr 
Thomas Ioeger of the Computer Science Department, for writing a script on which EKO 
is based, and for modifying it according to the issues we encountered when we attempted 
to use it.  Additionally, Dr Lisa M. Perez of The Molecular Simulations Laboratory at 
Texas A&M University played a pivotal role: she developed a script for running QMD, 
interfaced it with the algorithm, and refined the integrated package so that it ran on the 
supercomputer resource at TAMU. 
Recall that conformational analyses with QMD typically generate 600 low 
energy structures.  The first step in the implementation of the EKO algorithm is to input 
structural data based on PPIs.  EKO does not use raw data from the PDB.  After some 
searching, it was decided to base EKO on the protein database generated by “3D 
complex”.135  3D complex covers all protein structures that were released before 2008.  
Several attributes of this feature of 3D complex are ideal for its application in EKO, 
specifically it: 
 
• has none of  the redundancy and problematic PDB structures mentioned above; and, 
• identifies contacts between the chains. 
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The 3D complex database encompasses over 53,000 chain interactions in 15,736 
structures.  Not all the side-chains are pertinent to PPI-interfaces, so a user defined filter 
is applied to focus EKO on the most pertinent side-chains.  For a side-chain to be 
considered it must be within X Å of the other protein chain; typically, this distance “X” 
is set at 4 Å.  
Having applied the filter, EKO enumerates all combinations of three amino acids 
in the protein-protein interface.  She superposes each conformation of the molecule onto 
each combination of interface residues.  This is based on optimal superposition of three 
pairs of Cα - Cβ vectors from each conformation onto a triplet of amino acid side-chains 
in a protein chain.  
Each superposition is scored for goodness of fit, and the best candidate is 
returned.  The scoring system is the same as the ones described in Chapter 6 based on 
RMSD and “score”.  When we applied EKO with 368 conformations from compound 1 
for 15,736 different crystal structures from 3D complex, she found 186 hits 
corresponding to conformations of the small molecules that overlay on interface residues 
with RMSDs of 0.33 Å or less. 
To overcome this issue that we can screen only protein structures that were 
released before 2008, we developed a sister algorithm, “eKO” as a matching program for 
each crystal structure on the same principles.  eKO can; (i) match any good crystal 
structure, including those released after 2008; (ii) use all the conformations of the 
molecule without clustering; and, (iii) match for less CPU expenditure because only 
select PPI structures are considered.  The 3D database that EKO feeds on does not 
include NMR structures, but eKO can evaluate these from the PDB.  eKO is not intended 
for mining huge databases.  The remainder of this chapter describes applications of EKO 
and eKO for compound 1.   The dimer interface of HIV-1 protease was one of the 
several PPIs implicated from this analysis, so I took samples of 1 (prepared by Dr Arjun 
Raghuraman) and tested them to obtain experimental data to validate the approach.   
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7.3 Application of EKO to Pyrrolinone-pyrrolidine Oligomers 1 
QMD analysis of 1 generated 490 conformations in 166 families within 3.0 
kcal/mol of the global minimum; members of each family cluster on the Cα - Cβ 
coordinates to within 0.5 Å RMSD or less.  A computational subroutine was used to 
select representative conformers from these families according to the specifications 
outlined above; consequently, 368 conformers for molecule 1 were chosen for the next 
step.  EKO sampled these 368 conformers on 1,340,343 PP-interface residues that 
remained after the distance filter (4 Å) were applied to the 53,328 protein chain 
interactions in the 15,736 structures covered by the 3D database.  EKO scored each 
superposition, and then generated lists of PPIs that best match 1 based on RMSD of the 
small molecules preferred conformations.  Specifically, 186 hits within RMSD 0.33 Å 
were found in this process (Figure 7.3). 
 
 
 
Figure 7.3.  Mining preferred conformations of 1 on PP-interface side-chains using 
EKO. 
 
 
hierarchical classification of protein compleses by 3D complex
(over 53000 chain interactions in 15736 structures)
distinguish interface residues within 4 Å distance restriction
(1,340,343 residues in the PP-interfaces)
enumerating all combinations of three side-chains in the interfaces
368 conformations 
of compound 1 from QMD
superposition between each conformations from the compound and each combination from the residues
find hits and scoring
186 hits within RMSD 0.33 Å for the compound 1
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EKO was similarly applied for all eight stereomers of compound 1.  Table 7.1 
summarizes matches for all the stereoisomers.  To keep the numbers manageable, an 
RMSD 0.30 Å or less was chosen for all stereoisomers except LLL for which 0.33 Å was 
used; our thinking at the time was that we wanted to consider more hits for the “natural” 
stereoisomer.   
EKO found 183 hits for the LLL-isomer 1 corresponding to 58 different proteins.  
Redundancies occurred when different conformations overlay on the same protein with 
different RMSDs below the cutoff, and when the same conformations of the molecule 
overlay on different crystal structures of the same proteins.  In this series of stereomers, 
3 (LDL) gave most hits on the largest set of different proteins. 
 
 
Table 7.1.  The PDB Mining Results for Eight Stereomers of Compound 1. 
 
compounds 
stereomers 
(1-2-3) 
 # of resultsa 
# of  
unique hits 
    
1b LLL 183 58 
2 DLL 197 76 
3 LDL 304 130 
4 LLD 117 37 
5 LDD 55 22 
6 DDL 104 50  
7 DLD 57 29 
8 DDD 36 15 
a Results within RMSD 0.3 Å. b Results within RMSD 0.33 Å. 
N
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Table 7.2 presents mining results for stereomer 1 (LLL) within RMSD 0.33 Å.  
The best match was found for a monomer-monomer interface of a human protein called 
Rad52 (RMSD of only 0.14).  Analysis of the interface regions that matched showed 
compound 1 has a bias towards β-sheet regions, including strand, parallel β-sheet, and 
sheet-turn-sheet structures.  This observation correlates with the predictions from Cα - 
Cβ vector matching on secondary structures as described in Chapter 6.  However, most 
of the matches corresponded to undefined secondary structures or ones in which the 
mimic spanned two or more types.  This is consistent with the hypothesis we presented 
earlier that there is no absolute correspondence between secondary structure and 
interface (or hot-spot) mimics. 
 
 
Table 7.2.  Mining Analyses for Stereomer 1 (LLL). 
 
entry PDB proteins 
RMSD 
(Å) 
score 
residues 
(R1-R2-R3) 
secondary 
structure 
       
1 1kn0 Rad52 0.14 7.0 H121-S119-D117 
strand-
loop 
2 1n2c nitrogenase 0.19 11.7 K145-D76-S257  
3 1g0o 
trihydoxynaphtalene 
reductase 
0.23 12.3 P173-H122-V126  
4 1j3u aspartase 0.23 13.8 V236-T234-V232 loop 
5 1gl7 TrwB 0.23 15.6 T352-D349-S346 helix-loop 
6 1six trypsin-ecotin 0.24 11.3 Me5-T83-L52  
N
O
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L L L
1
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Table 7.2.  continued. 
entry PDB proteins 
RMSD 
(Å) 
score 
residues 
(R1-R2-R3) 
secondary 
structure 
7 3pcb 3,4-PCDa 0.24 15.7 Q177-175-K173  
8 1fcj 
O-acetylserine 
sulfinydrylase 
0.24 17.0 L268-S301-E303  
9 2f4f IS200 transposase 0.25 14.5 H60-V18-V107 β-sheet 
10 1mtp serpin 0.26 11.8 Y200-T210-A218 β-sheet 
11 1eef heat-labile enterotoxin 0.26 13.5 T47-I39-E29  
12 1b99 NDPb 0.26 16.1 V46-Q44-L42    β-sheet 
13 2bk6 ferroxidase 0.26 17.6 L65-P71-S73  
14 1w0k Bovine F1-ATPase 0.27 16.3 E84-I34-D36  
15 1thz AICAR Tfasec 0.28 17.8 A218-L220-T222 β-sheet 
16 3gpd GAPDHd 0.28 12.3 T228-M230-F232 β-sheet 
17 1wwh MPPN domain 0.28 14.6 F30-N60-T58  
18 1d2r TrpRse 0.28 15.8 L300-I79-D41  
19 2awd 
LacC (togatose-6-
phosphate kinase) 
0.28 16.2 D91-I15-V33 β-sheet 
20 1iql 
human coagulation 
factor Xa 
0.28 17.6 W114-E111-L109 helix-loop 
21 2dys cytochrome C oxidase 0.28 18.9 P176-L160-I199  
22 1de4 HFE/β2m 0.28 19.1 D96-Y10-R12  
23 1hpv HIV-1 protease 0.29 11.5 L97-C95-I93 β-sheet 
24 1oux lectin LecB 0.3 14.7 R13-P112-L87 β-sheet 
25 1lem lentil lectin 0.3 14.1 S7-S5-T3 β-sheet 
26 1m3y capsid protein 0.3 17.0 Q120-R122-E49 β-sheet 
27 2nvx RNA polymerase II 0.3 17.7 
R1159-Q1193-
L1191 
β-sheet 
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Table 7.2.  continued. 
entry PDB proteins 
RMSD 
(Å) 
score 
residues 
(R1-R2-R3) 
secondary 
structure 
28 3fru neonatal Fc receptor 0.3 18.5 F22-L65-Y63 β-sheet 
29 1mdl mandelate racemase 0.3 18.6 P77-A79-S82  
30 1af6 maltoporin 0.3 19.0 S9-I11-W13 β-sheet 
31 1n1q Dps protein 0.3 20.7 A73-P71-L65  
32 1rav recombinant avidin 0.3 21.0 K93-M95-L97 β-sheet 
33 1s5c cholera holotoxin 0.31 13.9 T47-I39-E29  
34 1ukj L-methionine-lyase 0.31 14.5 Q34-S248-A87  
35 1pmo 
glutamate 
decarboxylase (GadB) 
0.31 16.1 S318-P320-Q323  
36 1ko0 
diaminopimelate 
decarboxylase 
0.31 15.9 A366-V287-Q289  
37 1go3 RPB4/RPB7 0.31 20.1 E88-E86-L84 β-sheet 
38 1i7t class I MHC HLA A2 0.31 20.1 Q32-V25-I23 β-sheet 
39 1hng 
T lymphocyte antigen 
glycoprotein 
0.31 20.5 P175-N173-V171  
40 1nnu 
enoyl acyl carrier 
reductase 
0.31 20.6 A216-I214-I167  
41 1y14 Rpb4/7 0.31 21.4 V86-D88-T90 β-sheet 
42 2gyy ASADHf 0.32 12.5 L206-I246-V248  
43 1t3n DNA polymerase 0.32 15.1 L361-R317-C383  
44 1hle 
leucocyte elastase 
inhibitor 
0.32 16.4 R27-L25-L23 β-sheet 
45 1rs8 NOSg 0.32 17.0 A358-D355-L343  
46 1huu HU protein 0.32 17.2 F50-P77-K75  
47 2ltn lectin 0.32 17.6 V116-I139-N148  
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Table 7.2.  continued. 
entry PDB proteins 
RMSD 
(Å) 
score 
residues 
(R1-R2-R3) 
secondary 
structure 
48 1xs4 dCTP deaminase 0.32 19.3 L88-L90-V138 β-sheet 
49 2mpr maltoporin 0.32 20.6 W13-I11-S9 β-sheet 
50 1shs heat-shock protein 0.33 14.8 V128-I57-I47  
51 1m5h formyltransferase 0.33 14.2 I201-Y245-A243  
52 1lob isolectin I 0.33 19.3 I87-F85-F83 β-sheet 
53 1vgr 
formyl-CoA 
transferase 
0.33 19.4 C144-A150-R252  
54 1qqw catalase 0.33 20.3 P341-A418-Q415  
55 1ohh F1-ATPase 0.33 20.7 E84-I34-D36  
56 2f0c 
receptor binding 
protein 
0.33 21.8 T187-T185-R183 β-sheet 
57 1ama 
aspartate 
aminotransferase 
0.33 22.7 V35-A37-K250  
58 1rj7 EDA-A1 0.33 23.7 A121-V123-L125 β-sheet 
a 3,4-PCD: protococatechute 3,4-dioxygenase. b NDP: nucleoside diphosphate kinase.  
 c AICAR Tfase: avian aminoimidazole-4-carboxamide ribonucleotide transformylase.  
d GAPDH: D-glyceraldehyde 3-phosphate dehydrogenase. e TrpRs:tryptophanyl-tRNA-  
synhtetase.  f ASADH: aspartate semialdehyde dehydrogenase. g NOS: nitric-oxide 
synthase. 
 
 
Data in Table 7.2 suggests derivatives of compound 1 with appropriate side-
chains are candidates for disruption of several PPIs of biomedicine importance.  These 
potential targets include: heat-labile enterotoxin/cholera toxin, aminoimidazole-4-
carboxamide ribonucleotide transforylase (AICAR Tfase), D-glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), HIV-1 protease, and nitric-oxide synthase (NOS).  
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Heat-labile enterotoxin and cholera toxin are directly associated with causing cholera 
and related enteropathies in human and domestic animals.136  AICAR Tfase catalyzes the 
last two steps in purine biosynthesis, which is a pathway that becomes activated in 
cancer cell types.137,138  GAPDH mediates oxidative phosphorylation of the aldehyde in 
the glycolytic pathway and implicates in apoptosis of cells associated with several 
neurodegenerative diseases. 139,140  HIV-1 protease is essential for the viral infectivity 
and propagation of AIDS.141 NOS catalyzes biosynthesis of NO and concomitant 
transformation of L-arginine to L-citrulline; it is expressed in various human disease 
states including infection (e.g. HIV and Malaria), chronic inflammation, 
neurodegeneration, and cancer.142  The next section describes HIV-1 protease as a target 
for disruption of PPIs in detail.  Closer consideration of the other potential targets is 
included in Appendix G. 
 
7.4 Dimerization Inhibitors for HIV-1 Protease 
HIV-1 protease is essential for the viral infectivity, and propagation of AIDS.141  
Combination therapies including HIV-1 protease inhibitors are front-line strategies for 
slowing the progression of this disease.143  Nevertheless, this approach is imperfect; 
strains of HIV resistant to combination therapies have emerged, and there are several 
undesirable side-effects.144  
HIV-1 protease exists as a stable homodimer for which the Gibbs energy of 
stabilization has been estimated to be ca 14.5 kcal/mol at 25 oC (pH 5), corresponding to 
a dissociation constants about 3.4 nM at 37 oC.145,146  Dimers of HIV-1 protease form the 
active site as illustrated in Figure 7.4, and without which the enzyme cannot be active; it 
is “an obligatory dimer”. 
The dimerization interface in HIV-1 protease is mainly formed by four stranded 
β-sheets on the N- and C- termini.  Specially, Cys95-The96-Lue97-Asn98-Phe99 and 
Pro1-Ile3-Leu5 account for about 75 % of the total binding energy.147  Mutation of 
Cys95 to Ala has little impact on the protease activity, and presumably on the 
dimerization energy.148  This is fortunate because methyl side-chains can be used in 
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place of –CH2SH groups, so peptidomimetics for the region are more easily made and 
manipulated.  
Peptides have been designed to perturb the dimerization interface of HIV-1 
protease.  These were based on the C- terminus,146 the C- and N- termini separately,149-
151 the C- and N- termini linked by a hydrophobic chain, 152-154 or C- and N- terminal 
peptides linked through a side-chain.155  These peptide-based compounds are unlikely to 
be cell permeable, and we can find no evidence in the literature that indicates otherwise.  
This problem has motivated some researchers to combine these types of peptides with 
HIV-TAT.156 
A few peptidomimetics of “dimer-disrupting” peptides for HIV-1 protease have 
been prepared.  Chmielewski’s group synthesized a cross-linked peptoid scaffold for the 
C- and N- termini; these gave low micromolar IC50 values in fluorescence-based 
inhibition assays for HIV-1 protease.157  A few peptidic compounds were prepared by 
incorporating Bartlett’s @tide residues and gave compounds with Kd values of about 400 
nM.158  It has also emerged that some non-peptidic compounds that inhibit the enzymes 
activity by binding the active site can also act as dimerization inhibitors by binding at the 
protein-protein interface.159  
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Figure 7.4.  Structure of HIV-1 protease from 1hpv. 
 
 
Mining of the database using EKO for stereomer 1 gave six different results for 
HIV-1 protease within RMSD 0.33 Å (1hpv, 1gno, 1ytg, 2fde, 1mtb, and 9hvp); in all 
these cases the C- terminal interface residues Ile93-Cys95-Leu97 were implicated.  
These residues correspond to the region of the HIV-1 protease dimer where the C- and 
N-termini interact to form a four-strand sheet network (Figure 7.5). Cys95 and Leu97 
correspond to a hot-spot region that was suggested based on thermodynamic studies.147  
The best match (from 1hpv) has an RMSD 0.29 Å and score 11.5, and represents a 
conformer of 1 that is only 1.24 kcal/mol over the lowest energy conformation located.   
 
 
active site
dimerization site
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Figure 7.5.  Overlay identified from EKO. 
 
 
We applied eKO to the HIV-1 protease crystal structure 1hpv160 to find more 
possible matching regions sets for compounds 1.  This revealed stereomer 1 also 
overlaid Cys95-Leu97-Phe99, but with a higher RMSD 0.46 Å and score 19.8 (∆Go = 
1.38 kcal/mol, Figure 7.6a).  That residue set exactly corresponds to the hot-spot region 
on the C- terminus.  Moreover, we found N-terminal matches; specifically, preferred 
conformers of the template overlaid with Leu5-Ile3-Pro1 (RMSD (0.64 Å and score 
22.8; Figure 7.6b).  All these three residues are implicated in a hot-spot region.147  
Similar results were obtained from eKO-analyses of other crystal structures (1gno, 1ytg, 
2fde, 1mtb, and 9hvp).   
 
 
 
 
 
 
 
 
 
 
I93
C95 L97
 148 
a 
 
 
b 
 
Figure 7.6.  Overlays identified from eKO. 
 
 
Our ability to test compounds based on these analyses were limited because the 
structures are relatively difficult to make.  Dr Arjun Raghuraman could only prepare two 
deprotected putative analogs of the HIV-1 protease C-terminus in the time available.  
However, he also provided two protected forms, and several intermediates, and I was 
able to combine two of these intermediates to give a bridged compound with 2 x 2 side 
chains that we predicted might impact the C- and N-termini in the dimerization region. 
 
 
C95
L97
F99
L5 I3 P1
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7.5 Bioassays to Validate Disruption of HIV-1 Protease Dimerization 
The C-protected (1a and 1b) and unprotected (1a’ and 1b’) compounds in Figure 
7.7b were prepared for an inhibition assay.  Intermediates (9a, 9a’, 10a, 10a’, and 11a’) 
and the bivalent mimic (12) in Figure 7.7a and c were also tested.   
These compounds have side chains corresponding to the HIV-1 dimerization 
interface, except that the cysteine side-chain (corresponding to Cys95) was replaced by 
Ala.   Previous studies have shown HIV-1 protease mutants wherein Cys95 was replaced 
with Ala have almost the same Kd for the dimer dissociation,148 hence we used Ala 
instead of Cys95 in syntheses. 
 
 
a 
 
 
 
Figure 7.7.  Compounds for HIV-1 inhibition assay.  Prime on labels indicates the C-
unprotected forms. 
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Figure 7.7.  continued. 
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The HIV-1 protease inhibitory activities of the compounds were determined by a 
FRET method.156,157,161  HIV-1 protease (Q7K) was kindly provided by Dr Celia Schiffer 
at University of Massachusetts Medical School.  HIV-1 protease stock solution was 
diluted with assay buffer (0.1 M sodium acetate, 1.0 M sodium chloride, 1.0 mM EDTA, 
1.0 mM DTT, 10% DMSO, and 1.0 mg/mL BSA, pH 4.7).156  All inhibitors were 
dissolved in DMSO, and diluted to appropriate concentrations with deionized water such 
that the maximum concentration of DMSO in the buffer was 8.5 %.  EDANS/DABCYL-
based FRET peptide substrate (Ex/Em=340/490 nm) solution in SensoLyte® 490 HIV 
Protease Assay Kit (Cat. # 71127) and HiLyte FluorTM 488/QXLTM 520-based FRET 
peptide substrate (Ex/Em=490/520 nm) solution in SensoLyte® 520 HIV Protease Assay 
Kit (Cat. # 71147) were purchased from Anaspec.  We needed to use these two different 
substrates because the compounds without C-protection (1a’, 1b’, 9a’, 10a’, and 11a’) 
have weak fluorescence that interferes with that from the EDANS/DABCYL-based 
FRET peptide substrate (Ex/Em=340/490 nm) so an alternative substrate was used.  
Concentrations of the substrates are proprietary information of Anaspec, hence we 
followed a protocol for the substrate preparation in the assay kit. 
For the determination of IC50 values, HIV-1 protease (40 µL, 10.2 nM final 
concentration) and inhibitors (10 µL) were incubated for 15 min at 25 oC.  Substrate 
solutions (50 µL) in the buffer were added into the incubated solution to initiate the 
reaction.  EDANS/DABCYL-based FRET peptide substrate was used for C-protected 
inhibitors, and HiLyte FluorTM 488/QXLTM 520-based FRET peptide substrate was used 
for deprotected inhibitors.  The total assay volume was 100 µL.  Fluorescence was 
monitored for 5 min at 30 oC in a fluorescence microplate reader (BioTek) at 
Ex/Em=340/490 nm for C-protected inhibitors, and Ex/Em=490/520 nm for deprotected 
inhibitors.  The initial velocities were plotted against log[inhibitor] and a sigmoidal 
curve was fitted to the data points using Graphpad Prism 5 software to obtain IC50 
values. 
We obtained the best IC50 (3.7 ± 0.3 µM) for inhibition of HIV-1 protease from 
compound 1a’ (Figure 7.8).  Other results are summarized in Table 7.3.  Overall, the 
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compounds with three side-chains 1a, 1a’, 1b, and 1b’ gave better inhibition effects than 
two side-chain compounds 9a, 9a’, 10a, 10a’, and 11a’, and C-deprotected compounds 
1a’ and 1b’ showed better inhibition than protected forms (1a and 1b).  Comparison of 
10a, 10a’ and 12 reveals that compound 10a’ did not show any inhibition, but the 
corresponding bivalent compound 12 showed two times better inhibition than trimer 
10a. 
 
 
 
Figure 7.8.  Determination of the IC50 value for inhibition of HIV-1 protease using 1a’. 
 
 
To explore if these compounds inhibit dimerization of HIV-1 protease, we 
carried out a Zhang-Poorman kinetic assay.146,156  If a compound acts as a dimerization 
inhibitor, the Zhang-Poorman plot gives a line with a slope similar to that obtained for 
the uninhibited control but with a different intercept; active-site inhibitors yield different 
slopes compared with the uninhibited control.  For this assay, HIV-1 protease was used 
at concentrations from 0.6 to 5.1 nM.  Substrate solutions were diluted to 1/4 solution 
from the original solution, and then used for the kinetic assay.  HIV-1 protease (40 µL) 
was incubated with or without an inhibitor (10 µL) at the desired concentration for 15 
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min at 25 oC.  The diluted substrate solution (50 µL) was added to the incubated 
solution.  Fluorescence was monitored for 15 min at 30 oC in a fluorescence microplate 
reader (BioTek) at Ex/Em=340/490 nm for C-protected inhibitors, and Ex/Em=490/520 
nm for deprotected inhibitors. 
Figure 7.9a shows Zhang-Poorman plots for C-protected compounds, 1a and 1b.  
Slopes for 1a (10.4 ± 1.0) and 1b (9.5 ± 0.6) are similar with one for uninhibited HIV-1 
(9.7 ± 0.7) with significantly different y-intercepts (1a y-intercepts 2.6, 1b y-intercepts 
1.4, control y-intercepts 0.42); these observations indicate the compounds are acting as 
dimerization inhibitors (see below).  The deprotected compounds 1a’ and 1b’ also 
showed similar patterns as illustrated in Figure 7.9b.  Slopes for 1a’ (8.2 ± 0.6) and 1b’ 
(9.3 ± 1.2) compared with uninhibited HIV-1 (9.0 ± 0.6) have different y-intercepts (1a’ 
y-intercepts 0.19, 1b’ y-intercepts 0.73, control y-intercepts 0.013).  y-Intercepts of 
uninhibited HIV-1 have different values between experiments for C-protected and 
deprotected compounds because the substrates used in the assay are different (see 
above).  The results are consistent with 1a, 1a’, 1b, and 1b’ acting as dimerization 
inhibitors.  Ki values calculated from the y-intercepts using the Zhang-Poorman equation 
are summarized in Table 7.3.  We note that it has been reported that inhibition of HIV-1 
protease activities by dimerization inhibitors is dependent on the time of pre-incubation 
with the enzyme and inversely dependent on enzyme concentration; consequently, these 
factors must be standardized if comparing our data with those from different labs.   
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a                                                                   b 
 
Figure 7.9.  Zhang-Poorman analyses for (a) 1a (LAI-OtBu), 1b (FLA-OtBu), and 
uninhibited HIV-1 protease; and, (b) 1a’ (LAI-OH), 1b’ (FLA-OH), and uninhibited 
HIV-1 protease.  
 
 
Table 7.3.  Summary of IC50 and Ki. 
compounds sequences  IC50 (µM) Ki (µM) 
    
9a FL-OtBu 516.3  
9a’ FL-OH 418.7  
10a LA-OtBu 176.4 ± 16  
10a’ LA-OH - - 
11a’ LI-OH 623.2  
1a LAI- OtBu 111.1 ± 18 19.4 ± 4.1 (at 100 µM) 
1a’ LAI-OH 3.7 ± 0.4 0.38 ± 0.07 (at 5 µM) 
1b FLA- OtBu 54.9 ± 6 21.0 ± 2.1 (at 50 µM) 
1b’ FLA-OH 46.5 ± 8 0.93 ± 0.3 (at 50 µM) 
12 LA-LA 84.4 ± 10  
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7.6 Conclusion 
PPIs are important but under-exploited therapeutic targets.  Many methods have 
been developed to identify small molecules that disrupt PPIs.  Existing computational 
methods tend to focus on how small pharmacophores bind protein surfaces through 
analyses of protein surfaces and fragment methods.  However, these methods are limited 
by the difficulties in clustering fragments into one molecule, and they are only 
applicable to certain protein targets.  Thus, most active compounds have been found by 
screening huge libraries via high throughput screen (HTS).  However, there are several 
problems for HTS; it is time-consuming, expensive, slow, unreliable, and the rates for 
finding active compounds are low.  Therefore, more effective methods to design small 
molecules that mimic or disrupt PPIs are highly desirable. 
Exploring Key Orientations (EKO) is an algorithm that uses a virtual affinity 
approach to find PPIs for preferred conformations of semi-rigid molecular scaffolds that 
display amino acid side-chains.  EKO works by identifying conformations that adopt the 
same orientation as one protein component at the interface via matching Cα and Cβ 
coordinates for three side-chains.  This strategy is distinct from existing methods 
because it; (i) focuses on conformations of one molecule, not fragments from several 
molecules, (ii) mines the conformations for whole protein-protein interfaces, not for 
specific structures, active sites, or hot-spots, (iii) finds the best matching between three 
Cα – Cβ bond vectors of small molecule conformations and protein interface regions. 
We applied EKO for pyrrolinone-pyrrolidine oligomer scaffold 1.  EKO found 
58 different possible targets including heat-labile enterotoxin/cholera toxin (cholera), 
AICAR (cancer), GAPDH (neurodegenerative disease), HIV-1 protease (AIDS), and 
NOS (AIDS, neurodegenerative disease, and cancer).  HIV-1 protease dimerization 
inhibition assays were carried out to seek the first evidence for experimental validation.   
For the assays, compounds 1a and 1a’ that were obtained by EKO, compounds 
1b, and 1b’ that were obtained by eKO, and their intermediates 9 – 12 were synthesized, 
and tested for FRET based assays.  Three side-chains compounds 1a, 1a’, 1b, and 1b’ 
showed better inhibition effects than two side-chains compounds 9 - 12.  Unprotected 
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forms 1a’ and 1b’ gave better activities than C-protected form 1a and 1b.  Moreover, 
Zhang-Poorman analyses for the three side-chains compounds 1a, 1a’, 1b, and 1b’ 
proved that the compounds are inhibitors for HIV-1 protease dimerization, not for the 
active site.   
We developed the new method, EKO which can identify a small molecule being 
able to disrupt PPIs, and the biology data validated the function.  We have already 
applied EKO to other scaffolds, and have found many interesting targets.   
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CHAPTER VIII 
CONCLUSIONS 
Originally, our group designed small molecules that mimic β-turn regions that 
are known to be hot-spots for binding of neurotrophins to Trk receptors.  Our original 
leads, before I joined the group, were peptide-containing macrocycles, and I followed 
others in the group by relating these to minimalist mimics.  Specifically, I made small 
molecules based on rigid scaffolds with triazole or pyrrole units that substitute for 
peptide backbones; these are only peptidomimetics because they displayed amino acid 
side-chains, i.e. they are minimalist mimics.  Several triazole-based minimalist mimics 
were synthesized, then assembled into bivalent mimics via a combinatorial method.   
Four bivalent peptidomimetics that were prepared in Chapter I selectively bound 
to TrkC receptor, and showed partial antagonistic effects for the TrkC receptor.  It is 
important to find active compounds that selectively bind to Trk receptors, because the 
selective binding for each Trk receptor leads to different effects on cells such as growth 
and apoptosis.  Moreover, such compounds can be very useful pharmacological probes 
that target neurodegenerative diseases or cancers.  In fact, we applied another triazole-
based bivalent mimics that selectively bind to TrkC receptor to targeted drug delivery on 
TrkC overexpressed cells as described in Chapter III.  TrkC receptors are overexpressed 
in cancers such as prostate, medulloblastoma, neuroblastoma, malignant melanoma, and 
pancreatic cancer.  Antiproliferative assays showed the compounds conjugated with 
cytotoxic drugs targeted TrkC cells selectively over wild-type cells; more cytotoxicity 
for TrkC cells was shown than for wild-type cells.   
In previous studies, we had a target, Trk receptors, for our small molecules, and 
the compounds were designed to mimic specific secondary structure (in this case, β-turn) 
on neurotrophins that are natural ligands for Trk receptors.  However, application of 
triazole-based bivalent peptidomimetics in Chapter IV was different.  Although 
originally the triazole-based bivalent mimics were designed as mimics of β-turns, the 
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compounds were screened for various cancer cells via high-throughput screening 
(specifically through the Luciferase assay), and KB1005 in the library was found to 
target pancreatic cancer cells.  Cancer cells express a complicated set of cell surface 
receptors.  Therefore, we do not know through which pathway the compound targets the 
cancer cells.  This result is significant because we were able to find a mimic for an 
unknown target without any structural information.   
At this stage we became aware that some minimalist mimics could resemble 
more than one secondary structure, and this led us to develop the idea that some 
compounds could be “universal peptidomimetics”.  Universal peptidomimetics are small 
sets of such scaffolds designed to analog local pairs of amino acids including non-
contiguous ones in any secondary structures.  These types of compounds are especially 
useful for targets where binding conformations are unknown, because the compounds 
can mimic any structures in protein-protein interfaces.  Therefore, the peptidomimetics 
libraries are useful for high-throughput screening against various targets; our previous 
study that found KB1005 as a target for pancreatic cancer cells via HTS proved this.  
Moreover, we performed a molecular modeling, density functional theory (DFT) 
calculations, and quantum molecular dynamics (QMD) for other new templates such as 
oxazoline-, pyrrole-, dyine- “kinked” and “linear” bistrizole-based peptidomimetics to 
validate our idea more.   
In that work, we used Cβ - Cβ separations to give a “rough cut” to fit mimics to 
secondary structures.  However, Cα - Cβ bond vectors are a more sophisticated standard 
because they depict how the side-chains project.  Computational methods were required 
to match Cα - Cβ bond vectors for mimics and ideal secondary structures.  We 
developed the Cα - Cβ vector-matching program to do this, and applied the program to 
new templates such as omegatides and pyrrolinone-pyrrolidine oligomers with three 
amino acid side-chains.  We were especially interested in three side-chains because 
scaffolds with three side-chains roughly correspond to tripeptides; strands of three amino 
acids have been recognized minimal motifs for effective molecular interactions.  Both 
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omegatides and pyrrolinone-pyrrolidine oligomers matched better with strand structures 
than for helices.   
At this stage we became more convinced that structural information on protein-
protein interactions (PPIs) had to be more useful in discovery of small “drug-like” 
pharmacological probes and pharmaceutical leads for these targets than it currently was.  
Consequently, we developed the Exploring Key Orientations (EKO) algorithm that uses 
a virtual affinity approach to find PPIs for preferred conformations of semi-rigid 
molecular scaffolds that display amino acid side-chains.  This strategy is distinct from 
existing methods to find small molecules that can disturb PPIs because it; (i) focuses on 
conformations of one molecule, not fragments from several molecules, (ii) mines the 
conformations for whole protein-protein interfaces, not for specific structures, active 
sites, or hot-spots, (iii) finds the best matching between three Cα – Cβ bond vectors of 
small molecule conformations and protein interface regions.  We applied EKO to 
pyrrolinone-pyrrolidine oligomers to find targets, and she found several interesting 
targets relative to diseases, such as heat-labile enterotoxin/cholera toxin (cholera), 
AICAR (cancer), GAPDH (neurodegenerative disease), HIV-1 protease (AIDS), and 
NOS (AIDS, neurodegenerative disease, and cancer).  HIV-1 dimerization inhibition 
assays and Zhang-Poorman kinetic assays were performed to validate our hypothesis for 
one of these targets (HIV-1 protease), and the results showed that pyrrolinone-
pyrrolidine oligomer derivatives inhibited HIV-1 dimerization.   
Others in the group are already beginning to design and synthesize compounds 
that conform to our chemotype guidelines for small molecules to perturb protein protein 
interactions.  It is becoming clear that the pyrrolinone-pyrrolidine oligomer is not an 
optimal design mainly because we cannot make the compounds efficiently enough to 
explore all the targets that EKO has exposed.  Consequently, I expect better scaffold 
designs and more topical PPI targets than HIV-1 protease to emerge from the future 
work.  My studies are simply the first of what we anticipate will be a much longer-term 
program on data mining small molecules designed for PPIs. 
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APPENDIX A 
GENERAL EXPERIMENTAL PROCEDURES 
A. General Methods  
All reactions were carried out under an atmosphere of dry nitrogen. Glassware was 
oven-dried prior to use. Unless otherwise indicted, common reagents or materials were 
obtained from commercial source and used without further purification. All α-amino 
acids used were of the L-configuration, except where otherwise indicated. Triethylamine 
(TEA) was obtained anhydrous by distillation over calcium hydride and tetrahydrofuran 
(THF) was distilled over sodium metal and benzophenone. Acetonitrile, 
dichloromethane, methanol and diethyl ether were dried by a Mbraun solvent drying 
system.  
Flash column chromatography was performed using silica gel 60 (230-400 mesh). 
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel plates 
with QF-254 indicator and visualized by UV. Optical rotations were measured on Jasco 
DIP-360 digital polarimeter. 1H and 13C NMR spectra were recorded on a Varian 300 
(300 MHz 1H; 75 MHz 13C) or Varian 500 (500 MHz 1H; 125 MHz 13C) spectrometer at 
room temperature.  Chemical shifts were reported in ppm relative to the residual CDCl3 
(δ 7.27 ppm 1H; δ 77.0 ppm 13C), CD3OD (δ 3.31 ppm 1H; δ 49.86 ppm 13C), or d6-
DMSO (δ 2.49 ppm 1H; δ 39.5 ppm 13C).  NMR chemical shifts were expressed in ppm 
relative to internal solvent peaks, and coupling constants were measured in Hz. (br = 
broad). 
Analytical HPLC analyses were carried out on 150 x 4.6 mm C-18 column using 
gradient conditions (10 – 90% B, flow rate = 0.75 mL/min). Preparative HPLC was 
carried out on 100 x 21.2 mm C-18 column using gradient conditions (10 – 70% B, flow 
rate = 10.0 mL/min). The eluents used were: solvent A (H2O with 0.1% TFA) and 
solvent B (CH3CN with 0.1% TFA)  
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APPENDIX B 
EXPERIMENTAL FOR CHAPTER II 
A. General Procedure and Preparation of Monovalent Mimics 8  
Total 14 monovalent mimics were prepared by the following procedure in different 
sequence order of β-turn regions, e.g. i+1 and i+2 (TG) and i+2 and i+1 (GT).  To the 
solution of 11-bromoundecanoic acid (1.0 equiv) in CH2Cl2 (1.0 M) was added oxalyl 
chloride (10.0 equiv).  The mixture was stirred at 25 °C for 2 h, and then the solvent was 
removed.  To remove the excess oxalyl chloride, CH2Cl2 was added in the resulting 
residue, and then was removed under vacuum (x2).  The resulting residue was dissolved 
in CH2Cl2 (1.0 M), and then Boc-piperazine (1.0 equiv), and TEA (2.5 equiv) were 
added in the solution.  The mixture was stirred at 25 °C for 4 h.  After the solvent was 
removed under vacuum, the reaction mixture was diluted with H2O and extracted with 
EtOAc, and washed with brine.  The combined organic phases were dried over MgSO4. 
After completely removing the solvent, the compound 4 was purified by flash 
chromatography (1:3 EtOAc/Hexanes).  To the solution of compound 4 (1.0 equiv) in 
DMF (0.09 M) was added K2CO3 (1.05 equiv), and then the mixture was stirred at 90 °C 
for 14 h. The reaction mixture was diluted with H2O and extracted with EtOAc.  The 
combined organic phases were dried over Na2SO4. After completely removing the 
solvent, the compound 5 was purified by flash chromatography (2:5 EtOAc/Hexanes).  
The compound 6 (1.0 equiv) was dissolved in EtOH (0.16 M), and then hydrazine (4.0 
equiv) was added in the solution.  The mixture was refluxed at 90 °C for 4 h.  After the 
reaction, the mixture was filtered, and then the solution was concentrated.  Compound 6 
was used for the next step without further purification.  HOBt (1.1 equiv) and EDCI (1.1 
equiv) were added to the solution of compound 3 (1.0 equiv) in CH2Cl2 (0.2 M) at 0 °C. 
The mixture was stirred at 0 °C for 15 min, and then NMM (2.0 equiv) and compound 6 
(1.0 equiv) were added into the mixture.  After the solution was warmed up to 25 °C, the 
mixture was stirred at the temperature for 16 h. The solvent was removed, and then the 
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resulting residue was diluted with H2O and extracted with EtOAc. The combined organic 
layer was washed with 5% HCl (aq.), followed by 5% Na2CO3 (aq.), and brine, and then 
dried over Na2SO4. After completely removing the solvent, the compound 7 derivatives 
were purified by flash chromatography (EtOAc/Hexanes). Compound 7 (1.05 equiv) and 
6 (1.0 equiv) were dissolved in THF:H2O (5:1, 0.25 M), and then copper powder (1.0 
equiv) and 1N CuSO4 (aq., 0.01 equiv) were added. The mixture was stirred at 25 °C for 
24 - 48 h.  After the reaction, copper powder was filtered on celite with CH2Cl2 or 
EtOAc. The filtrate was washed with sat. NH4Cl (aq.): NH4OH (v:v=9:1), and brine. The 
organic layer was dried over Na2SO4. After completely removing the solvent, the 
compound 8 derivatives were purified by flash chromatography (MeOH:CH2Cl2).   
 
Scheme S1.   Preparation of Monovalent Mimics with Long Linkers.  
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B. General procedure and Preparation of Bivalent Mimics 1 
General syntheses for bivalent mimics were modified from the published papers.  
Compounds 8 (1.0 equiv) were treated with 50% TFA in CH2Cl2 for 12h at 25 ºC and 
then the solvent was removed.  The resulting residue was dissolved in THF (0.04 M), 
and DTAF (1.0 equiv or tag with biotin) and K2CO3 (4.0 equiv) were added.  The 
suspension was stirred for 18 h at 25 ºC and then the solvent was removed.  It was used 
for the next step without further purification.  The resulting crude product was dissolved 
in DMSO (0.04 M), and then another deprotected compound and K2CO3 (4.0 equiv) 
were added.  The suspension was stirred for 10 – 14 days at 25 °C.  After monitoring 
staring materials’ disappearance by analytical HPLC, the mixture was lyophilized to 
remove DMSO. The materials were re-dissolved in 1:1 mixture of H2O/CH3CN, and 
then purified by preparative HPLC to yield the final products.  HCl (30 ml) and brine (30 
ml), dried with Na2SO4, and concentrated under reduced pressure.  Flash 
chromatography of the residue provided pure bivalent mimics 1.   
 
 
 
 
 
 
 
R1
Cu powder, 1N CuSO4
THF/H2O (5:1)
25 oC, 24 - 48 h
N
H
N
NBoc
O
5
N
O
R2
NN
R1
8, 60-86%
2
R1R2 = IK, EK, GK, MS, SK, IR, TG
             KI, KE, KG, SM, KS, RI, GT
 179 
Scheme S2.   Preparation of the Tagged Bivalent Peptidomimetics 1. 
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Table S1. Characterization of Compounds with TEG. 
 
 
 
 
 
 compound 
code 
sequence 
(R1R2-
R3R4) 
SEDEX 
purity 
(%) 
retention 
time 
(min) 
chemical formula [M+H]
+ 
calculated 
[M+H]
+ found 
1 KB1365 KI-KI 100 19.0 C68H121N18O7 1302.0 1302.0 
2 KB1366 KI-KG 100 17.0 C64H113N18O7 1245.7 1245.9 
3 KB1367 KI-KE 100 17.2 C67H117N18O9 1317.9 1317.9 
4 KB1368 KI-KS 100 16.6 C65H115N18O8 1275.9 1275.8 
5 KB1369 KI-GT 100 16.7 C62H108N17O8 1218.9 1218.9 
6 KB1370 KI-RI 100 19.6 C68H121N20O7 1330.0 1330.0 
7 KB1371 KI-SM 100 17.0 C64H112N17O8S 1278.9 1278.9 
8 KB1372 KG-KG 100 15.6 C60H105N18O7 1189.8 1189.8 
9 KB1373 KG-KE 100 14.4 C63H109N18O9 1261.9 1262.0 
10 KB1374 KG-KS 100 13.2 C61H107N18O8 1219.9 1219.8 
11 KB1375 KG-GT 100 14.8 C58H100N17O8 1162.8 1162.7 
12 KB1376 KG-RI 100 17.6 C64H113N20O7 1273.9 1273.8 
13 KB1377 KG-SM 100 16.9 C60H104N17O8S 1222.8 1222.8 
14 KB1378 KE-KE 100 15.0 C66H113N18O11 1333.9 1333.9 
15 KB1379 KE-KS 91 14.9 C64H111N18O10 1291.9 1291.9 
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N NN
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16 KB1380 KE-GT 100 16.7 C61H104N17O10 1234.8 1234.7 
17 KB1381 KE-RI 100 17.1 C67H117N20O9 1345.9 1345.8 
18 KB1382 KE-SM 100 16.7 C63H108N17O10S 1294.8 1294.8 
19 KB1383 KS-KS 100 14.7 C62H109N18O9 1249.9 1249.9 
20 KB1384 KS-GT 100 14.4 C59H102N17O9 1192.8 1192.8 
21 KB1385 KS-RI 100 17.3 C65H115N20O8 1303.9 1303.9 
22 KB1386 KS-SM 100 17.0 C61H106N17O9S 1252.8 1252.8 
23 KB1387 GT-GT 100 15.3 C56H95N16O9 1135.7 1135.6 
24 KB1388 GT-RI 100 18.8 C62H108N19O8 1246.9 1246.9 
25 KB1389 GT-SM 98 18.1 C58H99N16O9S 1195.8 1195.6 
26 KB1390 RI-RI 100 18.9 C68H121N22O7 1358.0 1357.9 
27 KB1391 RI-SM 100 19.7 C64H112N19O8S 1306.9 1306.9 
28 KB1392 SM-SM 100 18.8 C60H103N16O9S2 1255.8 1255.7 
29 KB1393 SM 100 15.7 C24H45N6O3S 497.3 497.1 
30 KB1394 RI 100 11.3 C28H54N9O2 548.4 548.3 
31 KB1395 KI 100 11.5 C28H54N7O2 520.4 520.2 
32 KB1396 KG 100 10.0 C24H46N7O2 464.4 464.1 
33 KB1397 KE 100 10.1 C27H50N7O4 536.4 536.2 
34 KB1398 KS 100 8.6 C25H48N7O3 494.4 494.1 
35 KB1399 GT 100 9.7 C22H41N6O3 437.3 437.1 
36 KB1445 TG-TG 98 14.5 C56H95N16O9 1135.8 1135.5 
37 KB1446 TG-MS 100 15.8 C58H99N16O9S 1195.8 1195.6 
38 KB1447 TG-EK 96 13.8 C61H104N17O10 1234.8 1234.6 
39 KB1448 TG-GK 100 14.2 C58H100N17O8 1162.8 1162.5 
40 KB1449 TG-SK 100 14.4 C59H102N17O9 1192.8 1192.8 
41 KB1450 TG-IK 100 16.3 C62H108N17O8 1218.9 1218.6 
42 KB1451 TG-IR 94 17.1 C62H108N19O8 1246.9 1246.7 
43 KB1452 MS-MS 90 17.2 C60H103N16O9S2 1255.8 1255.8 
44 KB1453 MS-EK 93 14.9 C63H108N17O10S 1294.8 1294.8 
45 KB1454 MS-GK 100 16.8 C60H104N17O8S 1222.8 1222.6 
46 KB1455 MS-SK 100 14.9 C61H106N17O9S 1252.8 1252.7 
47 KB1456 MS-IK 92 17.7 C64H112N17O8S 1278.9 1278.7 
48 KB1457 MS-IR 100 17.8 C64H112N19O8S 1306.9 1306.7 
49 KB1458 EK-EK 100 12.9 C66H113N18O11 1333.9 1333.8 
50 KB1459 EK-GK 97 13.0 C63H109N18O9 1261.9 1261.9 
51 KB1460 EK-SK 100 12.5 C64H111N18O10 1291.9 1292.0 
52 KB1461 EK-IK 84 15.7 C67H117N18O9 1317.9 1318.0 
53 KB1462 EK-IR 98 17.0 C67H117N20O9 1345.9 1346.0 
54 KB1463 GK-GK 100 13.4 C60H105N18O7 1189.8 1190.1 
55 KB1464 GK-SK 95 13.5 C61H106N18O8 1218.8 1218.7 
56 KB1465 GK-IK 99 15.4 C64H113N18O7 1245.9 1245.7 
57 KB1466 GK-IR 96 15.6 C64H113N20O7 1273.9 1273.8 
58 KB1467 SK-SK 100 12.9 C62H109N18O9 1249.9 1249.7 
59 KB1468 SK-IK 100 14.8 C65H115N18O8 1275.9 1275.7 
60 KB1469 SK-IR 89 15.4 C65H115N20O8 1303.9 1303.7 
61 KB1470 IK-IK 100 16.5 C68H121N18O7 1302.0 1302.0 
 182 
62 KB1471 IK-IR 100 17.8 C68H121N20O7 1330.0 1329.8 
63 KB1472 IR-IR 100 17.6 C68H121N22O7 1358.0 1357.7 
64 KB1473 TG 100 8.9 C22H41N6O3 437.3 437.1 
65 KB1474 MS 97 11.1 C24H45N6O3S 497.3 497.2 
66 KB1475 EK 100 8.6 C27H50N7O4 536.4 536.3 
67 KB1476 GK 100 8.8 C24H46N7O2 464.4 464.2 
68 KB1477 SK 94 8.0 C25H48N7O3 494.4 494.2 
69 KB1478 IK 94 11.4 C28H54N7O2 520.8 520.3 
70 KB1479 IR 100 11.4 C28H54N9O2 548.4 548.4 
71 KB1480 TG-Cap 100 13.6 C38H64N11O7 786.5 786.3 
72 KB1481 MS-Cap 100 15.8 C40H68N11O7S 846.5 845.3 
73 KB1482 EK-Cap 100 10.9 C43H73N12O8 885.6 885.2 
74 KB1483 GK-Cap 100 14.2 C40H69N12O6 813.5 813.3 
75 KB1484 SK-Cap 99 12.3 C41H71N12O7 843.6 843.3 
76 KB1485 IK-Cap 100 16.1 C44H77N12O6 869.6 869.4 
77 KB1486 IR-Cap 100 18.0 C44H77N14O6 897.6 897.4 
78 KB1551 KI-IK 100 17.5 C68H121N18O7 1302.0 1301.8 
79 KB1552 KI-GK 100 15.6 C64H112N18NaO7 1267.9 1267.8  
80 KB1553 KI-EK 100 16.9 C67H117N18O9 1317.9 1318.1 
81 KB1554 KI-SK 100 15.1 C65H115N18O8 1275.9 1275.6 
82 KB1555 KI-TG 100 16.9 C62H108N17O8 1218.9 1219.0 
83 KB1556 KI-MS 100 18.7 C64H112N17O8S 1278.9 1278.9 
84 KB1557 KG-IK 100 17.0 C64H113N18O7 1245.9 1246.0 
85 KB1558 KG-GK 100 14.7 C60H104N18NaO7 1211.8 1211.8 
86 KB1559 KG-EK 100 14.6 C63H109N18O9 1261.9 1261.9 
87 KB1560 KG-SK 100 14.1 C61H107N18O8 1219.9 1219.8 
88 KB1561 KG-TG 100 14.1 C58H100N17O8 1162.8 1162.9 
89 KB1562 KG-IR 100 18.0 C64H113N20O7 1273.9 1274.1 
90 KB1563 KG-MS 100 16.6 C60H104N17O8S 1222.8 1222.6 
91 KB1564 KE-IK 100 16.4 C67H117N18O9 1317.9 1318.1 
92 KB1565 KE-GK 99 13.5 C63H109N18O9 1261.9 1261.8 
93 KB1566 KE-EK 100 15.0 C66H113N18O11 1333.9 1333.9 
94 KB1567 KE-SK 100 13.2 C64H110N18NaO10 1313.9 1313.9 
95 KB1568 KE-TG 87 14.3 C61H104N17O10 1234.8 1234.9 
96 KB1569 KE-IR 99 16.7 C67H117N20O9 1345.9 1346.0 
97 KB1570 KE-MS 100 15.4 C63H108N17O10S 1294.8 1294.6 
98 KB1571 KS-IK 100 16.0 C65H115N18O8 1275.9 1275.8 
99 KB1572 KS-GK 97 13.6 C61H107N18O8 1219.9 1219.9 
100 KB1573 KS-EK 100 14.9 C64H111N18O10 1291.9 1291.9 
101 KB1574 KS-SK 100 14.9 C62H109N18O9 1249.9 1249.8 
102 KB1575 KS-TG 100 14.6 C59H102N17O9 1192.8 1192.7 
103 KB1576 KS-MS 99 15.4 C61H106N17O9S 1252.8 1252.5 
104 KB1577 GT-IK 100 17.6 C62H108N17O8 1218.9 1218.7 
105 KB1578 GT-GK 100 14.4 C58H100N17O8 1162.8 1162.9 
106 KB1579 GT-EK 100 16.2 C61H104N17O10 1234.8 1234.8 
107 KB1580 GT-SK 100 14.4 C59H102N17O9 1192.8 1192.9 
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108 KB1581 GT-TG 100 14.9 C56H95N16O9 1135.7 1135.9 
109 KB1582 GT-IR 100 17.1 C62H108N19O8 1246.9 1247.0 
110 KB1583 GT-MS 100 16.4 C58H99N16O9S 1195.8 1195.7 
111 KB1584 RI-IK 100 19.3 C68H121N20O7 1330.0 1330.0 
112 KB1585 RI-GK 100 16.5 C64H113N20O7 1273.9 1273.9 
113 KB1586 RI-EK 100 17.3 C67H117N20O9 1345.9 1346.1 
114 KB1587 RI-SK 100 15.7 C65H115N20O8 1303.9 1304.1 
115 KB1588 RI-TG 100 17.2 C62H108N19O8 1246.9 1246.6 
116 KB1589 RI-MS 100 18.2 C64H112N19O8S 1306.9 1306.6 
117 KB1590 SM-IK 100 17.8 C64H112N17O8S 1278.9 1278.7 
118 KB1591 SM-GK 100 15.7 C60H104N17O8S 1222.8 1222.8 
119 KB1592 SM-EK 100 14.6 C63H108N17O10S 1294.8 1294.9 
120 KB1593 SM-SK 100 15.0 C61H106N17O9S 1252.8 1252.6 
121 KB1594 SM-TG 100 15.6 C58H99N16O9S 1195.8 1195.6 
122 KB1595 SM-IR 100 18.3 C64H112N19O8S 1306.9 1306.8 
123 KB1596 SM-MS 96 15.5 C60H103N16O9S2 1255.8 1255.6 
124 KB1597 KI-Cap 100 16.1 C44H77N12O6 869.6 869.6 
125 KB1598 KG-Cap 100 13.5 C40H69N12O6 813.5 813.4 
126 KB1599 KE-Cap 94 14.6 C43H73N12O8 885.6 885.5 
127 KB1600 KS-Cap 100 13.0 C41H71N12O7 843.6 843.5 
128 KB1601 GT-Cap 100 16.6 C38H64N11O7 786.5 786.5 
129 KB1602 RI-Cap 100 15.9 C44H77N14O6 897.6 897.6 
130 KB1603 SM-Cap 100 14.8 C40H68N11O7S 846.5 846.3 
131 KB1604 KI-IR 100 18.9 C68H121N20O7 1330.0 1329.9 
132 KB1605 KS-IR 100 15.3 C65H115N20O8 1303.9 1303.9 
133 KB1606 RI-IR 100 19.6 C68H121N22O7 1358.0 1357.7 
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Table S2. Characterization of Compounds with Biotin. 
 
 
 code TEG code 
seq.a 
(R1R2-
R3R4) 
SEDEX 
purity 
(%) 
timeb 
(min) chemical formula 
[M+H]+ 
calculated 
[M+H]+ 
found 
1 KB1923 KB1468 SK-IK 100 13.2 C65H115N20O6S 1303.9 1303.6 
2 KB1924 KB1471 IK-IR 100 14.8 C68H121N22O5S 1358.0 1358.0 
3 KB1925 KB1579 GT-EK 100 13.2 C61H104N19O8S 1262.8 1262.8 
4 KB1926 KB1588 RI-TG 100 14.2 C62H108N21O6S 1274.9 1274.8 
5 KB1927 KB1591 SM-GK 100 13.8 C60H104N19O6S2 1250.7 1250.7 
6 KB1811 KB1368 KI-KS 100 13.1 C65H116N20O6S 1304.9 1304.8 
a seq. = sequence. b time = retention time. 
  
N N
N NN
HN
NN
O O
N
H
N
N
H
N
55
O O
R4R2
NNNN
R3R1
R1R2-R3R4 S
HN NH
O
H
H
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APPENDIX C 
EXPERIMENTAL FOR CHAPTER III 
A. Syntheses For 6-Mercaptopurine Derivative 3 
General procedure for Compound 1 
To a solution of mercaptopurine (9.9 mmol, 1.0 equiv) in DMF (1.0 M) was added 
K2CO3 (9.9 mmol, 1.0 equiv) under N2 (g).  The solution was stirred at 25 °C for 15 min.  
To the mixture was added bromodiphenylmethane (9.9 mmol, 1.0 equiv), and the 
mixture was stirred at 25 °C for 4 h.  The mixture was diluted with water (90 mL), and 
then acidified with acetic acid.  The mixture was stirred vigorously for 30 min, filtered, 
and then dried to give an amorphous solid.  Recrystallization from MeOH gave 2.1 g (67 
%) of compound 1 as white powder. 
 
1H NMR (500 MHz, DMSO) δ 8.63 (s, 1H), 8.45 (s, 1H), 7.51 (d, 4H, J = 7.5 Hz), 7.33 
(t, 4H, J = 7.5 Hz), 7.24 (7, 2H, J = 7.5 Hz), 6.72 (s, 1H) 
 
N
N
H
N
H
N
S Br
Ph
Ph
K2CO3
DMF, 25 oC, 4 h
N
N NH
N
S
Ph
Ph
1
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1H NMR of 1 
 
General procedure for Compound 2 
To a solution of compound 1 (3.1 mmol, 1.0 equiv) in DMF (0.5 M) was added K2CO3 
(3.1 mmol, 1.0 equiv) and 2-[2-9chloroethoxyl)-ethoxy]ethanol (3.1 mmol, 1.0 equiv) 
under N2 (g) at 25 °C.  The solution was warmed to 80 °C and then stirred at the 
temperature for 2 h.  DMF was removed by lyophilizer, and then the mixture was 
purified by flash chromatography (1:19 MeOH/CH2Cl2).  1.2 g (82 %) of compound 2 
was obtained as colorless oil. 
 
N
N NH
N
S
Ph
Ph
Cl O O OH
K2CO3
DMF, 25 to 80 oC, 28 h
1
N
N N
N
S
Ph
Ph
O OH
2
2
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1H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 8.38 (s, 1H), 7.51 (d, 4H, J = 7.5 Hz), 7.30 
(dd, 4H, J = 7.0, 13.5 Hz), 7.22 (t, 2H, 7.5 Hz), 6.82 (s, 1H), 4.42 (t, 2H, J = 4.5 Hz), 
3.80 (t, 2H, J = 5.0 Hz), 3.73 (t, 2H, J = 4.5 Hz), 3.57 (m, 4H), 3.54 (t, 2H, J = 4.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 159.2, 151.5, 148.2, 144.3, 140.9, 130.1, 128.4, 128.2, 
127.0, 72.5, 70.3, 69.9, 68.6, 61.3, 50.5, 43.4 
MS (ESI, m/z) calcd for C24H27N4O3S (M+H)+ 451.1, found 451.2 
 
1H NMR of 2 
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13C NMR of 2 
 
General procedure for Compound 3 
To a solution of compound 2 (2.6 mmol, 1.0 equiv) in CH2Cl2 (0.15 M) was added 
DMAP (0.026 mmol, 0.01 equiv) and TEA (6.4 mmol, 2.5 equiv) under N2 (g) at 0 °C.  
4-Toluenesulfonyl chloride (5.13 mmol, 2.0 equiv) was portioned over 10 min at 0 °C. 
The solution was stirred at 0 °C for 10 min, and then the solution was warmed to 25 °C.  
After 2 h, DMAP (0.26 mmol, 0.1 equiv) was added more to the mixture, and then 
stirred at 25 °C for 14 h.  The mixture was diluted with water and then extracted with 
CH2Cl2.  The combined organic phases were dried over MgSO4.  After completely 
removing the solvent, tosyl-protected compound was purified by flash chromatography 
(1:49 MeOH/CH2Cl2).  1.3 g (84%) of compound tosyl-protected compound was 
obtained as colorless oil. 
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1H NMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 8.10 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.52 
(d, 4H, J = 8.0 Hz), 7.27 (m, 6H), 7.18 (t, 2H, J = 7.0 Hz), 6.85 (s, 1H), 4.32 (t, 2H, J = 
5.0 Hz), 4.08 (t, 2H, J = 3.0 Hz), 3.72 (t, 2H, J = 4.5 Hz), 3.55 (t, 2H, J = 4.5 Hz), 3.46 
(m, 4H), 2.34 (s, 3H) 
13C NMR (125 MHz, CDCl3) δ 158.8, 151.2, 148.3, 144.5, 143.7, 140.9, 132.4, 130.3, 
129.5, 128.2, 128.1, 127.5, 126.8, 70.2, 69.9, 68.9, 68,6, 68.2, 50.3, 43.2, 21.2 
 
 
1H NMR of 2’ 
N
N N
N
S
Ph
Ph
O OH
 TsCl, DMAP, TEA
CH2Cl2, 0 to 25 oC, 14h
2
2
N
N N
N
S
Ph
Ph
O OTs
2
2'
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13C NMR of 2’ 
 
To a solution of compound 2’ (2.1 mmol, 1.0 equiv) in MeCN (0.1 M) was added NaN3 
(3.1 mmol, 1.5 equiv) under N2 (g).  The mixture was refluxed for 25 h.  After 25 h, the 
mixture was cooled down to room temperature, and diluted with water, and then 
extracted with CH2Cl2.  The combined organic phases were dried over MgSO4.  After 
completely removing the solvent, compound 3 was purified by flash chromatography 
(3:97 MeOH/CH2Cl2).  1.0 g (97%) of compound 3 was obtained as yellowish oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H), 8.28 (s, 1H), 7.53 (d, 4H, J = 8.0 Hz), 7.31 
(t, 4H, J = 7.0 Hz), 7.23 (t, 2H, J = 80 Hz), 6.92 (s, 1H), 4.44 (t, 2H, J = 5.0 Hz), 3.82 (t, 
2H, J = 5.0 Hz), 3.59 (m, 6H), 3.33 (t, 2H, J = 5.0 Hz) 
NaN3
MeCN, reflux, 25 h
N
N N
N
S
Ph
Ph
O N3
2
3
N
N N
N
S
Ph
Ph
O OTs
2
2'
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13C NMR (125 MHz, CDCl3) δ 159.3, 151.5, 148.4, 143.9, 141.0, 130.5, 128.5, 128.3, 
127.1, 70.4, 69.9, 68.9, 50.6, 50.4, 43.6 
 
1H NMR of 3 
 192 
 
 
 
13C NMR of 3 
 
B. Syntheses For Bivalent Mimics Containing 6-Mercaptopurine 5 
Compounds 4 (IY-IY-TEG, IY-IW-TEG, IY-LW-TEG, and 2mol-TEG) were prepared 
via the previously published methodology in our group.  To a solution of compound 3 
(1.0 equiv) and compound 4 (1.0 equiv) in DMSO:H2O (5:1, 0.01 M) were added TBTA 
(0.01 equiv) at 25 °C.  CuSO4 (0.1 equiv, from 0.05 M aqueous solution) and fresh Na 
ascorbate (0.4 equiv, from 0.05 M aqueous solution) were added to the mixture at 25 °C.  
The mixture was stirred at 25 °C for 24 h.  The reactions were monitored by analytical 
HPLC.  The crude compounds were lyophilized to remove DMSO, and then purified 
with RP-reparative HPLC to obtain the bivalent mimics 4’.  
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Table S3. Characterization of Compounds 4’. 
com’
d 
sequence 
(R1R2-R3R4) 
retention time 
(min) chemical formula 
[M+H]+ 
calculated 
[M+H]+ 
found 
4’a IY-IY 14.4 C76H100N23O9S 1510.8 1510.6 
4’b IY-IW 15.0 C78H101N24O8S 1533.8 1533.4 
4’c IY-LW 15.0 C78H101N24O8S 1533.8 1533.9 
4’d 2mol 17.2 C44H59N13O7S 913.4 913.9 
 
Deprotection of diphenylmethyl group from thione 4’ was performed with 50 % 
TFA/CH2Cl2 and phenol (3.0 equiv) at 25 °C.  The mixture was stirred at 25 °C for 16 h.  
The reactions were monitored by analytical HPLC.  The crude compounds were purified 
with RP-reparative HPLC to obtain the bivalent mimics 5.  The final products 5 were 
lyophilized three times in 1.0 % acetic acid to remove TFA. 
 
N N
N
HN
N
O
N
NN
O
R2
N
N
NN NN
R4
H2N
R1 R3
NH2
O O O
  3
CuSO4, Na ascorbate
TBTA
DMSO:H2O (5:1)
25 oC, 24 h
4
R1R2-R3R4 : IY-IY, IY-IW, IY-LW, 2mol
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N N
O ONN NN
R2 R4
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3 2
S
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NH2H2N
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R1R2-R3R4 : IY-IY, IY-IW, IY-LW, 2mor Ph
Ph
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Table S4. Characterization of Compounds 5. 
com’
d 
sequence 
(R1R2-R3R4) 
retention time 
(min) chemical formula 
[M+H]+ 
calculated 
[M+H]+ 
found 
5a IY-IY 10.6 C63H90N23O9S 1344.7 1345.1 
5b IY-IW 11.4 C65H91N244O8S 1367.7 1367.8 
5c IY-LW 11.6 C65H91N244O8S 1367.7 1367.5 
5d 2mol 10.5 C31H49N13O7S 747.4 746.7 
 
C. Antiproliferative Assay 
TrkC overexpressed NIH-3T3 cells were kindly provided by Dr David Kaplan at 
University of Toronto in Canada, and wild-type NIH-3T3 cells were provided by Dr 
Jean-Philippe Pellois at Texas A&M University.  TrkC+ NIH-3T3 cells (TrkC) (10,000 
cells/well, 50 µL in Dulbecco’s Modified Eagle Medium/nutrient mixture F-12 
(DMEM/F12) including G418) were plated on 96-well plates and allowed to adhere at 
N N
N NN
HN
NN
O
N N
O ONN NN
R2 R4
N N
N
O N N
N
N
3 2
S
R3
NH2H2N
R1
4'
R1R2-R3R4 : IY-IY, IY-IW, IY-LW, 2mor Ph
Ph
 50 % TFA/CH2Cl2, Phenol
25 oC, 16 h
N N
N NN
HN
NN
O
N N
O ONN NN
R2 R4
N N
N
O N N
HN
N
3 2
S
R3
NH2H2N
R1
5
R1R2-R3R4 : IY-IY, IY-IW, IY-LW, 2mor
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37 °C in 5 % CO2 and 95 % air for 3 h.  Thereafter, the cells were treated with 50 µL 
aliquot of each test compounds in PFHM-II and 10 % NBCS (newborn calf serum) at 
different concentrations, ranging from 0.1 µM to 160 µM.  The final concentration of 
NBCS was 5 %.  The cells were then incubated for 60 h. For wild-type NIH-3T3 cells, 
50 µL in Dulbecco’s Modified Eagle Medium/nutrient mixture F-12 (DMEM/F12) that 
does not include G418 was used, but other process are the same to TrkC Cells’ one.    
The cell’s viability was assessed through an MTT conversion assay.  Briefly, 20 µL of 
MTT (5mg/mL, in Hank’s balanced salt solution, HBSS) were added and the cells were 
incubated for an additional 2 – 3 h.  Thereafter, the cells were lysed and the dark blue 
crystals solubilized with 100 µL of an aqueous solution containing 35 % (v/v) DMF, 15 
% (v/v) glacial acetic acid, 15 % (w/v) SDS with an adjusted pH of 3.8. 
The optical density (OD) of each well (at 570 mm) was measured with a BioTek 
Synergy 4 Microplate Reader.  The viability of each cell line in response to the treatment 
with tested compounds was calculated as: % dead cells = 100 – (OD treated/OD control) 
×100.   
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APPENDIX D 
EXPERIMENTAL FOR CHAPTER IV 
A. General Procedure and Preparation of Bivalent Mimics 10a and 10e 
Boc-protected triazole-based monovalent mimics 4 were prepared by Dr Yu Angell.  
Boc-protecting group in compound 4 was deprotected with 50 % TFA/CH2Cl2 at 25 °C 
for 14 h.  To solution of cyanuric chloride (1.0 equiv) and TEA (1.1 equiv) in CH2Cl2 
(0.1 M) was Boc-piperazine (1.0 equiv) at -15 °C.  The mixture was stirred at -15 oC for 
1 h, and then purified by flash column chromatography to obtain compound 8.  To a 
solution of compound 5 (2.0 equiv) or morpholine (2.0 equiv) were added K2CO4 (4.0 
equiv) and DMSO (0.05 M) at 25 °C for 4 d.  The reaction was monitored by analytical 
HPLC.  After the reaction was done, the crude compound was lyophilized to remove 
DMSO, and then purified with RP-preparative HPLC to get a pure compound 9.  
Compound 9 was deprotected with 50 % TFA/CH2Cl2.  After removing the solvent, the 
deprotected compound was neutralized to pH 7-8 with K2CO3 in deionized water, and 
then p-SCN-Bn-PCTA (0.09 equiv) was added into the solution at 25 °C.  pH of the 
solution was adjusted to pH 7-8 again with K2CO3 after adding p-SCN-Bn-PCTA.  The 
reaction was monitored by analytical HPLC, and after the reaction was done, the mixture 
was purified with RP-preparative HPLC to get a pure compound 10a or 10e.  
 
Scheme S1.   Preparation of the Tagged Bivalent Peptidomimetics 10a and 10e. 
 
N N
O NN
R1
BocN R2
N N
O NN
R1
HN R2
50 % TFA/CH2Cl2
25 oC, 14 h
4 5
R1R2 = RI, SY, KT
KG, SG, TG, KI
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B. General Procedure and Preparation of Bivalent Mimics 10b - d 
Boc-protecting group in compounds 4 for SY, SG, and TG was deprotected with 50 % 
TFA/CH2Cl2 at 25 °C for 14 h.  To a solution of the deprotected compound (1.0 equiv) in 
THF (0.05 M) was added KHCO3 (about 4.0 equiv) at 0 °C.  The mixture was stirred at 0 
°C for 4 h.  The reaction was monitored by analytical HPLC.  After the reaction was 
done, the second deprotected monovalent mimics (KT, KG, and KI, 1.0 equiv) were 
added into the mixture 11, and the solution was basified with K2CO3 (about 4.0 equiv) at 
25 °C.  The mixture was stirred at 25 °C for 24 h.  The reaction was monitored by 
analytical HPLC, and the compound 12 was purified with RP-preparative HPLC.  
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N
N
N
Cl
Cl
N NBoc
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CH2Cl2, -15 oC, 1 h
8
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N
N
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N
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N
O ONN NN
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R2 R4
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N
N CO2HHO2C
HO2C
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R1 R3
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R1R2-R3R4 = RI-RI (10a), 2mor (10e)
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Compound 2 was deprotected with 20 % TFA/CH2Cl2 at 0 °C for 2.5 h to obtain 
compound 3.  To a solution of compounds 12 (1.0 equiv) in DMSO (0.05 M) were added 
K2CO3 (4.0 equiv) and compound 3 (1.0 equiv) at 25 °C.  The mixture was stirred at 25 
°C for 3 ~ 4 d.  The reaction was monitored by analytical HPLC, and the compound 10b 
- d was purified with RP-preparative HPLC. 
Scheme S2.   Preparation of the Tagged Bivalent Peptidomimetics 10b - d. 
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C. Syntheses For Compound 8 and 2 
Preparation of Compound 8 
To solution of cyanuric chloride (1.0 equiv) and TEA (1.1 equiv) in CH2Cl2 (0.1 M) was 
Boc-piperazine (1.0 equiv) at -15 °C.  The mixture was stirred at -15 oC for 1 h, and then 
purified by flash column chromatography (1:9 EtOAc/Hexanes) to obtain 8 (82 %) as 
white solid. 
 
1H NMR (500 MHz, CD3OD) δ 3.87 (s, 4H), 3.52 (s, 4H), 1.50 (s, 9H) 
N N
N
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N N
N
S N
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N
N
N
N CO2HHO2C
HO2C
N NN
N
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CH2Cl2, -15 oC, 1 h
8
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1H NMR of 8 
 
Preparation of Compound 2 
SCN-Bn-PCTA was bought from Macrocyclics.inc.   
To a solution of SCN-Bn-PCTA•3HCl (1.0 equiv) and Boc-piperazine (1.0 equiv) in 
H2O (0.1 M) was added K2CO3 (about 4.0 equiv) at 25 °C.  The solution was adjusted to 
pH 7~8 with K2CO3.  The mixture was stirred at 25 °C for 4 h.  The crude compounds 
were lyophilized to remove H2O.  The compound 2 was used without further 
purification.   
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2
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1H NMR (500 MHz, CD3OD) δ 7.74 (s, 1H), 7.38 (s, 1H), 7.30 (s, 3H), 7.20 (s, 2H), 
4.36 -4.31 (br, 2H), 4.15-4.00 (m, 8H), 3.69-3.57 (m, 11H), 3.41-3.15 (m, 8H), 1.50 (s, 
9H) 
MS (ESI, m/z) calcd for C32H48N7O8S (M+H)+ 714.3, found 714.3 
 
1H NMR of 2 
 
D. Syntheses Of Eu-labeled Bivalent Mimics 1a – e 
For Eu-binding, the compounds 10a - e (1.0 equiv) were dissolved in 0.1 M 
sodium acetate buffer (pH 5.5, 0.05M).  EuCl3·6H2O (3.0 equiv) in the acetate buffer 
(pH 5.5, 0.1 M) was added to the solution, and the mixture was stirred at 25 oC for 24 h.  
The reaction was monitored by analytical HPLC.  After the reaction was done, the 
mixture was purified with RP-preparative HPLC.  0.1 % acetic acid was used to remove 
the TFA three times under lyophilization.   
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Table S1. Characterization of Compounds 5. 
com’
d 
sequence 
(R1R2-R3R4) 
retention time 
(min) chemical formula 
[M+H]+ 
calculated 
[M+H]+ 
found 
1a RI-RI 12.2 C64H93EuN26O8S 1539.7 1539.4 
1b SY-KT 10.1 C63H82EuN21O11S 1494.6 1494.4 
1c KG-SG 9.3 C54H72EuN21O9S 1344.5 1344.4 
1d TG-KI 11.0 C59H82EuN21O9S 1414.6 1414.4 
1e 2mor 10.9 C40H51EuN12O8S 1013.3 1014.0 
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APPENDIX E 
GENERAL EXPERIMENTAL PROCEDURES 
E. Molecular Modeling  
Templates For Cα  – Cβ  Distances And Overlay 
Templates for ideal type I β-turns, and for γ-turns were obtained from standard torsion 
angles.  A standard template for overlays with an α-helix was obtained from Discovery 
Studio 2.5, and a β-sheet template for overlays was obtained by β-sheet builder. 
 
Procedure For Overlays 
The contracted and extended Cβ - Cβ distances of compound 2 were obtained by 
rotation of the bonds (red arrows shown below). The possible secondary structures 
mimicked by compound 2 were obtained by comparing the values between the Cβ - 
Cβ distances for compound 2 against the distances in common secondary structures 
shown in table 1. After identifying possible secondary structures that compound 2 can 
mimic, the model of compound 2 was overlaid with the model of the secondary 
structure.  Free rotation about the bonds was allowed to give a good matching of the Cβ 
atoms on compound 1 with the secondary structure.  The overlays for compounds 3, 4, 5, 
and 6 were also obtained in a similar way.     
 
Procedures For Calculating Energy Barriers 
Reaction path calculations were performed at the B3LYP level of theory with the 6-
31G(d’) basis set. Full geometry optimizations were performed for each fragment and 
stationary points were verified by frequency calculations and water solvation 
calculations. All B3LYP calculations were performed using Gaussian 03. 
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The energy barriers for rotation of the bonds (red arrows) in compound 2 were 
calculated on fragments 2A and 2B. The energy barrier for the whole structure was 
calculated by combination of the results for the fragments. The energy barriers for 
compounds 5 and 6 were also obtained in a similar way. For compounds 3 and 4, the 
whole structures were used for the calculation. 
 
 
Procedure For Quenched Molecular Dynamics Studies 
NAMD was used for the molecular simulations performed in this work (compounds 2, 5 
and 6).  Explicit atom representations were used throughout the study.  The protein 
structure files (PSF) for all the peptidomimetics were built using Discovery Studio 2.5 
(Accelrys Inc) using the CHARMm force field.  
Quenched molecular dynamics simulations were performed using the CHARMm force 
field as implemented in Discovery Studio 2.5.  All four molecules were modeled as 
neutral compounds in a dielectric continuum of 80 (simulating H2O).  Thus, the starting 
conformers were minimized using 3000 steps of conjugate gradient.  The minimized 
structures were then subjected to heating, equilibration, and dynamics simulation.  
Throughout, the equations of motions were integrated using the Verlet algorithm with a 
time step 1 fs.  Each peptidomimetic was heated to 1000 K over 10 ps and equilibrated 
for another 10 ps at 1000 K, then molecular dynamics runs were performed for a total 
time of 600 ps with trajectories saved every 1 ps.  The resulting 600 structures were 
thoroughly minimized using 1000 steps of SD followed by 3000 steps of conjugate 
2
H2N
R1 N N
O
HN
R2
O
H
N
2A
H2N
R1 N N
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N N
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+
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gradient. Structures with energies less than 0.3 (compound 2 and 5) and 1.0 (compound 
6) kcal mol-1 relative to the global minimum were selected for further analysis. 
The VMD package was again used to display, overlay, and classify the selected 
structures into conformational groups.  The best clustering was obtained using a 
grouping method based on calculation of RMS deviation of a subset of atoms, in this 
study these were the Cα - and Cβ- atoms.  Thus, threshold cutoff values 0.3 Å were 
selected to obtain families with reasonable homogeneity.  The lowest energy 
conformation from each family was considered to be a typical representative of the 
family as a whole. 
 
F. Syntheses for 1,3-Butadyne-based Peptidomimetics 
General Procedure for Compound 7a - h  
To a solution of Boc-L-amino acid (1.0 equiv) in dichloromethane (0.24 M) were added 
HOBt (1.1 equiv) and EDC (1.2 equiv) at 0 oC.  The solution was stirred at 0 oC for 15 
min and then N,O-dimethylhydroxylamine hydrochloride salt (1.15 equiv) and N-methyl 
morpholine (1.2 equiv) were added.  The reaction mixture was stirred at 25 oC for 14 h.  
After the solvent was removed under vacuum, the resulting residue was partitioned 
between 1N HCl (aq.) and EtOAc.  The phases were separated and the organic layer was 
washed with 1N HCl (aq.), followed by saturated NaHCO3 and brine, and then dried 
over MgSO4.  After completely removing the solvent, the Weinreb’s amides 7a - d, f - h 
were purified by flash chromatography. 
 
For compound 7e, the obtained Boc-Tyr-Weinreb amide was used for next step without 
further purification.  To a solution of Boc-Tyr-Weinreb amide (1.0 equiv) in DMF (0.25 
M) was added imidazole (3.0 equiv) and TBDPS-Cl (1.7 equiv) at 0 oC.  The reaction 
mixture was stirred at 25 oC for 18 h.  The reaction mixture was diluted with H2O and 
extracted with EtOAc.  The combined organic phases were dried over MgSO4.  After 
completely removing the solvent, the 7e was purified by flash chromatography. 
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Scheme S3.   Synthesis of Compounds 7a - h. 
 
Preparation of Compound 7a 
 
7a 
Compound 7a was prepared from Boc-Leu-OH (9.00 g, 38.9 mmol).  Flash 
chromatography (1:4 EtOAc/Hexanes) afforded 10.7 g (quant.) 7a as a white solid.   
1H NMR (500 MHz, CDCl3) δ 5.04 (d, 1H, J = 14.0 Hz), 4.72 (br, 1H), 3.78 (s, 3H), 
3.19 (s, 3H), 1.76-1.66 (m, 2H), 1.42 (br, 10H), 0.96 (d, J = 11.0 Hz), 0.92 (d, J = 11.0 
Hz) 
13C NMR (125 MHz, CDCl3) δ 173.85, 155.61, 79.40, 61.54, 48.92, 42.04, 32.08, 28.32, 
24.69, 23.32, 21.54 
MS (ESI, m/z) calcd for C13H27N2O4 (M+H)+ 275.20, found 275.20 
N
O
BocHN
R1
 MeNH(OMe)HCl, EDC
HOBt, NMM
CH2Cl2, 0 - 25 °C, 14 h
BocHN OH
O
R1
O
7a - h
N
O
BocHN O
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1H NMR of 7a 
 
13C NMR of 7a 
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Preparation of Compound 7b 
 
7b 
Compound 7b was prepared from Boc-Phe-OH (4.00 g, 15.0 mmol).  Flash 
chromatography (1:5 EtOAc/Hexanes) afforded 4.65 g (quant.) 7b as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 7.27 (t, 2H, J = 7.5 Hz), 7.20 (t, 1H, J = 7.5 Hz), 7.26 (d, 
2H, J = 7.0), 5.17 (d, 1H, J = 7.0 Hz), 4.94 (br, 1H), 3.64 (s, 3H), 3.15 (s, 3H), 3.04 (dd, 
1H, J = 4.5, 13.5 Hz), 2.86 (dd, 1H, J = 7.0, 13.0 Hz), 1.37 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 172.18, 155.07, 136.50, 129.37, 128.25, 126.66, 79.47, 
61.48, 51.42, 38.74, 31.96, 28.23 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C16H25N2O4 (M+H)+ 309.18, found 309.17 
 
1H NMR of 7b 
N
O
BocHN O
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13C NMR of 7b 
 
Preparation of Compound 7c 
 
7c 
Compound 7c was prepared from Boc-Ile-OH (5.00 g, 21.6 mmol).  Flash 
chromatography (1:3 EtOAc/Hexanes) afforded 5.93 g (quant.) 7c as a colorless oil.   
1H NMR (500 MHz, CDCl3) δ 5.11 (d, 1H, J = 10.0 Hz), 4.61 (br, 1H), 3.78 (s, 3H), 
3.22 (s, 3H), 1.75-1.69 (m, 2H), 1.59-1.51 (m, 1H), 1.43 (s, 9H), 0.92 (d, 3H, J = 6.5 
Hz), 0.89 (t, 3H, J = 8.5 Hz)  
13C NMR (125 MHz, CDCl3) δ 172.89, 155.52, 79.12, 61.32, 53.94, 37.80, 31.60, 28.13, 
24.07, 15.27, 11.12 
MS (ESI, m/z) calcd for C13H27N2O4 (M+H)+ 275.20, found 275.19 
N
O
BocHN O
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1H NMR of 7c 
 
13C NMR of 7c 
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Preparation of Compound 7d 
 
7d 
Compound 7d was prepared from Boc-Lys(Boc)-OH (5.00 g, 14.4 mmol).  Flash 
chromatography (1:3 EtOAc/Hexanes) afforded 5.40 g (96 %) 7d as a colorless oil.   
1H NMR (500 MHz, CDCl3) δ 5.21 (d, 1H, J = 8.5 Hz), 4.66 (br, 1H), 4.63 (br, 1H), 3.77 
(s, 3H), 3.20 (s, 3H), 3.15-3.09 (m, 2H), 1.75-1.68 (m, 2H), 1.58-1.49 (m, 2H), 1.44 (s, 
18H), 1.42-1.37 (m, 2H)  
13C NMR (125 MHz, CDCl3) δ 172.97, 155.91, 155.56, 79.42, 78.83, 61.49, 49.96, 
40.12, 32.46, 31.94, 29.24, 28.31, 28.25, 22.42 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C18H36N3O6 (M+H)+ 390.26, found 390.27 
 
N
O
BocHN O
NHBoc
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1H NMR of 7d 
 
13C NMR of 7d 
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Preparation of Compound 7e 
 
                                                                                                   7e 
Compound 7e was prepared from Boc-Tyr-OH (3.1 g, 11.0 mmol).  Flash 
chromatography (1:6 EtOAc/Hexanes) afforded 2.5 g (71 % over 2 steps) 7e as a white 
solid.   
1H NMR (500 MHz, CDCl3) δ 7.71 (d, 4H, J = 7.0 Hz), 7.43 (dd, 2H, J = 7.5, 7.5 Hz), 
7.36 (dd, 4H, J = 7.5, 7.5 Hz), 6.89 (d, 2H, J = 8.0 Hz), 6.68 (d, 2H, 8.5 Hz), 5.09 (d, 1H, 
J = 8.5 Hz), 4.86-4.84 (m, 1H), 3.54 (s, 3H), 3.09 (s, 3H), 2.90 (dd, 1H, J = 6.5, 13.5 
Hz), 1.39 (s, 9H), 1.09 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 172.46, 155.15, 154.44, 135.53, 132.98, 130.20, 129.86, 
128.98, 127.74, 119.56, 79.52, 61.42, 51.49, 38.16, 31.98, 28.34, 26.53, 19.47 
MS (ESI, m/z) calcd for C32H42N2NaO5Si (M+Na)+ 585.28, found 585.26 
 
N
O
BocHN
(i)  MeNH(OMe)HCl, EDC
HOBt, NMM
CH2Cl2, 0 - 25 °C, 14 h
(ii) TBDPS-Cl, imidazole
DMP, 0 ot 25 oC
BocHN OH
O
O
HO TBDPSO
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1H NMR of 7e 
 
13C NMR of 7e 
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Preparation of Compound 7f 
 
7f 
Compound 7f was prepared from Boc-Trp(Boc)-OH (3.00 g, 9.9 mmol).  Flash 
chromatography (1:7 EtOAc/Hexanes) afforded 3.30 g (quant.) 7f as a white solid.   
1H NMR (500 MHz, CDCl3) δ 8.11 (br, 1H), 7.53 (d, 1H, J = 7.5 Hz), 7.44 (s, 1H), 7.30 
(t, 1H, J = 7.5 Hz), 7.23 (t, 1H, 8.0 Hz), 5.30 (d, 1H, J = 7.5 Hz), 5.01-4.96 (m, 1H), 3.71 
(s, 3H), 3.17 (s 3H), 3.17-3.15 (m, 1H), 3.02 (dd, 1H, J = 6.5, 14.0 Hz), 1.67 (s, 9H), 
1.41 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 172.03, 155.16, 149.62, 135.29, 130.65, 124.30, 123.95, 
122.41, 118.76, 115.49, 115.19, 83.42, 79.58, 61.62, 50.42, 32.10, 28.29, 28.18, 27.71 
(107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C23H34N3O6 (M+H)+ 448.24, found 448.25 
 
N
O
BocHN O
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1H NMR of 7f 
 
13C NMR of 7f 
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Preparation of Compound 7g 
 
7g 
Boc-Arg(Boc)2-OH was prepared from H-Orn-OH⋅ HCl according to the literature 
procedure.  Compound 7g was prepared from Boc-Arg(Boc)2-OH (3.10 g, 6.5 mmol).  
Flash chromatography (1:3 to 1:2 EtOAc/Hexanes) afforded 3.38 g (68 %) 7g as a white 
solid.   
1H NMR (500 MHz, CDCl3) δ 8.33 (s, 1H), 5.23 (d, 1H, J = 9.0 Hz), 4.69 (br, 1H), 3.77 
(s, 3H), 3.43 (td, 2H, J = 3.5, 10.0 Hz), 3.21 (s, 3H), 1.80-1.74 (m, 1H), 1.69-1.52 (m, 
3H), 1.52 (s, 9H), 1.51 (s, 9H), 1.45 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 172.69, 163.58, 156.14, 155.50, 153.23, 83.05, 79.64, 
79.22, 61.60, 50.11, 40.33, 32.04, 30.07, 28.33, 28.27, 28.04, 25.12 (107.25 is noise 
from NMR.) 
MS (ESI, m/z) calcd for C23H44N5O8 (M+H)+ 518.32, found 518.34 
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O
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1H NMR of 7g 
 
13C NMR of 7g 
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Preparation of Compound 7h 
 
7h 
Compound 7h was prepared from Boc-Ser(tBu)-OH (3.50 g, 13.4 mmol).  Flash 
chromatography (1:9 EtOAc/Hexanes) afforded 4.06 g (quant.) 7h as a colorless oil.   
1H NMR (500 MHz, CDCl3) δ 5.35 (d, 1H, J = 9.0 Hz), 4.77 (br, 1H), 3.77 (s, 3H), 3.61 
(dd, 1H, J = 5.0, 9.0 Hz), 3.55 (dd, 1H, J = 5.0, 8.5 Hz), 3.22 (s, 3H), 1.44 (s, 9H), 1.14 
(s, 9H)  
13C NMR (125 MHz, CDCl3) δ 171.06, 155.41, 79.43, 73.36, 61.97, 61.35, 51.19, 32.08, 
28.26, 27.23 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C14H29N2O5 (M+H)+ 305.21, found 305.20 
 
 
1H NMR of 7h 
N
O
BocHN O
tBuO
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13C NMR of 7h 
 
General Procedure for Compounds 8a - h 
The alkynes 8a - h were prepared by a procedure previously described in detail.  The 
Weinreb’s amide (1.0 equiv) was dissolved in dry ether (0.15 M) and cooled to 0 °C 
under N2 (g).  A solution of LiAlH (1.1 equiv, 1.0 M in Et2O) was added via syringe over 
a period of 20 min.  The resulting reaction mixture was stirred at 0 °C for 1 h and then 
quenched by dropwise addition of 5% KHSO4 (aq.).  The phases were separated and the 
aqueous phase was extracted with ether.  The combined organic phases were dried over 
MgSO4, and then the solvent was removed to get the amino aldehyde, which was used 
immediately for next step without further purification. 
To a solution of TsN3 (1.3 equiv) in dry MeCN (0.1 M) were added K2CO3 (3.0 equiv) 
and dimethyl 2-oxopropylphosphonate (1.3 equiv), and was stirred at 25 °C for 2 hours.  
The amino acid aldehyde obtained above was dissolved in MeOH (0.37 M) and this 
solution was added into the reaction mixture all in once.  The resulting solution was 
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stirred at 25 °C for 18 hours before the solvent was removed.  The residue was 
partitioned between ether and water.  The layers were separated and the aqueous phase 
was extracted with ether.  The combined organic phases were dried over MgSO4. After 
completely removing the solvent, the amino alkynes 8a - h were purified by flash 
chromatography. 
 
Scheme S4.   Synthesis of compounds 8a - h. 
 
Preparation of Compound 8a 
 
8a 
Compound 8a was prepared from 7a amide (3.90 g, 18.1 mmol).  Flash chromatography 
(1:6 EtOAc/Hexanes) afforded 2.57 g (67 %) 8a as a white solid.   
1H NMR (500 MHz, CDCl3) δ 4.52(br, 1H), 4.30 (br, 1H), 2.11 (d, 1H, J = 3.0 Hz), 
1.70-1.62 (m, 1H), 1.38 (t, 2H, J = 7.5 Hz), 1.30 (s, 9H), 0.80 (d, 3H, J = 5.0 Hz), 0.79 
(d, 3H, J = 5.0 Hz) 
13C NMR (500 MHz, CDCl3) δ 154.78, 83.82, 79.79, 70.77, 45.09, 41.20, 28.35, 24.95, 
22.70, 21.85 
MS (ESI, m/z) calcd for C13H27N2O4 (M+H)+ 212.17, found 212.16 
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1H NMR of 8a 
 
13C NMR of 8a 
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Preparation of Compound 8b 
 
8b 
Compound 8b was prepared from 7b amide (4.00 g, 13.0 mmol).  Flash chromatography 
(1:5 EtOAc/Hexanes) afforded 2.07 g (65 %) 8b as a white solid.   
1H NMR (500 MHz, CDCl3) δ 7.34-7.25 (m, 5H), 4.70 (br, 2H), 3.02-3.00 (m, 1H), 2.95 
(dd, 1H, J = 7.0, 13.5 Hz), 2.29 (s, 1H), 1.45 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 154.56, 136.29, 129.78, 128.28, 126.88, 82.74, 80.00, 
72.15, 43.80, 41.66, 28.30 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C15H20NO2 (M+H)+ 246.15, found 246.14 
 
1H NMR of 8b 
 
BocHN
H
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13C NMR of 8b 
 
Preparation of Compound 8c 
 
8c 
Compound 8c was prepared from 7c (5.00 g, 18.2 mmol).  Flash chromatography (1:9 
EtOAc/Hexanes) afforded 2.41 g (63 %) 8c as a colorless oil.   
1H NMR (500 MHz, CDCl3) δ 4.77 (br, 1H), 4.44 (br, 1H), 2.24 (s, 1H), 1.65 (br, 1H), 
1.55-1.49 (m, 1H), 1.45 (s, 9H) 1.28-1.19 (m, 1H), 0.97 (d, 3H, J = 7.0 Hz), 0.94 (t, 3H, 
J = 8.5 Hz)  
13C NMR (125 MHz, CDCl3) δ 154.84, 81.72, 79.73, 71.91, 47.24, 39.17, 28.33, 25.98, 
14.31, 11.51 
MS (ESI, m/z) calcd for C12H22NO2 (M+H)+ 212.16, found 212.16 
BocHN
H
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1H NMR of 8c 
 
13C NMR of 8c 
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Preparation of Compound 8d 
 
8d 
Compound 8d was prepared from 7d (5.20 g, 13.4 mmol).  Flash chromatography (1:9 
EtOAc/Hexanes) afforded 2.18 g (51 %) 8d as a white solid.   
1H NMR (500 MHz, CDCl3) δ 4.74 (br, 1H), 4.56 (br, 1H), 4.39 (br, 1H), 3.14-3.12 (m, 
2H), 2.26 (s, 1H), 1.72-1.63 (m, 2H), 1.55-1.45 (m, 4H), 1.45 (s, 9H), 1.44 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 155.99, 154.82, 83.39, 79.92, 79.09, 71.07, 42.53, 40.26, 
35.70, 29.51, 28.41, 28.34, 22.69 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C17H31N2O4 (M+H)+ 327.23, found 327.20 
 
1H NMR of 8d 
BocHN
H
NHBoc
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13C NMR of 8d 
 
Preparation of Compound 8e 
 
8e 
Compound 8e was prepared from 7e (2.5 g, 4.4 mmol).  Flash chromatography (3:97 
EtOAc/Hexanes) afforded 1.50 g (67 %) 8e as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 7.72 (d, 4H, J = 8.0 Hz), 7.43 (dd, 2H, J = 7.0, 15.0 Hz), 
7.39 (dd, 4H, J = 8.5, 8.5 Hz), 6.99 (d, 2H, J = 8.5 Hz), 6.71 (d, 2H, 8.5 Hz), 4.63 (br, 
1H), 4.59 (br, 1H), 2.86 (dd, 1H, J = 5.0, 14.0 Hz), 2.81 (dd, 1H J = 7.0, 13.5 Hz), 2.23 
(s, 1H), 1.42 (s, 9H), 1.11 (s, 9H)  
BocHN
H
OTBDPS
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13C NMR (125 MHz, CDCl3) δ 154.50, 154.45, 135.42, 135.41, 134.75, 132.86, 130.43, 
129.77, 129.38, 128.70, 127.65, 127.53, 119.41, 82.86, 79.74, 71.93, 43.73, 40.69, 
28.23, 26.45, 19.35 (107.25 is noise from NMR.) 
MS (MALDI, m/z) calcd for C31H37NNaO3Si (M+Na)+ 522.71, found 522.20 
 
1H NMR of 8e 
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13C NMR of 8e 
 
Preparation of Compound 8f 
 
8f 
Compound 8f was prepared from 7f (3.20 g, 7.2 mmol).  Flash chromatography (1:9 
EtOAc/Hexanes) afforded 1.90 g (77 %) 8f as a white solid.   
1H NMR (500 MHz, CDCl3) δ 8.13 (br, 1H), 7.63 (d, 1H, J = 6.5 Hz), 7.55 (s, 1H), 7.33 
(t, 1H, J = 8.5 Hz), 7.25 (t, 1H, 8.5 Hz), 4.85 (br, 1H), 4.79 (br, 1H), 3.10 (d, 2H, J = 6.5 
Hz), 2.29 (s, 1H), 1.68 (s, 9H), 1.44 (s, 9H) 
BocHN
H
N
Boc
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13C NMR (125 MHz, CDCl3) δ 154.60, 149.66, 135.23, 130.73, 124.32, 124.32, 122.43, 
119.21, 115.36, 115.13, 83.52, 82.96, 79.96, 71.96, 42.97, 31.35, 28.27, 28.17 (107.25 is 
noise from NMR.) 
MS (ESI, m/z) calcd for C22H29N2O4 (M+H)+ 385.21, found 385.21 
 
1H NMR of 8f 
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13C NMR of 8f 
Preparation of Compound 8g 
 
8g 
Compound 8g was prepared from 7g (1.86 g, 3.6 mmol).  Flash chromatography (1:9 
EtOAc/Hexanes) afforded 0.50 g (31 %) 8g as a colorless oil.   
1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 4.86 (d, 1H, J = 6.5 Hz), 4.44 (br, 1H), 3.46-
3.44 (m, 2H), 2.28 (s, 1H), 1.73-1.70 (m, 4H), 1.50 (s, 9H), 1.49 (s, 9H), 1.44 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 163.47, 156.08, 154.68, 153.20, 83.03, 79.88, 79.50, 
79.18, 71.35, 42.43, 40.24, 33.08, 28.26, 28.21, 27.98, 25.29 (107.25 is noise from 
NMR.) 
MS (MALDI, m/z) calcd for C22H39N4O6 (M+H)+ 455.29, found 455.23 
BocHN
H
NH
BocN NHBoc
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1H NMR of 8g 
 
13C NMR of 8g 
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Preparation of Compound 8h 
 
8h 
Compound 8h was prepared from 7h (2.30 g, 9.2 mmol).  Flash chromatography (1:9 
EtOAc/Hexanes) afforded 1.50 g (68 %) 8h as a colorless solid.   
1H NMR (500 MHz, CDCl3) δ 5.03 (br, 1H), 4.49 (br, 1H), 3.49 (br, 2H), 2.24 (s, 1H), 
1.45 (s, 9H), 1.20 (s, 9H 
13C NMR (125 MHz, CDCl3) δ 154.93, 82.11, 79.87, 73.50, 70.60, 63.84, 43.38, 28.31, 
27.39 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C13H24NO3 (M+H)+ 242.18, found 242.18 
 
1H NMR of 8h 
 
BocHN
H
OtBu
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13C NMR of 8h 
 
General Procedure for Compounds 9a - c  
To a solution of the amino acid alkyne (1.0 equiv) in anhydrous THF (0.37 M) was 
added nBuLi (2.0 equiv, 2.5 M in hexane) at -78 oC under N2 (g).  After stirring for 1h, 
bromine (1.0 equiv) was added dropwise to the solution of the lithium acetylide.  The 
reaction mixture was stirred at -78 oC under N2 (g) for 2 h.  The mixture was then 
quenched by adding saturated Na2S2O3 (aq.) and allowed to heat up to 25 oC.  The 
reaction mixture was extracted with diethyl ether.  The combined ether fractions were 
washed with brine, dried over MgSO4 and then concentrated under vacuum.  The 
compounds 9a - c were purified by Flash chromatography.   
Scheme S5.   Synthesis of compounds 9a - c. 
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Preparation of Compound 9a 
 
9a 
Compound 9a was prepared from 8a (1.50 g, 7.1 mmol).  Flash chromatography (3:97 
EtOAc/Hexanes) afforded 2.01 g (98 %) 9a as a white solid.   
 1H NMR (500 MHz, CDCl3) δ 4.65 (br, 1H), 4.49-4.46 (m, 1H), 1.82-1.73 (m, 1H), 
1.53-1.50 (m, 2H), 1.45 (s, 9H), 0.94 (d, 3H, J = 5.5 Hz), 0.93 (d, 3H, J = 5.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 154.72, 113.78, 79.95, 45.16, 42.33, 28.36, 24.99, 22.67, 
21.91 
 
1H NMR of 9a 
BocHN
R1
Br2, nBuLi
THF, -78 oC, 2 h
BocHN
R1
Br
9a-c8a, c, h
BocHN
Br
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13C NMR of 9a 
 
Preparation of Compound 9b 
 
9b 
Compound 9b was prepared from 8c (0.68 g, 3.2 mmol).  Flash chromatography (1:19 
EtOAc/Hexanes) afforded 0.88 g (94 %) 9b as a yellowish solid.   
 1H NMR (500 MHz, CDCl3) δ 4.80 (d, 1H, J = 3.0 Hz), 4.45 (dd, 1H, J = 5.0, 8.5 Hz), 
1.64-1.60 (m, 1H), 1.53-1.46 (m, 1H), 1.44 (s, 9H), 1.26-1.17 (m, 1H), 0.94 (d, 3H, J = 
6.5 Hz), 0.92 (t, 3H, J = 8.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 154.75, 79.85, 78.11, 48.39, 42.86, 39.54, 28.31, 25.99, 
14.48, 11.49 (107.25 is noise from NMR.) 
BocHN
Br
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1H NMR of 9b 
 
13C NMR of 9b 
 238 
 
Preparation of Compound 9c 
 
9c 
Compound 9c was prepared from 8h (0.40 g, 1.7 mmol).  Flash chromatography (1:9 
EtOAc/Hexanes) afforded 0.45 g (84 %) 9c as a yellowish solid.   
 1H NMR (500 MHz, CDCl3) δ 5.02 (br, 1H), 4.51 (br, 1H), 3.47 (br, 2H), 1.45 (s, 9H), 
1.20 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 154.86, 79.95, 78.38, 73.61, 63.85, 44.50, 42.18, 28.31, 
27.40 (107.25 is noise from NMR.) 
 
1H NMR of 9c 
BocHN
Br
OtBu
 239 
 
13C NMR of 9c 
 
General Procedure for Compounds 10a - f  
To a solution of 8b, d - g (1.0 equiv) in MeOH (0.72 M) were added CuCl (0.1 equiv), 
NH2OH⋅H2O (0.95 equiv) and ethyl amine (25.0 equiv) at 0 oC under N2 (g).  A THF 
solution of 9a - c (1.2 equiv) was added dropwise to the reaction mixture at 0 oC over 1 
h.  After adding the THF solution, the mixture was stirred at 0 oC for 2 h.  The mixture 
was then quenched by added H2O and extracted with diethyl ether.  The combined ether 
fractions were dried over MgSO4 and then concentrated under vacuum.  The compounds 
10a - f were purified by Flash chromatography.  
 
For compound 10d’, to a solution of 10d (1.0 equiv) in THF (0.082 M) was added TBAF 
(1.2 equiv) at 0 oC.  After stirring at 0 oC for 15 min, the reaction mixture was warmed to 
25 oC and then stirred for 45 min.  The reaction mixture was diluted with H2O and 
 240 
extracted with EtOAc.  The combined organic phases were dried over MgSO4.  After 
completely removing the solvent, the 10d’ was purified by flash chromatography. 
 
Scheme S6.   Synthesis of compounds 10a - f. 
 
 
 
Preparation of Compound 10a 
 
10a 
Compound 10a was prepared from 9a (0.26 g, 0.88 mmol) and 8b (0.18 g, 0.73 mmol).  
Flash chromatography (1:19 to 1:9 EtOAc/Hexanes) afforded 0.31g (94 %) 10a as a 
white solid.   
1H NMR (500 MHz, CDCl3) δ 7.33 (t, 2H, J = 7.5 Hz), 7.29-7.24 (m, 3H), 4.76 (br, 1H), 
4.69 (br, 1H), 4.62 (br, 1H), 4.52 (br, 1H), 3.00-2.98 (m, 1H), 2.94 (dd, 1H, J = 7.0, 13.5 
Hz), 1.81-1.73 (m, 1H), 1.52 (dd, 2H, J = 7.5, 7.5 Hz), 1.45 (s, 9H), 1.42 (s, 9H), 0.94 (d, 
3H, J = 6.5 Hz), 0.93 (d, 3H, J = 5.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 154.61, 154.44, 135.93, 129.70, 128.41, 126.99, 80.15, 
80.04, 78.84, 77.44, 68.31, 66.91, 44.96, 44.37, 41.84, 28.32, 28.27, 24.97, 22.63, 21.85 
(107.25 is noise from NMR.) 
MS (MALDI, m/z) calcd for C27H38N2NaO4 (M+Na)+ 477.27, found 477.34 
NHBoc
R2
BocHN
R1
Br +
CuCl, EtNH2
 NH2OH HCl
MeOH/THF 
0 oC, 3 h
BocHN
R1 R2
NHBoc
10a - f9a - c 8b, d - g
NHBocBocHN
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1H NMR of 10a 
 
13C NMR of 10a 
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Preparation of Compound 10b 
 
10b 
Compound 10a was prepared from 9a (0.27 g, 0.94 mmol) and 8f (0.30 g, 0.78 mmol).  
Flash chromatography (1:9 EtOAc/Hexanes) afforded 0.39 g (84 %) 10a as a white 
solid.   
1H NMR (500 MHz, CDCl3) δ 8.13 (br, 1H), 7.59 (d, 1H. J = 8.0 Hz), 7.52 (br, 1H), 7.32 
(t, 1H, J = 7.0 Hz), 7.25 (t, 1H, J = 8.0 Hz), 4.85 (br, 1H), 4.79 (br, 1H), 4,61 (br, 1H), 
4.50 (br, 1H), 3.09 (d, 2H, 6.0 Hz), 1.79-1.72 (m, 1H), 1.68 (s, 9H), 1.51 (dd, 2H, J = 
7.5, 7.5 Hz), 1.45 (s, 9H), 1.43 (s, 9H), 0.94 (d, 3H, 7.0 Hz), 0.92 (d, 3H, 6.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 154.56, 154.47, 149.55, 135.25, 130.51, 124.34, 124.34, 
122.46, 119.12, 115.09, 115.03, 83.48, 80.06, 79.90, 78.78, 77.63, 68.10, 66.82, 44.89, 
43.51, 41.71, 31.36, 28.26, 28.22, 28.13, 24.89, 22.61, 21.74  
MS (MALDI, m/z) calcd for C34H47N3NaO6 (M+Na)+ 616.34, found 616.40 
NHBocBocHN
N
Boc
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1H NMR of 10b 
 
13C NMR of 10b 
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Preparation of Compound 10c 
 
10c 
Compound 10c was prepared from 9b (0.25 g, 0.85 mmol) and 8d (0.23 g, 0.70 mmol).  
Flash chromatography (1:19 EtOAc/Hexanes) afforded 0.27 g (71 %) 10c as a colorless 
oil.   
1H NMR (500 MHz, CDCl3) δ 4.73 (br, 2H), 4.55 (br, 1H), 4.49 (br, 2H), 3.14-3.12 (m, 
2H), 1.69-1.61 (m, 3H), 1.54-1.45 (m, 5H), 1.28-1.20 (m, 1H), 0.97 (d, 3H, J = 6.5 Hz), 
0.92 (t, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 156.02, 154.71, 154.71, 80.12, 80.01, 80.01, 79.14, 
77.71, 67.97, 67.36, 47.95, 43.14, 40.21, 39.70, 35.66, 29.53, 28.42, 28.33, 28.33, 26.04, 
22.74, 14.60, 11.50 (107.25 is noise from NMR.) 
MS (MALDI, m/z) calcd for C29H49N3NaO6 (M+Na)+ 558.35, found 558.17 
 
NHBocBocHN
NHBoc
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1H NMR of 10c 
 
13C NMR of 10c 
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Preparation of Compound 10d 
 
10d 
Compound 10d was prepared from 9b (0.12 g, 0.41 mmol) and 8e (0.17 g, 0.34 mmol).  
Flash chromatography (1:19 EtOAc/Hexanes) afforded 0.18 g (74 %) 10d as a yellowish 
solid.   
1H NMR (500 MHz, CDCl3) δ 7.72 (d, 4H, J = 7.0 Hz), 7.43 (dd, 2H, J = 7.5, 7.5 Hz), 
7.37 (dd, 4H, J = 7.5, 7.5 Hz), 6.97 (d, 2H, J = 8.5 Hz), 6.71 (d, 2H, J = 9.0 Hz), 4.73 (d, 
1H, J = 8.5 Hz), 4.65 (br, 1H), 4.61 (br, 1H), 4.50 (br, 1H), 2.88-2.83 (m, 1H), 2.81 (dd, 
1H, J = 6.5, 13.5 Hz), 1.68-1.62 (m, 1H), 1.53-1.46 (m, 1H), 1.46 (s, 9H), 1.41 (s, 9H), 
1.27-1.19 (m, 1H), 1.10 (s, 9H), 0.95 (d, 3H, J = 6.0 Hz), 0.93 (t, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 154.71, 154.62, 154.41, 135.49, 132.89, 130.42, 129.84, 
128.31, 127.71, 119.61, 79.99, 79.99, 77.34, 77.34, 68.09, 67.97, 47.90, 44.34, 40.76, 
39.68, 28.31, 28.26, 26.49, 26.00, 19.3, 14.56, 11.49 (107.25 is noise from NMR.) 
MS (MALDI, m/z) calcd for C43H56N2NaO5Si (M+Na)+ 731.39, found 731.40 
 
NHBocBocHN
OTBDPS
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1H NMR of 10d 
 
13C NMR of 10d 
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Preparation of Compound 10d’ 
 
10d’ 
Compound 10d’ was prepared from 10d (94.50 mg, 0.13 mmol).  Flash chromatography 
(1:5 EtOAc/Hexanes) afforded (57.10 mg, 91 %) 10d’ as a yellowish solid.   
1H NMR (500 MHz, CDCl3) δ 7.11 (d, 2H, J = 8.0 Hz), 6.79 (d, 2H, J = 8.5 Hz), 5.59 
(br, 1H), 4.78 (d, 1H, J = 8.0 Hz), 4.72 (br, 2H), 4.50 (br, 1H), 2.94-2.89 (m, 1H), 2.87 
(dd, 1H, J = 6.5, 13.0 Hz), 1.67-1.64 (m, 1H), 1.54-1.46 (m, 1H), 1.46 (s, 9H), 1.43 (s, 
9H), 1.27-1.18 (m, 1H), 0.96 (d, 3H, J = 7.0 Hz), 0.92 (d, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 155.23, 154.89, 154.69, 130.75, 127.45, 115.37, 80.34, 
80.21, 77.13, 77.13, 68.24, 68.00, 47.96, 44.68, 40.91, 39.65, 28.31, 28.27, 25.97, 14.57, 
11.45 (107.25 is noise from NMR.) 
MS (MALDI, m/z) calcd for C27H38N2NaO5 (M+Na)+ 493.27, found 493.33 
 
NHBocBocHN
OH
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1H NMR of 10d’ 
 
13C NMR of 10d’ 
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Preparation of Compound 10e 
 
10e 
Compound 10e was prepared from 9b (0.11 g, 0.4 mmol) and 8g (0.15 g, 0.33 mmol).  
Flash chromatography (1:19 to 1:5 % EtOAc/Hexanes) afforded 0.21 g (95 %) 10e as a 
yellowish solid.   
1H NMR (500 MHz, CDCl3) δ 8.35 (t, 1H, J = 4.5 Hz), 4.88 (d, 1H, J = 7.5 Hz), 4.76 (d, 
1H, J = 13.5 Hz), 4.51 (br, 2H), 3.44 (br, 2H), 1.71-1.67 (m, 7H), 1.54-1.51 (m, 1H), 
1.51 (s, 9H), 1.50 (s, 9H), 1.44 (s, 18H), 1.30-1.15 (m, 1H), 0.96 (d, 3H, J = 6.5 Hz), 
0.93 (d, 1H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 163.42, 156.08, 154.66, 154.58, 153.18, 83.05, 83.05, 
79.99, 79.88, 79.18, 79.18, 67.86, 67.43, 47.82, 42.99, 40.14, 39.59, 32.94, 28.24, 28.18, 
27.97, 27.97, 25.94, 25.38, 14.51, 11.43  
MS (MALDI, m/z) calcd for C34H57N5NaO8 (M+Na)+ 686.41, found 686.43 
NHBocBocHN
NH
BocN
NHBoc
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1H NMR of 10e 
 
13C NMR of 10e 
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Preparation of Compound 10f 
 
10f 
Compound 10f was prepared from 9c (0.16 g, 0.51 mmol) and 8d (0.14 g, 0.43 mmol).  
Flash chromatography (1:19 EtOAc/Hexanes) afforded 0.18 g (73 %) 10f as oil.   
1H NMR (500 MHz, CDCl3) δ 5.05 (br, 1H), 4.84 (d, 1H, J = 8.0 Hz), 4.64 (br, 1H), 4.54 
(br, 1H), 4.46-4.40 (m, 1H), 3.45 (d, 2H, J = 4.5 Hz), 3.11-3.07 (m, 1H), 1.67-1.59 (m, 
2H), 1.49-1.42 (br, 31H), 1.17 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 155.96, 154.74, 154.69, 79.95, 78.99, 78.99, 77.66, 
77.11, 73.63, 67.38, 66.68, 63.71, 43.93, 43.00, 40.13, 35.54, 29.42, 28.35, 28.25, 28.25, 
27.33, 22.66 (107.25 is noise from NMR.) 
MS (MALDI, m/z) calcd for C30H51N3NaO7 (M+Na)+ 588.36, found 588.41 
 
1H NMR of 10f 
NHBocBocHN
NHBoc
tBuO
 253 
 
13C NMR of 10f 
 
General Procedure for Compounds 4a - f  
The compounds 10a - f were treated with 50% TFA/CH2Cl2 at 0 oC for 3-5 h.  
Evaporating solvent under nitrogen afforded the desired product 4a - f. 
 
Scheme S7.   Synthesis of compounds 4a - f. 
 
 
 
 
50 % TFA
CH2Cl2
0 oC, 3-5 h
H2N
R1 R2
NH2
4a-f
BocHN
R1 R2
NHBoc
10a - f
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Preparation of Compound 4a 
 
4a 
Compound 4a was prepared from 10a (10.0 mg, 0.022 mmol).  4a was obtained as a 
yellowish amorphous solid (90 %, 2TFA salt).   
1H NMR (500 MHz, CD3OD) δ 7.31-7.23 (m, 5H), 4.45 (dd, 1H, J = 5.5, 9.5 Hz), 4.20 
(dd, 1H, J = 5.5, 10.5 Hz), 3.15 (dd, 1H, J = 5.5, 13.5 Hz), 2.99 (dd, 1H, J = 9.5, 13.5 
Hz), 1.76-1.71 (m, 1H), 1.71-1.65 (m, 1H), 1.57-1.52 (m, 1H), 0.94 (d, 3H, J = 6.5 Hz), 
0.89 (d, 3H, J = 6.5 Hz) 
13C NMR (125 MHz, CD3OD) δ 136.36, 131.40, 130.81, 129.80, 77.11, 76.67, 72.48, 
71.82, 46.55, 43.95, 43.71, 41.01, 27.26, 24.01, 22.32 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C17H23N2 (M+H)+ 255.19, found 255.21 
optical rotation [α]D19.6 = +63.7 (c = 0.96 in MeOH) 
 
1H NMR of 4a 
NH2H2N
 255 
 
13C NMR of 4a 
 
Preparation of Compound 4b 
 
4b 
Compound 4b was prepared from 10b (9.50 mg, 0.016 mmol).  4b was obtained as a 
yellowish amorphous solid (87 %, 2TFA salt).   
1H NMR (500 MHz, CD3OD) δ 7.57 (d, 1H, J = 8.0 Hz), 7.35 (d, 1H. J = 8.5 Hz), 7.20 
(s, 1H), 7.10 (dd, 1H, J = 9.5, 9.5 Hz), 7.02 (dd, 1H, J = 8.0 Hz), 4.51 (dd, 1H, 7.5, 8.5 
Hz), 4.22 (dd, 1H, J = 5.0, 10.5 Hz), 3.31-3.29 (m, 2H), 1.79-1.74 (m, 1H), 1.74-1,67 (m, 
1H), 1.60-1.54 (m, 1H), 0.97 (d, 3H, J = 9.0 Hz), 0.92 (d, 3H, J = 6.5 Hz)  
NH2H2N
N
H
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13C NMR (125 MHz, CD3OD) δ 136.79, 126.89, 124.07, 121.46, 118.83, 117.66, 
111.18, 106.63, 75.34, 74.52, 69.79, 69.66, 43.85, 41.69, 41.48, 29.22, 24.95, 21.78, 
20.00  (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C19H24N3 (M+H)+ 294.20, found 294.21 
optical rotation [α]D18.3 = +34.8 (c = 0.72 in MeOH) 
 
 
1H NMR of 4b 
 257 
 
13C NMR of 4b 
Preparation of Compound 4c 
 
4c 
Compound 4c was prepared from 10c (4.80 mg, 0.009 mmol).  4c was obtained as a 
yellowish amorphous solid (quant., 3TFA salt).   
1H NMR (500 MHz, CD3OD) δ 4.28 (d, 2H, J = 3.5 Hz), 4.27 (d, 2H, J = 10.5 Hz), 2.92 
(t, 2H, J = 8.0 Hz), 1.90-1.80 (m, 3H), 1.73-1.66 (m, 2H), 1.53-1.44 (m, 2H), 1.35-1.27 
(m, 2H), 1.04 (d, 3H, J = 6.5 Hz), 0.95 (t, 3H, J = 10.5 Hz) 
13C NMR (125 MHz, CD3OD) δ 76.31, 75.45, 72.55, 71.85, 44.89, 40.95, 39.75, 34.42, 
28.56, 28.15, 24.26, 24.26, 14.81, 12.22 
MS (ESI, m/z) calcd for C14H26N3 (M+H)+ 236.21, found 236.22 
optical rotation [α]D19.8 = +32.6 (c = 0.21 in MeOH) 
NH2H2N
NH2
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1H NMR of 4c 
 
13C NMR of 4c 
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Preparation of Compound 4d 
 
4d 
Compound 4d was prepared from 10d (10.0 mg, 0.013 mmol).  4d was obtained as a 
yellowish amorphous solid (93 %, 2TFA salt).   
1H NMR (500 MHz, CD3OD) δ 7.05 (d, 2H, J = 8.5 Hz), 6.71 (d, 2H, J = 8.5 Hz), 4.38 
(dd, 1H, J = 5.5, 9.0 Hz), 4.23 (d, 1H, J = 5.0 Hz), 3.04 (dd, 1H, J = 5.5, 13.5 Hz), 2.91 
(dd, 1H, J = 9.5, 13.5 Hz), 1.83-1.78 (m, 1H), 1.83-1.78 (m, 1H), 1.47 (m, 1H), 1.30 (m, 
1H), 1.00 (d, 3H, J = 7.0 Hz), 0.92 (t, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CD3OD) δ 156.98, 130.21, 124.46, 115.20, 74.40, 73.19, 70.50, 
70.08, 44.49, 44.49, 38.03, 37.61, 26.03, 12.66, 10.11 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C17H23N2O (M+H)+ 271.18, found 271.19  
optical rotation [α]D18.6 = +40.2 (c = 0.60 in MeOH) 
 
NH2H2N
OH
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1H NMR of 4d 
 
13C NMR of 4d 
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Preparation of Compound 4e 
 
4e 
Compound 4e was prepared from 10e (9.80 mg, 0.015 mmol).  4e was obtained as a 
yellowish amorphous solid (93 %, 3TFA salt).   
1H NMR (500 MHz, CD3OD) δ 4.31 (dd, 1H, J = 5.5, 9.0 Hz), 4.27 (d, 1H, J = 4.5 Hz), 
3.22 (t, 2H, J = 7.0 Hz), 1.94-1.87 (m, 1H), 1.86-1.80 (m, 2H), 1.79-1.66 (m, 2H), 1.50-
1.44 (m, 1H), 1.36-1.25 (m, 1H), 1.03 (d, 3H, J = 6.5 Hz), 0.95 (t, 3H, J = 10.5) 
13C NMR (125 MHz, CD3OD) δ 157.32, 74.04, 73.40, 70.39, 69.82, 42.65, 40.07, 37.62, 
37.62, 29.96, 26.04, 24.63, 12.68, 10.11 
MS (ESI, m/z) calcd for C14H26N5 (M+H)+ 264.39, found 264.23 
optical rotation [α]D19.4 = +8.7 (c = 0.84 in MeOH) 
 
1H NMR of 4e 
NH2H2N
NH
HN
NH2
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13C NMR of 4e 
Preparation of Compound 4f 
 
4f 
Compound 4f was prepared from 10f (10.30 mg, 0.018 mmol).  4f was obtained as a 
yellowish amorphous solid (90%, 3TFA salt).   
1H NMR (500 MHz, CD3OD) δ 4.24 (dd, 1H, J = 1.5, 2.0 Hz), 4.22 (d, 1H, J = 5.0 Hz), 
3.80 (dd, 1H, J = 4.5, 11.5 Hz), 3.66 (dd, 1H, J = 6.5, 11.5 Hz), 2.88 (t, 2H, J = 7.5 Hz), 
1.87-1.75 (m, 2H), 1.68-1.62 (m, 2H), 1.58-1.52 (m, 1H), 1.50-1.45 (m, 1H) 
13C NMR (125 MHz, CD3OD) δ 76.56, 75.25, 72.10, 71.91, 63.56, 47.05, 44.98, 41.10, 
34.57, 28.70, 24.40 (107.25 is noise from NMR.) 
MS (ESI, m/z) calcd for C11H20N3O (M+H)+ 210.16, found 210.17 
optical rotation [α]D19.1 = +1.4 (c = 0.85 in MeOH) 
NH2H2N
NH2
HO
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1H NMR of 4f 
 
13C NMR of 4f 
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G. Syntheses of Pyrrole-based Peptidomimetics 3 and 13 
 
General Procedure and Preparation of Weinreb’s amides  
The procedure for preparation of Weinreb’s amides is the same to one for preparation of 
compounds 7a – h.  The data for Leu and Ile Weinreb’s amides were shown in the 
previous section 7a and 7c.  
 
Preparation of Val Weinreb’s amide 
 
Val Weinreb’s amide was prepared from Boc-Val-OH (5.0 g, 23.0 mmol).  Flash 
chromatography (1:5 EtOAc/Hexanes) afforded 5.35 g (89 %) Val Weinreb’s amide as a 
colorless oil.   
1H NMR (500 MHz, CDCl3) δ 5.14 (d, 1H, J = 9.0 Hz), 4.57 (br, 1H), 3.77 (s, 3H), 3.20 
(s, 3H), 1.99-1.96 (m, 1H), 1.42 (s, 9H), 0.95 (d, 3H, J = 6.0 Hz), 0.90 (d, 3H, J = 6.5 
Hz) 
13C NMR (125 MHz, CDCl3) δ 172.9, 155.8, 79.4, 61.5, 54.9, 31.8, 31.3, 28.3, 19.4, 
17.5 
MS (ESI, m/z) calcd for C12H25N2O4 (M+H)+ 261.18, found 261.18 
N
O
BocHN O
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1H NMR of Val Weinreb’s amide 
 
13C NMR of Val Weinreb’s amide 
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Preparation of Tyr Weinreb’s amide 
 
Tyr Weinreb’s amide was prepared from Boc-Tyr(Bn)-OH (5.0 g, 13.5 mmol).  Flash 
chromatography (1:4 EtOAc/Hexanes) afforded 5.50 g (99 %) Tyr Weinreb’s amide as a 
white solid.   
1H NMR (500 MHz, CDCl3) δ7.53 (d, 2H, J = 7.0 Hz), 7.39 (t, 2H, J = 7.5 Hz), 7.33 (t, 
1H, J = 7.0 Hz), 7.09 (d, 2H, J = 8.5 Hz), 6.90 (d, 2H, J = 9.0 Hz), 5.16 (d, 1H, J = 8.5 
Hz), 5.04 (s, 2H), 4.91 (br, 1H), 3.66 (s, 3H), 3.17 (s, 3H), 3.00 (dd, 1H, J = 6.0, 13.5 
Hz), 2.84 (dd, 1H, J = 6.0 Hz, J = 13.0 Hz), 1.40 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 172.3, 157.6, 155.1, 137.0, 130.4, 128.8, 128.5, 127.8, 
127.4, 114.6, 79.5, 69.8, 61.5, 51.5, 37.8, 32.0, 28.2 
MS (ESI, m/z) calcd for C23H31N2O5 (M+H)+ 415.22, found 415.23 
 
1H NMR of Tyr Weinreb’s amide 
N
O
BocHN O
BnO
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13C NMR of Tyr Weinreb’s amide 
 
Preparation of Met Weinreb’s amide 
 
Met Weinreb’s amide was prepared from Boc-Met-OH (1.0 g, 4.0 mmol).  Flash 
chromatography (1:3 EtOAc/Hexanes) afforded 1.13 g (80 %) Met Weinreb’s amide as a 
colorless oil.   
1H NMR (500 MHz, CDCl3) δ 5.24 (d, 1H, J = 8.5 Hz), 4.80 (br, 1H), 3.79(s, 3H), 3.21 
(s, 3H), 2.60-2.52 (m, 2H), 2.10 (s, 3H), 1.83-1.73 (m, 2H), 1.44 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 172.3, 155.3, 79.3, 61.4, 49.5, 32.1, 31.9, 29.9, 28.1, 
15.1 
MS (ESI, m/z) calcd for C12H25N2O4S (M+H)+ 293.15, found 293.15 
N
O
BocHN O
S
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Preparation of Thr Weinreb’s amide 
 
6f 
Thr Weinreb’s amide was prepared from Boc-Thr(Bn)-OH (4.0 g, 14.0 mmol).  Flash 
chromatography (1:3   EtOAc/Hexanes) afforded 4.30 g (94 %) Thr Weinreb’s amide as 
a colorless oil.   
1H NMR (500 MHz, CDCl3) δ 7.35-7.26 (m, 5H), 5.90 (d, 1H, J = 9.0 Hz), 4.62 (dd, 1H, 
J = 2.5, 9.0 Hz), 4.57 (d, 1H, J = 12.0 Hz), 4.43 (d, 1H, J = 12.5 H), 3.92-3.88 (m, 1H), 
3.68 (s, 3H), 3.16 (s, 3H), 1.45 (s, 9H), 1.25 (d, 3H, J = 6.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 170.8, 156.0, 138.0, 128.1, 127.7, 127.5, 79.3, 73.5, 
70.6, 61.1, 55.0, 32.0, 28.2, 16.7 
MS (ESI, m/z) calcd for C18H29N2O5 (M+H)+ 353.21, found 353.20 
 
 
1H NMR of Thr Weinreb’s amide 
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13C NMR of Thr Weinreb’s amide 
 
General Procedure and Preparation of Amino-alkyne 
The procedure for preparation of amino-alkyne is the same to one for preparation of 
compounds 8a – h.  The data for Leu alkyne were shown in the previous section 8a. 
 
Preparation of Tyr-alkyne 
 
Tyr-alkyne was prepared from Boc-Tyr(Bn)-OH (3.86 g, 10.9 mmol).  Flash 
chromatography (1:5   EtOAc/Hexanes) afforded 3.24 g (85 %) Tyr-alkyne as a white 
solid.   
BocHN
H
OBn
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1H NMR (500 MHz, CDCl3) δ 7.45 (d, 2H, J = 7.0 Hz), 7.40 (t, 2H, J = 7.0 Hz), 7.34 (t, 
1H, J = 7.0 Hz), 7.20 (d, 2H, J = 3.5Hz), 6.94 (d, 2H, 8.5 Hz), 5.06 (s, 2H), 4.72 (br, 
1H), 4.65 (br, 1H),  
13C NMR (125 MHz, CDCl3) δ 157.6, 154.5, 136.9, 130.6, 128.5, 128.4, 127.8, 127.3, 
114.5, 82.8, 79.7, 72.3, 69.7, 43.8, 40.6, 28.2 
MS (ESI, m/z) calcd for C22H26NO3 (M+H)+ 352.19, found 352.17 
 
 
1H NMR of Tyr-alkyne 
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13C NMR of Tyr-alkyne 
 
General Procedure for Gly-alkyne 
To a solution of propargylamine (1.0 equiv) in acetonitrie (1.8 M) was added di-tert-
butyldicarbonate (2.5 equiv) followed by DMAP (1.0 equiv).  The reaction mixture was 
stirred at 25 oC for 16 h and then diluted with ethyl acetate.  The organic layer was 
washed with water and brine and dried over MgSO4.  After completely removing the 
solvent, the amino alkyne was purified by flash chromatography. 
 
Preparation of Gly-alkyne 
 
7c 
(Boc)2N
H
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Gly-alkyne was prepared from propagylamine (0.6 g, 10.9 mmol).  Flash 
chromatography (1:19   EtOAc/Hexanes) afforded 0.9 g (32 %) Gly-alkyne as a 
colorless oil.   
1H NMR (500 MHz, CDCl3) δ 4.35 (d, 2H, J = 4.0 Hz), 2.19 (t, 1H, J = 4.0 Hz), 1.53 (s, 
18H)  
13C NMR (125 MHz, CDCl3) δ 151.5, 82.9, 79.5, 70.4, 35.6, 27.9 
MS (ESI, m/z) calcd for C13H22NO4 (M+H)+ 256.15, found 256.15 
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13C NMR of Gly-alkyne 
 
General Procedure and Preparation of Compounds 11a - f 
The Weinreb’s amide (1.0 equiv) was dissolved in dry ether (0.15 M) and cooled to 0 °C 
under N2 (g).  Solution of LiAlH (1.0 equiv, 1.0 M in Et2O) was added via syringe over a 
period of 20 min.  The resulting reaction mixture was stirred at 0 °C for 1 h and then 
quenched by dropwise addition of 5% KHSO4 (aq.).  The phases were separated and the 
aqueous phase was extracted with ether.  The combined organic phases were dried over 
MgSO4, and then the solvent was removed to get the amino aldehyde, which was used 
immediately for next step without further purification. 
 
To a solution of the amino alkyne (2.5 equiv) in anhydrous THF (0.3 M) was added 
lithium bis(trimethylsilyl)amide (6.5 equiv) at -78 oC under N2 (g).  The resulting 
solution was stirred at -78 oC for 1 h.  The aldehyde (1.0 equiv) in anhydrous THF (0.3 
M) was added via cannula over a 20 min period.  The reaction mixture was stirred at -78 
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oC under N2 (g) for 5 - 12 h.  The mixture was then quenched by adding saturated NH4Cl 
(aq) and extracted with diethyl ether.  The combined ether fractions were dried over 
MgSO4 and concentrated under vacuum.  The compounds 11a - f were purified by Flash 
chromatography. 1,2  
Scheme S8.   Synthesis of compounds 11a - f. 
 
 
 
Preparation of Compound 11a 
 
11a 
Compound 11a was prepared from Ile-Weinreb’s amide (0.28 g, 1.0 mmol) and Leu-
alkyne (0.55 g, 2.5 mmol).  Flash chromatography (1:3 EtOAc/Hexanes) afforded 0.25 g 
(57 %) 11a as a white solid.   
 1H NMR (500 MHz, CDCl3) δ 4.88 (d, 1H, J = 9.5 Hz), 4.78 (br, 1H), 4.45-4.43 (m, 
1H), 4.61-4.42 (m, 1H), 3.49-3.42 (m, 1H), 3.07 (br, 1H), 1.90 (br, 1H), 1.78-1.73 (m, 
2H), 1.58-1.54 (m, 1H), 1.53-1.49 (m, 1H), 1.45 (s, 9H), 1.43 (s, 9H), 0.96-0.88 (m, 
12H)  
13C NMR (125 MHz, CDCl3) δ 156.7, 154.8, 85.0, 82.3, 79.6, 79.4, 63.0, 59.9, 45.2, 
41.4, 35.6, 28.4, 24.9, 22.7, 21.8, 16.0, 11.2 
MS (ESI, m/z) calcd for C23H43N2O5 (M+H)+ 427.32, found 427.30 
N
O
BocHN
R1
O
H
NHBoc
R2
R1
OH
BocHN
R2
NHBoc
2.5
11a - f
(ii)
(i)  LiAlH4, Et2O, 0 °C, 1 h
6.5  LHMDS, THF, -78 to -20oC, 5-12 h
BocHN
OH
NHBoc
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Preparation of Compound 11b 
 
11b 
Compound 11b was prepared from Val-Weinreb’s amide (3.70 g, 14.0 mmol) and Leu-
alkyne (7.50 g, 35.5 mmol).  Flash chromatography (1:5 EtOAc/Hexanes) afforded 1.95 
g (33 %) 11b as a white solid.   
 1H NMR (500 MHz, CDCl3) δ 4.85 (d, 1H, J = 9.5 Hz), 4.76 (br, 1H), 4.46 (br, 2H), 
3.43-3.39 (m, 1H), 2.61 (br, 1H), 2.05-2.00 (m, 1H), 1.79-1.73 (m, 1H), 1.52-1.49 (m, 
2H), 1.46 (s, 9H), 1.44 (s, 9H), 0.98 (d, 3H, J = 9.0 Hz), 0.94-0.92 (m, 9H) 
13C NMR (125 MHz, CDCl3) δ 156.9, 154.8, 85.3, 82.1, 79.7, 79.5, 63.6, 60.9, 45.2, 
41.5, 29.0, 25.0, 22.8, 21.8, 20.1, 18.3 
MS (ESI, m/z) calcd for C22H41N2O5 (M+H)+ 413.30, found 413.31 
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Preparation of Compound 11c 
 
11c 
Compound 11c was prepared from Tyr-Weinreb’s amide (0.83 g, 2.0 mmol) and Leu-
alkyne (1.06 g, 5.0 mmol).  Flash chromatography (1:3 EtOAc/Hexanes) afforded 0.40 g 
(35 %) 11c as yellowish solid.  Two isomers weren’t separated by flash chromatography. 
MS (MALDI, m/z) calcd for C33H46N2NaO6 (M+Na)+ 589.33, found 589.44 
 
1H NMR of 11c 
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Preparation of Compound 11d 
 
11d 
Compound 11d was prepared from Leu-Weinreb’s amide (0.55 g, 2.0 mmol) and Tyr-
alkyne (1.02 g, 4.8 mmol).  Flash chromatography (1:5 EtOAc/Hexanes) afforded 0.31 g 
(29 %) 11d as a yellow oil.   
1H NMR (500 MHz, CDCl3) δ 7.43 (d, 2H, J = 7.0 Hz), 7.39 (t, 2H, J = 7.0 Hz), 7.33 (t, 
1H, J = 7.0 Hz), 7.19 (d, 2H, J = 8.0 Hz), 6.93 (d, 2H. J = 8.0 Hz), 5.04 (s, 2H), 4.90 (br, 
1H), 4.86 (br, 1H), 4.61 (br, 1H), 4.47 (d, 1H, J = 4.0 Hz), 3.43 (br, 1H), 2.93 (br, 1H), 
2.83 (dd, 1H, J = 7.5, 12.5 Hz), 1.69 (br, 1H), 1.52 (br, 1H), 1.46 (s, 9H). 1.42 (s, 9H), 
1.01-1.08 (m, 1H), 0.93 (d, 3H, J = 6.5 Hz), 0.88 (t, 3H, J = 7.5 Hz)  
13C NMR (125 MHz, CDCl3) δ 157.8, 156.9, 154.7, 137.1, 130.8, 130.8, 129.1, 128.6, 
127.9, 127.5, 114.6, 84.4, 83.6, 79.8, 79.6, 70.0, 63.3, 59.9, 44.5, 41.1, 35.4, 28.4, 28.3, 
24.9, 16.1, 11.3  
MS (MALDI, m/z) calcd for C33H47N2O6 (M+H)+ 589.33, found 589.45 
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Preparation of Compound 11e 
 
11e 
Compound 11e was prepared from Met-Weinreb’s amide (0.29 g, 1.0 mmol) and Tyr-
alkyne (0.84 g, 2.4 mmol).  Flash chromatography (1:3 to 1:1 EtOAc/Hexanes) afforded 
0.17 g (29 %) 11e as a brown solid.   
1H NMR (500 MHz, CDCl3) δ 7.42 (d, 2H, J = 7.5 Hz), 7.38 (t, 2H, J = 7.5 Hz), 7.32 (t, 
1H, J = 7.5 Hz), 7.17 (d, 2H, J = 8.0 Hz), 6.94 (d, 2H, J = 8.0 Hz), 5.04 (s, 2H), 4.85 (br, 
1H), 4.71 (d, 1H, J = 8.5 Hz), 4.63 (br, 1H), 4.38 (br, 1H), 3.78-3.73 (m, 1H), 2.93 (br, 
1H), 2.83 (dd, 1H, J = 7.5, 13.5 Hz), 2.57-2.45 (m, 2H), 2.07 (s, 3H), 1.94 (br, 2H), 1.45 
(s, 9H), 1.42 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 157.8, 156.1, 154.7, 137.0, 130.7, 128.9, 128.5, 127.9, 
127.4, 114.7, 84.9, 82.5, 80.1, 79.8, 69.9, 64.6, 54.2, 44.3, 40.9, 30.7, 28.3, 25.6, 15.5  
MS (MALDI, m/z) calcd for C32H44N2NaO6Si (M+Na)+ 607.28, found 607.49 
BocHN
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NHBoc
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Preparation of Compound 11f 
 
11f 
Compound 11f was prepared from Thr-Weinreb’s amide (400.0 mg, 1.14 mmol) and 
Gly-alkyne (720.0 mg, 2.84 mmol).  Flash chromatography (1:5 EtOAc/Hexanes) 
afforded 74.4 mg (12.0 %) 11f as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 7.41-7.27 (m, 5H), 5.11 (d, 1H, J = 9.5 Hz), 4.58 (d, 1H, J 
=11.0 Hz), 4.47 (d, 1H, J = 7.5 Hz), 4.40-4.37 (m, 3H), 4.09-4.05 (m, 1H), 3.65 (t, 1H, J 
= 9.0 Hz), 1.50 (s, 9H), 1.44 (s, 9H), 1.25 (d, J = 5.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 157.5, 151.6, 137.9, 128.4, 127.9, 127.9, 83.0, 82.2, 
81.2, 79.9, 74.2, 71.3, 65.0, 60.3, 36.0, 28.3, 28.0, 16.6  
MS (ESI, m/z) calcd for C29H44LiN2O8 (M+Li)+ 555.33, found 555.32 
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13C NMR of 11f 
 
General Procedure and Preparation of 12a - f and 14a - f  
To a solution of the 11a - f (1.0 equiv) in anhydrous 1,4-dioxane (0.03 M) was added 
platinum (II) chloride (0.05 equiv).  The solution was refluxed for 24 h.  The mixture 
was concentrated under vacuum.  The compounds 12a - f and 14a - f were purified by 
Flash chromatography.  
Scheme S9.   Synthesis of compounds 12a - f and 14a - f. 
 
 
 
0.05 PtCl2 
1,4-dioxane
100oC, 24 h
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Preparation of Compound 12a 
 
12a 
Compound 12a was prepared from 11a (97.8 mg, 0.23 mmol).  Flash chromatography 
(3:97 EtOAc/Hexanes) afforded 76.7 mg (82 %) 12a as a yellowish oil.   
 
1H NMR (500 MHz, CDCl3) δ 6.04 (d, 1H, J = 3.5 Hz), 5.84 (dd, 1H, J = 0.5, 3.5 Hz), 
5.22 (d, 1H, J = 8.0 Hz), 5.14 (dt, 1H, J = 7.0, 15.0 Hz), 3.17-3.13(m, 1H), 1.76-1.71 (m, 
1H), 1.63 (s, 9H), 1.60-1.53 (m, 4H), 1.14 (d, 3H, J = 6.5 Hz), 0.99-0.91 (m, 9H) 
13C NMR (125 MHz, CDCl3) δ 154.9, 150.9, 142.3, 134.8, 110.3, 106.6, 84.3, 78.8, 
47.4, 44.3, 33.4, 29.4, 28.4, 27.8, 25.3, 22.7, 22.5, 20.6, 11.8 
MS (MALDI, m/z) calcd for C23H40N2NaO4 (M+Na)+ 431.29, found 431.37 
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13C NMR of 12a 
Preparation of Compound 14a 
 
14a 
Compound 14a was prepared from 11a (97.8 mg, 0.23 mmol).  Flash chromatography 
(3:97 EtOAc/Hexanes) afforded 8.3 mg (12 %) 14a as a yellow oil.   
1H NMR (500 MHz, CDCl3) δ 6.53 (d, 1H, J = 16.0 Hz), 6.18 (d, 1H, J = 3.5 Hz), 5.91 
(d, 1H, J = 4.0 Hz), 5.89 (dd, 1H, J = 7.0, 16.0 Hz), 3.29-3.22 (m, 1H), 2.45-2.38 (m, 
1H), 1.61 (s, 9H), 1.72-1.64 (m, 1H), 1.50-1.42 (m, 1H), 1.18 (d, 3H, J = 7.0 Hz), 1.18 
(d, 6H, J = 6.5 Hz), 0.90 (t, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 150.4, 142.0, 136.3, 133.7, 119.0, 108.3, 107.8, 83.7, 
33.3, 31.4, 29.9, 28.0, 22.5, 22.5, 20.3, 11.7 
MS (ESI, m/z) calcd for C18H30NO2 (M+H)+ 292.23, found 292.22 
N
Boc
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Preparation of Compound 12b 
 
12b 
Compound 12b was prepared from 11b (297.3 mg, 0.72 mmol).  Flash chromatography 
(3:97 EtOAc/Hexanes) afforded 204.2 mg (72 %) 12b as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 6.03 (d, 1H, J = 3.0 Hz), 5.86 (dd, 1H. J = 1.0, 3.5 Hz), 
5.29 (br, 1H), 5.13 (br, 1H), 3.37-3.31 (m, 1H), 1.67-1.48 (m, 12H), 1.44 (s, 9H), 1.23 
(d, 3H, J = 7.0 Hz), 1.16 (d, 3H, J = 6.5 Hz), 0.91(d, 6H, J = 6.5 Hz)  
13C NMR (125 MHz, CDCl3) δ 154.9, 150.8, 143.2, 135.0, 110.3, 106.1, 84.3, 78.8, 
47.4, 44.1, 28.4, 27.7, 26.9, 25.3, 23.6, 22.7, 22.7, 22.5  
MS (ESI, m/z) calcd for C22H39N2O4 (M+H)+ 395.29, found 395.29 
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13C NMR of 12b 
 
Preparation of Compound 14b 
 
14b 
Compound 14b was prepared from 11b (297.3 mg, 0.72 mmol).  Flash chromatography 
(3:97 EtOAc/Hexanes) afforded 5.7 mg (3 %) 14b as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 6.54 (d, 1H, J = 16 Hz), 6.17 (d, 1H, J = 3.5 Hz), 5.93 (d, 
1H, J = 3.5 Hz), 5.89 (dd, 1H, J = 7.0, 16.0 Hz), 3.45-3.40 (m, 1H), 2.42 (m, 1H), 1.62 
(s, 9H), 1.21 (d, 6H, J = 6.5 Hz), 1.06 (d, 6H, J = 7.0 Hz)  
13C NMR (125 MHz, CDCl3) δ 150.3, 143.1, 136.5, 134.1, 119.1, 108.3, 107.2, 83.7, 
31.4, 28.0, 27.0, 23.2, 23.0, 22.5 
MS (ESI, m/z) calcd for C17H28NO2 (M+H)+ 278.21, found 278.21 
N
Boc
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Preparation of Compound 12c 
 
12c 
Compound 12c was prepared from 11c (93.0 mg, 0.16 mmol).  Flash chromatography 
(1:9 EtOAc/Hexanes) afforded 19.2 mg (21 %) 12c as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 7.44 (d, 2H, J = 8.0 Hz), 7.39 (t, 2H, J = 7.5 Hz), 7.32 (t, 
1H, J = 8.0 Hz), 7.02 (d, 2H, J = 8.0 Hz), 6.91 (d, 2H, 8.5 Hz), 6.03 (d, 1H, J = 2.5 Hz), 
5.65 (d, 1H, J = 2.5 Hz), 5.35 (br, 1H), 5.16 (br, 1H), 5.06 (s, 2H), 4.05 (s, 2H), 1.61 (br, 
3H), 1.46 (s, 9H), 1.44 (s, 9H), 0.93 (d, 3H, 3.0 Hz), 0.92 (d, 3H, 3.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 157.2, 155.0, 150.5, 137.1, 136.0, 135.0, 132.0, 129.6, 
128.5, 127.9, 127.4, 114.8, 111.3, 110.7, 105.0, 84.4, 78.8, 70.0, 47.6, 44.2, 34.8, 28.5, 
27.6, 25.3, 22.7, 22.6  
MS (ESI, m/z) calcd for C33H44LiN2O5 (M+Li)+ 555.34, found 555.33 
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Preparation of Compound 14c 
 
14c 
Compound 14c was prepared from 11c (93.0 mg, 0.16 mmol).  Flash chromatography 
(1:9 EtOAc/Hexanes) afforded 7.2 mg (10 %) 14c as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 7.43 (d, 2H, J = 7.0 Hz), 7.38 (t, 2H, J = 9.0 Hz), 7.32 (t, 
1H, J = 7.0 Hz), 7.04 (d, 2H, J = 9.0 Hz), 6.90 (d, 2H, J = 9.0 Hz), 6.61 (d, 1H, J = 16.0 
Hz), 6.18 (d, 1H, J = 3.5 Hz), 5.92 (dd, 1H, J = 6.5, 15.5 Hz), 5.74 (d, 1H, J = 3.5), 5.05 
(s, 2H), 4.10 (s, 2H), 2.47-2.40 (m, 1H), 1.46 (s, 9H), 1.07 (d, 6H, J = 6.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 157.1, 150.1, 137.2, 136.9, 134.8, 134.7, 132.3, 129.6, 
128.5, 127.9, 127.4, 119.0, 114.7, 112.2, 108.3, 83.8, 70.0, 34.7, 31.4, 27.9, 22.4  
MS (ESI, m/z) calcd for C28H34NO3 (M+H)+ 432.25, found 432.23 
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N
Boc
BnO
 295 
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Preparation of Compound 12d 
 
12d 
Compound 12d was prepared from 11d (164.8 mg, 0.29 mmol).  Flash chromatography 
(1:5 EtOAc/Hexanes) afforded 98.0 mg (61 %) 12d as a yellowish oil. 
1H NMR (500 MHz, CDCl3) δ 7.42 (d, 2H, J = 7.0 Hz), 7.38 (t, 2H, J = 7.5 Hz), 7.33 (t, 
1H, J = 7.0 Hz), 6.99 (d, 2H, J = 8.0 Hz), 6.84 (d, 2H, J = 8.5 Hz), 5.90 (d, 1H, J = 2.5 
Hz), 5.81 (d, 1H, J = 3.0 Hz), 5.37-5.34 (td, 1H, J = 6.5, 14.5 Hz), 5.21 (d, 1H, J = 8.5 
Hz), 5.02 (s, 2H), 3.23-3.16 (m, 1H), 3.03 (dd, 1H, J = 7.0, 14.0 Hz), 2.96 (dd, 1H, J = 
6.5, 13.5 Hz), 1.74-1.67 (m, 1H), 1.64 (s, 9H), 1.47-1.42 (m, 1H), 1.39 (s, 9H), 1.16 (d, 
3H, J = 7.0 Hz), 0.92 (t, 3H, J = 7.0 Hz) 
N
Boc
NHBoc
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13C NMR (125 MHz, CDCl3) δ 157.3, 154.9, 150.9, 142.6, 137.2, 134.2, 130.4, 130.3, 
128.6, 127.9, 127.5, 114.5, 111.0, 106.9, 84.4, 79.0, 70.0, 50.5, 40.7, 33.5, 29.6, 28.4, 
27.9, 20.6,11.7 
MS (MALDI, m/z) calcd for C33H44N2NaO5 (M+Na)+ 571.31, found 571.43  
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Preparation of Compound 14d 
 
14d 
Compound 14d was prepared from 11d (164.8 mg, 0.29 mmol).  Flash chromatography 
(1:5 EtOAc/Hexanes) afforded 21.0 mg (17 %) 14d as a yellowish solid.  Most products 
were a mixture of isomers, and they were not separated easily by flash chromatography.  
1H NMR (500 MHz, CDCl3) δ 8.01 (s, 1H), 7.42 (d, 2H, J = 7.0 Hz), 7.40 (t, 2H, J = 7.5 
Hz), 7.35 (d, 2H, J = 8.5 Hz), 6.95 (d, 2H, J = 8.5 Hz), 6.80 (d, 1H, J = 16.5 Hz), 6.53 (d, 
1H, J = 16.5 Hz), 6.20 (t, 1H, J = 3.0 Hz), 5.93 (t, 1H, J = 3.0 Hz), 5.08 (s, 2H), 2.74-2.7 
(m, 1H), 1.72-1.66 (m, 1H), 1.64-1.60 (m, 1H), 1.57 (s, 9H), 1.28 (d, 3H, J = 3.0 Hz), 
0.93 (t, 3H, J = 7.5 Hz) 
N
Boc
OBn
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MS (MALDI, m/z) calcd for C28H34NO3 (M+H)+ 432.25, found 432.27 
 
1H NMR of 14d 
 
Preparation of Compound 12e 
 
12e 
Compound 12e was prepared from 11e (30.0 mg, 0.052 mmol).  Flash chromatography 
(3:97 EtOAc/Hexanes) afforded 8.8 mg (30.0 %) 12e as a yellowish solid.   
1H NMR (500 MHz, CDCl3) δ 7.42 (d, 2H, J = 7.0 Hz), 7.38 (t, 2H, J = 7.0 Hz), 7.32 (t, 
1H, J = 7.0 Hz), 6.99(d, 2H, J = 8.5 Hz), 6.85 (d, 2H, J = 8.5 Hz), 5.91 (d, 1H, J = 3.0 
Hz), 5.85 (d, 1H, J = 3.0Hz), 5.43-5.41 (m, 1H), 5.17 (d, 1H, J = 8.0 Hz), 5.02 (s, 2H), 
3.06-3.01 (m, 2H), 2.74-2.79 (m, 3H), 2.95 (dd, 1H, J = 6.0 Hz), J = 13.5 Hz), 2.13 (s, 
3H), 1.64 (s, 9H), 1.38 (s, 9H) 
N
Boc
NHBocS
OBn
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13C NMR (125 MHz, CDCl3) δ 157.3, 150.9, 150.3, 137.1, 135.4, 134.8, 130.4, 130.3, 
128.5, 127.9, 127.5, 114.5, 111.1, 110.3, 84.7, 79.1, 70.0, 50.4, 40.6, 33.9, 30.0, 28.4, 
28.0, 15.7  
MS (MALDI, m/z) calcd for C32H42N2NaO5S (M+Na)+ 589.27, found 589.45 
 
1H NMR of 12e 
 300 
 
13C NMR of 12e 
 
Preparation of Compound 14e 
 
14e 
Compound 14e was prepared from 11e (30.0 mg, 0.052 mmol).  Flash chromatography 
(3:97 EtOAc/Hexanes) afforded trace amount as a yellowish solid. 
1H NMR (500 MHz, CDCl3) δ 7.47-7.30 (m, 9H), 6.94 (d, 2H, J = 8.5 Hz), 6.74 (d, 1H. J 
= 16.0 Hz), 6.37 (d, 1H, J = 3.5 Hz), 6.01 (d, 1H, J = 3.5 Hz), 5.08 (s, 2H), 3.12 (t, 2H, J 
= 7.5 Hz), 2.75 (t, 2H, J = 7.5 Hz), 2.14 (s, 3H), 1.57 (s, 9H) 
13C NMR was not obtained. 
MS (MALDI, m/z) calcd for C27H32NO3S (M+H)+ 450.21, found 450.20 
 
N
Boc
S
OBn
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1H NMR of 14e 
Preparation of Compound 12f 
 
12f 
Compound 12f was prepared from 11f (47.9 mg, 0.087 mmol).  Flash chromatography 
(1:5 EtOAc/Hexanes) afforded 6.2 mg (13 %) 12f as a yellow oil.   
1H NMR (500 MHz, CDCl3) δ 7.32-7.25 (m, 5H), 6.24 (d, 1H, J = 3.5 Hz), 5.93 (d, 1H, J 
= 3.5 Hz), 5.09 (q, 1H, J = 6.0, 12.5 Hz), 4.97 (d, 1H, J = 17.5 Hz), 4.89 (d, 1H, J = 17.0 
Hz), 4.60 (d, 1H, J = 12.0 Hz), 4.38 (d, 1H, J = 12.0 Hz), 1.58 (br, 3H), 1.54 (s, 9H), 
1.48 (s, 18H) 
13C NMR (125 MHz, CDCl3) δ 152.6, 149.7, 138.8, 137.9, 132.8, 128.3, 127.7, 127.4, 
109.3, 108.5, 84.4, 82.5, 71.1, 70.3, 45.6, 28.0, 27.9, 22.4  
MS (MALDI, m/z) calcd for C29H42N2NaO7 (M+Na)+ 553.29, found 553.35 
 
N
Boc
N(Boc)2BnO
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1H NMR of 12f 
 
13C NMR of 12f 
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Preparation of Compound 14f 
 
14f 
Compound 14f was prepared from 11f (47.9 mg, 0.087 mmol).  Flash chromatography 
(1:5 EtOAc/Hexanes) afforded trace amount.   
1H NMR (500 MHz, CDCl3) δ 7.02 (dd, 1H, J = 11.5, 17.5 Hz), 6.30 (d, 1H, J = 3.5 Hz), 
5.92 (d, 1H, J  = 3.0 Hz), 5.43 (d, 1, J = 17.5 Hz), 5.04 (d, 1H, J = 11.0 Hz), 4.94 (s, 2H), 
1.61 (s, 9H), 1.48 (s, 18H) (3.48 and 1.22 from diethyl ether contamination.)  
13C NMR was not obtained. 
MS (MALDI, m/z) calcd for C22H34N2NaO6 (M+Na)+ 445.50, found 445.41  
 
 
1H NMR of 14f 
 
N
Boc
N(Boc)2
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General Procedure and Preparation of Compounds 13a - e  
To a solution of the 12a - e (1.0 equiv) in anhydrous THF (0.2 M) was added 6.5 M 
NaOMe/MeOH (5.0 equiv).  The mixture solution was stirred for 30 min at 25 oC.  The 
mixture was diluted with H2O and then extracted with chloroform.  The combined 
chloroform fractions were dried over MgSO4 and concentrated under vacuum.  The 
compound 13a - e were purified by Flash chromatography. 
Scheme S10.   Synthesis of compounds 13a - e. 
 
 
Preparation of Compound 13a 
 
13a 
Compound 13a was prepared from 12a (26.2 mg, 0.064 mmol).  Flash chromatography 
(1:9 EtOAc/Hexanes) afforded 14.0 mg (93 %) 13a as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 6.05 (s, 1H), 6.01 (dd, 1H, J = 0.5, 1.5 Hz), 5.86 (dd, 1H, 
J = 1.5, 2.0 Hz), 4.55 (t, 1H, J = 6.5 Hz), 3.31-3.23 (m, 1H), 1.90-1.81 (m, 1H), 1.80-
1.72 (m, 1H), 1.64- 1.51(m, 3H), 1.25 (d, 3H, J = 7.0 Hz), 1.00 (d, 3H, J = 2.5 Hz), 0.99 
(d, 3H, J = 2.0 Hz), 0.91 (t, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 154.4, 135.5, 135.2, 110.5, 100.9, 50.7, 44.5, 31.9, 29.4, 
25.2, 22.6, 19.9, 11.7  
MS (ESI, m/z) calcd for C14H23N2O (M+H)+ 235.35, found 235.17 
 
NR1
NH
O
R2
N
Boc
R1
R2
NHBoc
NaOMe/MeOH
THF, 25oC, 30 min
12a - e 13a - e
N
NH
O
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1H NMR of 13a 
 
13C NMR of 13a 
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Preparation of Compound 13b 
 
13b 
Compound 13b was prepared from 12b (7.6 mg, 0.026 mmol).  Flash chromatography 
(1:9 EtOAc/Hexanes) afforded 4.4 mg (99 %) 13b as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 6.02 (dd, 1H, J = 1.0, 2.5 Hz), 5.85 (dd, 1H, J = 2.5, 3.5 
Hz), 5.56 (s, 1H), 4.55 (t, 1H, J = 7.0 Hz), 3.47-3.41 (m, 1H), 1.88-1.80 (m, 1H), 1.65-
1.53 (m, 2H), 1.29 (d, 3H, J = 1.5 Hz), 1.28 (d, 3H, J = 1.5 Hz), 1.01 (d, 3H. J = 4.5Hz), 
0.99 (d, 3H, J = 5.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 153.1, 136.4, 135.6, 109.8, 100.9, 50.8, 44.6, 25.4, 25.2, 
22.7, 22.6, 22.5, 22.3 
MS (ESI, m/z) calcd for C13H21N2O (M+H)+ 221.16, found 221.17 
 
1H NMR of 13b 
N
NH
O
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13C NMR of 13b 
Preparation of Compound 13c 
 
13c 
Compound 13c was prepared from 12c (2.6 mg, 0.0047 mmol).  Flash chromatography 
(1:7 EtOAc/Hexanes) afforded 1.8 mg (99 %) 13c as an orange solid.   
1H NMR (500 MHz, CDCl3) δ 7.43 (d, 2H, J = 7.5 Hz), 7.38 (t, 2H, J = 7.0 Hz), 7.32 (t, 
1H, J = 7.5 Hz), 7.22 (d, 2H, J = 8.5 Hz), 6.91 (d, 2H, J = 8.5 Hz), 5.91 (d, 1H, J = 3.0 
Hz), 5.85 (dd, 1H, J = 1.0, 8.0 Hz), 5.40 (s, 1H), 5.04 (s, 2H), 4.55 (t, 1H, J = 7.0 Hz), 
4.16 (d, 2H, J = 5.0 Hz), 1.85-1.80 (m, 1H), 1.64-1.52 (m, 2H), 0.99 (t, 6H, J = 6.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 157.3, 153.0, 137.2, 135.7, 131.8, 129.9, 128.6, 128.5, 
127.9, 127.5, 114.7, 113.5, 101.3, 70.0, 50.8, 44.6, 31.0, 25.2, 22.6, 22.5 
MS (ESI, m/z) calcd for C24H27N2O2 (M+H)+ 375.21, found 375.16 
N
NH
O
BnO
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1H NMR of 13c 
 
13C NMR of 13c 
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Preparation of Compound 13d 
 
13d 
Compound 13d was prepared from 12d (31.1 mg, 0.054 mmol).  Flash chromatography 
(1:7 EtOAc/Hexanes) afforded 13.1 mg (77 %) 13d as a yellowish oil.   
1H NMR (500 MHz, CDCl3) δ 7.45 (d, 2H, J= 7.0 Hz), 7.41 (t, 2H, J = 7.5 Hz), 7.35 (t, 
1H, J = 7.5 Hz), 7.14 (d, 2H, J = 8.5 Hz), 6.94 (d, 2H, J = 9.0 Hz), 6.01 (d, 1H, J = 3.0 
Hz), 5.78 (dd, 1H, J = 1.5, 3.0 Hz), 5.56 (s, 1H), 4.66 (t, 1H, J = 7.5 Hz), 3.30-3.24 (m, 
1H), 3.03 (dd, 1H, J = 5.5, 13.5 Hz), 2.83 (dd, 1H, J = 8.5, 14.0 Hz), 1.79-1.70 (m, 1H), 
1.62-1.52 (m, 1H), 1.25 (d, 3H, J = 7.0 Hz), 0.90 (t, 3H, 7.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 157.9, 152.9, 136.9, 135.4, 134.4, 130.2, 128.7, 128.6, 
128.0, 127.5, 115.1, 110.5, 101.4, 70.0, 53.7, 41.2, 31.8, 29.4, 20.0, 11.6 
MS (ESI, m/z) calcd for C24H27N2O2 (M+H)+ 375.21, found 375.21 
 
N
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O
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1H NMR of 13d 
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Preparation of Compound 13e 
 
13e 
Compound 13e was prepared from 12e (2.7 mg, 0.0048 mmol).  Flash chromatography 
(1:9 EtOAc/Hexanes) afforded 1.5 mg (94 %) 13e as a white solid.   
1H NMR (500 MHz, CDCl3) δ 7.44 (d, 2H, 7.0 Hz), 7.40 (t, 2H, J = 7.0 Hz), 7.34 (t, 1H, 
J = 7.5 Hz), 7.14 (d, 2H, J = 9.0 Hz), 6.95 (d, 2H, J = 8.5 Hz), 6.08 (d, 1H, J = 3.5 Hz), 
5.77 (dd, 1H, J = 1.5, 3.0 Hz), 5.33 (s, 1H), 5.07 (s, 2H), 4.66 (t, 1H, 8.0 Hz), 3.17-3.12 
(m, 2H), 3.03 (dd, 1H, J = 5.5, 14.0 Hz), 2.83 (t, 2H, 7.5 Hz), 2.80 (dd, 1H, J = 9.0, 15.0 
Hz), 2.13 (s, 3H) 
13C NMR (125 MHz, CDCl3) δ 158.0, 152.6, 136.8, 134.9, 130.2, 128.6, 128.6, 128.0, 
127.5, 127.3, 115.2, 113.6, 101.7, 70.1, 53.9, 41.2, 33.7, 26.0, 15.4 
MS (ESI, m/z) calcd for C23H25N2O2S (M+H)+ 393.16, found 393.13 
 
N
NH
O
OBn
S
 312 
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13C NMR of 13e 
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General Procedure and Preparation of Compound 3a  
To a solution of the 12a (1.0 equiv) and 2,6-lutidine (5.0 equiv) in anhydrous CH2Cl2 
(0.1 M) and was added TMSOTf (4.0 equiv) at 0 oC.  The mixture solution was stirred 
for 15 min at 0 oC.  The mixture was warmed up to 25 oC and then stirred for 2 h at 25 
oC.  To the mixture was added Sat. NH4Cl (aq) and then extracted with EtOAc.  The 
combined organic layer was dried over MgSO4 and concentrated under vacuum.  The 
compound was purified by Flash chromatography.  
 
Scheme S11.   Synthesis of compounds 3a. 
 
Compound 3a was prepared from 12a (3.0 mg, 0.0073 mmol).  Flash chromatography 
(1:1 EtOAc/Hexanes) afforded 1.5 mg (67 %) 3a as a colorless oil.   
1H NMR (500 MHz, CD3OD) δ 6.31 (d, 1H, J = 3.5 Hz), 6.03 (d, 1H, J = 3.5 Hz), 4.70-
4.62 (m, 1H), 4.59 (t, 1H, J = 8.5 Hz), 1.92-1.88 (m, 1H), 1.74-1.70 (m, 1H), 1.66 (s, 
9H), 1.64-1.58 (m, 2H), 1.50-1.44 (m, 1H), 1.22 (d, 3H, J = 6.5 Hz), 0.95 (d, 3H, J = 7.0 
Hz), 0.92 (d, 3H, J = 7.0 Hz), 0.89 (d, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CD3OD) δ 152.2, 143.6, 135.6, 111.6, 108.8, 86.4, 48.0, 44.5, 
34.9, 31.3, 28.2, 26.1, 23.0, 22.7, 20.6, 11.9 
MS (ESI, m/z) calcd for C18H33N2O2 (M+H)+ 309.25, found 309.26 
N
Boc
NHBoc
N
Boc
NH2TMSOTf, 2,6-lutidine
CH2Cl2, 0 - 25oC, 2 h
12a 3a
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1H NMR of 3a 
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13C NMR of 3a 
 
Optimization of Reactions  
Table S1. Screening of Reaction Conditions for the Formation of Propargyl Alcohols or Propargyl 
Ketones. 
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(C)
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entry reactiona base or catalyst solvent temp. (oC) yield (%)j 
      
1b A LHMDS THF -78 57 
2c A nBuLi THF -78 NR 
3d A nBuLi + HMPA THF -78 36 
4e A nBuLi + 
diisopropylamine 
THF -78 40 
5f A EtMgBr THF 0 34 
6g B CrCl2+NiCl2 THF/DMF 
(1:1) 
25  NR 
7h C nBuLi THF -78 NR 
8i D PdCl2(dppf) + P(2-
furyl)3 + CuI  
DMF/TEA 
(5:1) 
50 21 
a Aldehyde (1.0 equiv), Weinreb amide (1.0 equiv), thioester (1.0 equiv), terminal alkyne (2.5 equiv), and 
iodoalkyne (2.0 equiv) were used. b LHMDS (6.5 equiv). c nBuLi (6.5 equiv). d nBuLi (6.3 equiv) and HMPA 
(12.0 equiv). e nBuLi (6.5 equiv) and diisopropylamine (6.5 equiv). f EtMgBr (6.5 equiv). g CrCl2 (10.0 equiv) 
and NiCl2 (0.1 equiv).  h nBuLi (6.5 equiv). i PdCl2(dppf) (0.1 equiv), P(2-furyl)3 (0.25 equiv) and CuI (1.7 
equiv). j isolated yields.  
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Table S2. Screening of Reaction Conditions for Hydroamination. 
 
  
entry catalyst ligand conversion 
yield (%)a 
12a:14aa 
     
1 PtCl2 - 94 6.8:1.0 
2 Pd(OAc)2 - 13 1.0:trace 
3 PdCl2(PPh3)2 - 10 1.0:trace 
4 PtCl2 citric acid 87 5.8:1.0 
5 PtCl2 acetic acid 90 5.9:1.0 
6 PtCl2 K2CO3 87 5.6:1.0 
7 PtCl2 Cs2CO3 70 6.0:1.0 
8 PtCl2 PPh3 90 5.3:1.0 
9 PtCl2 (2-biphenyl)di-tert-
butylphosphine 
88 6.0:1.0 
a determined by NMR.  
  
N
Boc
NHBoc
12a
OH
BocHN
NHBoc
11a
N
Boc
+
14a
0.05 catalyst, 0.1 ligand
1.4-dioxane, MW 110 oC, 1 h
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APPENDIX F 
EXPERIMENTAL FOR CHAPTER VI 
A. Templates For Secondary Structures 
Standard template for overlays with 310-helix, α-helix, π-helix, and β-strand were 
obtained from Discovery Studio 2.5.   Parallel β-sheet and sheet/turn/sheet templates 
were obtained by modified β-sheet builder.   
(http://www-lbit.iro.umontreal.ca/bBuilder/index.html) 
B. Procedure For Overlays 
After minimization in the QMD process, the conformers were grouped into families 
based on their Cα-Cβ coordinates.  The process of systematically matching preferred 
conformers with secondary structures was performed in the following way.   All the 
conformers within 3.0 kcal/mol were considered to be “preferred”.  Each of these was 
overlaid on ideal secondary structures using an in house generated algorithm that 
compared Cα-Cβ coordinates of the side chains which generates a list of structures 
ranked in terms of the RMSD for the overlay process.  The lowest energy structures 
from each family were each overlaid on the ideal secondary structures shown in chapter 
6, Table 6.1 and Table 6.2. 
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C. Procedure For Ramachandran Plot 
 
Definition of torsional angles: φ (H1-N2-C3-C4), ψ (N2-C3-C4-N5), φ’ (C4-N5-C6-C7) and 
ψ’ (N5-C6-C7-O8) 
For each compound, 600 conformers within 3.0 kcal/mol were obtained by QMD.  
Ramachandran plot for the conformers was obtained from UCSF Chimera 1.5.2. 
www.cgl.ucsf.edu/chimera/ 
 
D. Overlays of Compound 6 Conformers On The Secondary Structures 
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overlay on 310-helix overlay on α-helix
overlay on π-helix overlay on β-strand
overlay on parallel β-sheet overlay on sheet/β-turn/sheet
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APPENDIX G 
EXPERIMENTAL FOR CHAPTER VII 
A. Enterotoxin and Cholera Toxin as Targets for Pyrrolinone-pyrrolidine 
Oligomers 1  
Structure and Function of Cholera Toxin and Enterotoxin 
These toxins are directly associated with causing cholera and related enteropathies in 
humans and domestic animals.  Diarrhea is perhaps the leading worldwide cause of 
mortality for children under five, and the featured toxins are responsible for a significant 
fraction of these.164   
Structurally, both toxins consist of a 27 kDa A fragment which sits on top of a cyclic 
homopentamer of 11.7 kDa B fragments giving an AB5 quaternary arrangement.165  Over 
80 % of both the A and B fragments in the two toxins share the same amino acid 
sequence.165  Figure S1 shows side and front views of E. coli enterotoxin from a 
structure pdb:1eef;166 template 1 (LLL) overlaid with a region of this structure is just 
visible in these pictures, and expansions are given below. 
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Figure S1. Side and front views of the E. coli enterotoxin from PDB:1eef. 
 
In the progression of the parent diseases, bacterial cells express the constituent A and B 
fragments, and these assemble into the AB5 hexamer units.  It is the B5 units of the AB5 
structures that bind the ganglioside GM1 receptor of the host’s epithelial cells.  Binding 
of the B5 pentamer unit triggers down-regulation of pro-inflammatory immune 
responses.164,167  Receptor-mediated endocytosis delivers the toxin into the cells, and 
then the A unit is proteolytically cleaved.  This fragment catalyzes ADP ribosylation of 
the Gαs subunit of the heterotrimeric G protein resulting in constitutive cAMP 
production, secretion of water and salts into the lumen of the small intestine resulting in 
rapid dehydration and other factors associated with cholera.  
Each B-unit in the B5 structure shares an extended protein-protein interface, making the 
pentamers extremely stable.  They maintain their secondary structures in ionic 
detergents, 8.0 M urea, 7.0 M guanadinium hydrochloride, and to temperatures in excess 
of 80 °C in aqueous solution.   Correspondingly, high activation energy (151 kJ/mol) has 
been measured for disassembly on the pentamer units, but they can be denatured into 
monomeric fragments at pH 2 or less.  Dissociated toxins fragments at low pH assemble 
at experimentally convenient rates once the medium is made neutral again. 
b
top view
overlaid
ligand
a
side view
overlaid
ligand
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We propose that a small molecule interface mimic is unlikely to be able to cleave the 
preformed AB5 hexamers of these toxins, since they are so stable.  However, the impact 
of the mimics could be assayed in vitro by monitoring their effect on their rate of re-
assembly after pH reduction then restoration to neutrality.  A possible therapeutic mode 
of action for compounds that suppress assembly of the B5 units would be via penetration 
of the small molecule into bacterial cells in the gut of the host, preventing expression 
and formation of the mature hexamer before it is released. 
 
Data From EKO and eKO  
Mining of the database using EKO for stereomer 1 (LLL) gave thirteen different results 
for cholera/enterotoxins within RMSD 0.33 Å (1eef, 1b44, 1lts, 1lt4, 1fd7, 1djr, 1s5c, 
1chq, 1pzi, 1lt6, 1ltg, 1ltt, 1lti).  In all results, conformers of stereomer 1 were on Thr47-
Ile39-Glu29 residues set of B5 units.  Figure S1 shows an overlay for the best matching 
from EKO.  The conformer that is 2.89 kcal/mol over the lowest energy conformation 
was matched with RMSD 0.26 on Thr47-Ile39-Glu29.  Application of eKO to the 
enterotoxin crystal structure 1eef gave Met31-Glu29-Tyr27 (RMSD 0.42 Å, ∆Go = 1.78 
kcal/mol, Figure S2 a) and Lys102-Ser100-Ala98 (RMSD 0.49 Å, ∆Go = 1.78 kcal/mol, 
Figure S2 b).  The Met31-Glu29-Tyr27 residues set correspond to a region of the 
interface that is known to be vital for H-bonding.7 
 
a 
 
 
T47
I39
E29
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b                                                                   c 
 
Figure S2. (a) Mining 1 (L,L,L) gave a good overlay on the T47-I39-E29 from EKO; (b) relaxing the RMSD 
requirement exposed two other matches (b) and (c) at Met31-Glu29-Tyr27 and Ala98-Ser100-Lys102 
from eKO. 
 
Structures of the featured toxins were mined for all 8 amino acid-based epimers of 1.  
Twenty hits were observed for 1 (LLL), and all of them matched on the same protein 
region T47-I39-E29.  Only 1 (LDL) of the other isomers matched, and this time with I31-
E29-Y27 of the cholera toxin, which corresponds to the “second tier” hit (M31-E29-
Y27) for matching 1 (LLL) on the enterotoxin (5 hits); all the matches were C-to-N.  
 
Table S1. Matching of Stereoisomers of 1 on Toxin Structures. 
 conformer PDB RMSD (Å) score residues direction source 
# of 
conformers 
         
1 LLL 1eef 0.26  13.2 T47-I39-E29 C -> N E.Coli 2 
2 LLL 1b44 0.26 13.5 T47-I39-E29 C -> N E.Coli 2 
3 LLL 1lts 0.27 14.3 T47-I39-E29 C -> N E.Coli 2 
4 LLL 1djr 0.28 15.0 T47-I39-E29 C -> N E.Coli 2 
5 LLL 1fd7 0.30 14.0 T47-I39-E29 C -> N E.Coli 1 
6 LLL 1efi 0.30 15.2 T47-I39-E29 C -> N E.Coli 2 
7 LLL 1pzi 0.30 15.7 T47-I39-E29 C -> N E.Coli 4 
8 LLL 1g8z 0.30 16.0 T47-I39-E29 C -> N E.Coli 1 
9 LLL 1s5c 0.31 13.9 T47-I39-E29 C -> N cholera 1 
10 LLL 1chq 0.31 13.9 T47-I39-E29 C -> N cholera 1 
11 LLL 1lt4 0.31 14.1 T47-I39-E29 C -> N E.Coli 2 
12 LLL 1ct1 0.31 15.0 T47-I39-E29 C -> N cholera 1 
M31
E29
Y27
K102
S100
A98
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13 LLL 1lt5 0.31 15.2 T47-I39-E29 C -> N E.Coli 1 
14 LLL 1efi 0.31 15.5 T47-I39-E29 C -> N E.Coli 1 
15 LLL 1lt6 0.31 15.9 T47-I39-E29 C -> N E.Coli 2 
16 LLL 1s5f 0.31 16.1 T47-I39-E29 C -> N cholera 1 
17 LLL 1lta 0.31 16.2 T47-I39-E29 C -> N E.Coli 1 
18 LLL 1s5e 0.31 16.2 T47-I39-E29 C -> N cholera 1 
19 LLL 1ltg 0.32 16.1 T47-I39-E29 C -> N E.Coli 2 
20 LLL 1lti 0.33 16.4 T47-I39-E29 C -> N E.Coli 1 
         
21 LDL 1g8z 0.27 18.1 L31-E29-Y27 C -> N cholera 1 
22 LDL 1md2 0.29 18.3 L31-E29-Y27 C -> N cholera 3 
23 LDL 1s5c 0.29 20.3 L31-E29-Y27 C -> N cholera 1 
24 LDL 1pzj 0.30 18.2 L31-E29-Y27 C -> N cholera 1 
25 LDL 1rdp 0.30 18.6 L31-E29-Y27 C -> N cholera 1 
 
B. AICAR as Targets for Pyrrolinone-pyrrolidine Oligomers 1 
Structure and Function of AICAR 
5-Aminoimidazole-4-carboxamide ribonucleotide transformylase (AICAR Tfase) is one 
component of a bifunctional enzyme, the other being inosine 5’-monophosphate 
cyclohydrolase (IMPCH).169,170  These catalyze the last two steps in purine biosynthesis 
(Figure S3).171,172  Formyl transfer from the cofactor 10-formyl-tetrahydrofolate (10-f-
THF) to the aminoimidazole functionality is mediated by AICAR Tfase, then IMPCH 
promotes cyclization of this N-formyl group to give the purine framework (of IMP).  
Normal cells generate most of the purine they require by a salvage pathway; for them, de 
novo biosynthesis as illustrated in Figure S3 is relatively unimportant.173-176  However, 
cancer cells depend heavily on the de novo pathway, hence they are vulnerable to 
inhibitors.   
 
 
Figure S3. The bifunctional enzyme ATIC completes purine syntheses: formyl transfer mediated by AICAR Tfase, 
then ring closure by IMPCHase. 
 326 
AICAR Tfase is one of several folate-dependent enzyme targets for chemotherapy {cf 
thymidylidyl synthase, dihydrofolate reductase, and glycinamide ribonucleotide 
transformylase}.  Inhibitors of AICAR Tfase that are not based on folate have 
advantages over other anti-folate drugs (cf DHFR, “DDATHF” {lometrexol}177,178 and 
LY231514179) because they are unlikely to impact non-targeted folate-dependent 
enzymes giving unpredictable side effects.  Two validated strategies for disabling 
AICAR Tfase that do not involve mimicry of folate are: (i) disruption of the active site 
function; and, (ii) perturbation the interface in the dimer.  AICAR Tfase is only active in 
the dimeric form, and some molecules that disrupt the dimer interface are known to 
inhibit the enzyme.  These molecules are cyclic peptides (Ki 17 µM or more),180 or 
flexible small molecules (from HTS, e.g. Ki 17 µM).181  Thus the only approaches used 
so far to disrupt AICAR Tfase dimerization have been combinatorial, involving large 
numbers of randomly produced compounds; they give relatively weak inhibition. 
 
Data From EKO and eKO  
The best hit for screening 1 (LLL) had the sequence Ala218-Ley220-Thr222; these align 
with a sheet region on the interface (RMSD 0.28 and 0.31, Figure S5a).  Relaxing the 
RMSD requirement gave three more hits (RMSD 0.39, 0.40, and 0.42, Figure S5c - d).  
Mining all the amino acid-based stereoisomers of 1 gave only one more hit, for 1 (LDL) 
and this matched a different region of the protein Lue329-Glu331-Lys333.  All the 
mimics aligned parallel with the strand. 
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Figure S4. Structure of the bifunctional enzyme with key interface regions where scaffold 1 overlays well 
highlighted. 
 
a                                                                       b 
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c                                                                           d 
 
Figure S5. (a) – (d) Expansions of these regions with key side-chain residues shown in the red boxes, and with 
preferred conformations of scaffold 1 overlaid.  Key comparisons are for the Cα and Cβ atoms.  There 
have been no thermodynamic analyses of AICAR mutants to determine hot-spots.  
 
Table S2. Matching of Stereoisomers of 1 on AICAR Structures. 
 conformer PDB RMSD (Å) score residues direction source 
        
1 LLL 1thz 0.28  17.6 A218-L220-T222 N -> C chicken 
2 LLL 1m9n 0.31 19.3 A218-L220-T222 N -> C chicken 
        
3 LDL 1zcz 0.26 17.0 L329-E331-K333 N -> C thermotoga maritima 
 
C. GAPDH as Targets for Pyrrolinone-pyrrolidine Oligomers 1 
Structure and Function of GAPDH 
D-GlycerAldehyde-3-Phosphate DeHydrogenase (GAPDH) mediates oxidative 
phosphorylation of the aldehyde after which it is named; this is a key step in the 
glycolytic pathway (Figure S6a).182  The structure of GAPDH is a homotetramer or, 
more accurately, a dimer of dimers, wherein the active site is a NAD+ binding groove 
found on each monomer component (Figure S6b and c). 
K267
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Figure S6. (a) Normal glycolytic function of GAPDH; (b) dimer of GAPDH; and (c) dimers of GAPDH 
associate to give a tetrameric quaternary structure. 
 
More sinister roles, however, have been attributed to GAPDH, because this enzyme is 
implicated in apoptotic cell death, particularly in neurodegeneration.  Thus, in cellular 
assays, rescue from apoptosis can be affected by antisense suppression of GAPDH or 
using the Parkinson’s therapy (R)-deprenyl (Selegiline).183,184  Further, a tricyclic 
deprenyl analog, CGP3466, binds and stabilizes the dimeric form of GAPDH and has 
100x the rescuing effect of deprenyl in vitro; CGP3466 is a neuroprotective drug that has 
featured in clinical trials for Parkinson’s disease and ALS.  Consistent with these 
observations, certain fractions of cerebrospinal fluid (CSF) from Parkinson’s patients 
cause apoptosis when added to cells in culture, whereas CSF from healthy patients does 
not.  Further, the apoptidic effects of CSF from Parkinson’s patients is prevented by 
antisense targeting of GAPDH or by (R)-deprenyl.185,186  
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Based on the assertions above, nefarious roles of GAPDH in several neurodegenerative 
diseases are implicated.  Exact mechanisms that tie GAPDH to apoptosis in neurological 
diseases like Huntington’s, Parkinson’s, Alzheimer’s, ALS, stroke and glaucoma 
(neurodegeneration of retinal ganglion cells) are not known, but this has been an area of 
intense recent interest (GAPDH in human neurodegenerative diseases has been 
reviewed)185-187 and some clues are emerging. 
GAPDH has to be imported into the nucleus to trigger apoptosis.  After this, nuclear 
accumulation of GAPDH, or an isoform of it,188 occurs in the neurological diseases 
mentioned so far.  Association of cystolic GAPDH with the E3 ubiquitin ligase Siah 1 is 
critical for importing the former into the nucleus, because only the latter has a nuclear 
localization signal.189  It has been proposed that CGP3466 may bind the NAD+ site 
causing structural changes that reduce the affinity of GAPDH for Siah 1; in other words, 
the drug inhibits apoptotic activity of GAPDH by preventing its nuclear localization.190 
Precisely what form of nuclear GAPDH triggers apoptosis is unclear; some evidence 
suggests that GAPDH-complex stabilizes the otherwise short-lived Siah 1,189 but another 
explanation is that activation of transcription induced by nuclear GAPDH initiates 
apoptotic cell death via a network of signaling mechanisms.185  Once inside the nucleus, 
there appears to be a change in GAPDH structure associated with oxidative modification 
of a channel Cys residue (#149 or 150 depending on the species).187,189  It has been 
suggested that this modification might be a signal for transcriptional activation of its 
own gene, but there is no evidence for this at present.   
GAPDH binds to unusual oligopeptides that are found in neurodegenerative diseases, but 
the relevance of this is unclear.  Polyglutamine-repeat regions localized in cell nuclei 
correlate to disease progression and severity in several neurological conditions.  Some 
proteins are known to selectively bind (Gln)n strands, and one of those is GAPDH.  
Consequently, even though the neurological effects of GAPDH/(Gln)n accumulation in 
cell nuclei are currently unknown, there is an open possibility that this may have 
causative deleterious effects.  Similarly, in Alzheimer’s disease, GAPDH binds the 
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cytoplasmic carboxyl terminus of the β-amyloid protein,191 and the significance of this is 
also unresolved. 
Overall, there are many possibilities for ways in which GAPDH could be perturbed in 
therapeutic approaches, particularly in view of the unknowns surrounding its role in the 
onset and progression of neurological diseases.  Our hypothesis is that the quaternary 
structure of GAPDH may influence the role of this protein in programmed apoptosis, 
impacting accumulation of the enzyme in the nucleus and what it does there.  We are 
intrigued by the observation that the dimeric forms do not induce apoptotic activities, 
even though they are more active in glycolysis because this supports our supposition that 
interface mimics to perturb the dimerization state of GAPDH may selectively effects 
apoptosis in neurodegeneration (cf, when CGP3466 binds rabbit GAPDH in vitro, it 
converts the tetramer to a dimeric form,192 and that is more active than the parent 
tetramer in glycolysis).193  The fact that CGP3466 gives 100x the apoptotic rescuing 
effect of deprenyl may be because it changes the enzyme to the dimeric form more 
effectively via a different allosteric binding mode.  In other words, perhaps deprenyl has 
less influence on the interface region than CGP3466, converts it to the dimeric form less 
effectively, and gives less of an apoptotic rescuing effect.192  Our preliminary studies 
have uncovered an opportunity to prepare small molecule interface mimics to perturb 
assembly and persistence of GAPDH monomers into dimers-of-dimers, and we propose 
to test compounds that are designed to disrupt these interface regions.   
 
Data From EKO and eKO  
There are two types of interfaces in the GAPDH tetramer; one composed of mainly sheet 
regions that appears to be the most important for binding, and another where the 
interface is a much less well-defined loop.  Overlay of template 1 on the loop region was 
only observed when the RMSD constraint was relaxed to approximately 0.7; we judged 
this fit to be unsatisfactory, so that interface is not considered further.  However, the fit 
of template 1, and the stereoisomers of this, on the other interface gave some excellent 
matches.    
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Mining of the database in the usual way showed overlay (RMSD 0.28 Å) of the core 
molecule 1 (LLL) on an interface region of the human GAPDH (pdb: 3gpd in which 
NAD+ is also bound).194  Specifically, it overlays in a parallel fashion (i.e. N-termini of 
protein and peptidomimetic are head-to-head) with residues Phe232-Met230-Thr228.  
These are located on a strand of a β-sheet at the hydrophobic interface formed with a β-
sheet on the other monomer (Figure S7a).  Consideration of matches for the same 
peptidomimetic stereoisomer 1 (LLL) for overlay on the same crystal structure but at 
slightly higher RMS deviations gave a second hit (Figure S7b).  This second hit was 
interesting in three respects: (i) it overlaid with a different interface region (though also a 
sheet); (ii) the side-chains involved were on discontiguous residues (K308, 65 residues 
displaced from D243, and V241); and, (iii) unlike the first hit, the peptidomimetic is 
antiparallel with the primary sequence. 
 
a                                                                      b 
 
Figure S7. (a) Original; and, (b) secondary hits for overlay of 1 (LLL) on human GAPDH. 
 
Some of the 78 GAPDH structures in the PDB are symmetrical homotetramers, but 
others have NAD+ bound to some units.184  Comparisons (DALI)195 suggest that the 
overall fold of GAPDH structures is highly conserved in different organisms.184  
In the next phase of the mining exercise we modeled all the other stereoisomers (D,L,L-, 
L,D,L-, L,L,D-, D,D,L-, D,L,D-, L,D,D-, and D,D,D-) of 1 on all the available GAPDH 
F232
M230 T228
K308
D243
V241
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structures, and many leads emerged (Table S3).  Molecules 1 overlaid N -> C or C -> N 
with the protein.  Interestingly, 1 (LDL) gave more matches than any other isomer, and 
these could be aligned or inverse oriented.  Before synthesis of the compounds, we will 
check the sequence correspondence between organisms for each of the three amino acid 
combinations outlined in Table S3, and match them to the source of GAPDH used in the 
assay (human is preferred; GAPDH is commercially available for all the organisms 
listed below, rabbit is one of the least expensive, and human is the most). 
SAR will be performed around the hits from this first group of compounds.  However, 
all proposed small molecule structures would be matched on GAPDH first to prioritize 
the syntheses (assuming there are no other factors to be addressed more urgently, e.g. 
water solubility issues). 
 
Table S3. Interface Mimics Identified using EKO for Overlay on GAPDH 
 conformer PDB RMSD (Å) score residues directionality source 
        1 LLL 3gpd 0.28 12.30 F232-M230-T228 N -> C human 
2 LLL 1j0x 0.32 16.80 F230-M228-T226 N -> C rabbit 
        
3 DLL 1gd1 0.30 18.69 D242-V244-E246 N -> C bacillus stearothermophilus 
        4 LDL 2hki 0.24 14.41 K309-I311-W313 N -> C spinach 
5 LDL 1znq 0.26 13.40 L177-T179-V181 N -> C human 
6 LDL 1cer 0.25 12.55 F306-K304-M302 C -> N thermus aquaticus 
7 LDL 1dc3 0.27 12.54 L171-T173-V175 N -> C E-coli 
8 LDL 1qxs 0.27 13.19 L189-T191-I193 N -> C trypanosoma cruzi  
9 LDL 1ml3 0.29 12.54 L189-T191-I193 N -> C trypanosoma cruzi  
10 LDL 2b4t 0.29 12.55 L183-T185-V187 N -> C plasmodium falciparum 
11 LDL 1i33 0.29 13.38 L189-T191-I193 N -> C leishmania mexicana 
12 LDL 1rm3 0.29 13.98 W313-I311-K309 C -> N spinach 
13 LDL 2prk 0.3 13.39 W313-I311-K309 C -> N engyodontium album 
14 LDL 1j0x 0.3 17.71 W310-I308-K306 C -> N rabbit 
15 LLD 1nqa 0.12 7.74 M231-T175-M173 C -> N bacillus stearothermophilus 
16 LLD 2dbv 0.14 8.09 M231-T175-M173 C -> N bacillus stearothermophilus 
      N -> C  
17 DDL 1cf2 0.29 12.85 T215-V213-I183 N -> C methanothermus fervidus 
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D. Caspases 1 and 3 as Targets for Pyrrolinone-pyrrolidine Oligomers 1 
Structure and Function of Caspases 1 and 3 
Caspases (cysteinyl aspartate-specific proteases) are intracellular cysteine proteases that 
specifically cleave substrates at aspartic acid residues.  Intracellular modulation of 
caspases is achieved, in the first instance, by activator (e.g. APAF-1, Fas/FADD) and 
inhibitor IAPs) proteins.  At a second level, the activators are controlled by Bcl-2-family 
proteins, and the SMAC proteins modulate the inhibitors.  Above that level are Bcl-2-
family modulators like Bim, Bad, and Bid).196,197  
Eight of the eleven caspases that are encoded by the human genome are function in 
apoptosis: these include caspase 3.  Two processes turn on caspases: (i) extrinsic 
pathways spurred by activation of cell surface death receptors and mediated by 
activation of a caspase zymogen by an “up-stream” caspase (e.g. caspase 8); or, (ii) 
intrinsic pathways originating in the mitochondria for which caspase 9 is a typical 
upstream activator.  Signals from both the intrinsic and extrinsic pathways converge at 
downstream caspases like 3.198  
Three human caspases activate a subset of proinflammatory cytokines, and these include 
caspase 1 (of “interleukin-1β-converting enzyme, ICE”).    Selective inhibition of 
caspase 1 prevents production of IL-1β at sites of inflammation.  Activation of caspase 1, 
on the other hand, causes mature IL-1β to bind to its type 1 receptor and this plays an 
important role in mediating neuronal cell death.199  
Selective inhibition of caspase 1 or 3 could have a range of biochemical consequences.  
These are difficult to predict, but the evidence that enhanced caspase 1 and 3 activity is 
associated with many neurological conditions (reviewed several times)200-202 is 
indisputable.  Ischemic or traumatic injury causes upregulation of caspase 1 and 3 and 
this has been associated with cell death and neurological deterioration.203  In Huntington 
disease, the protein huntingtin is cleaved by caspase 1 and 3 to afford toxic fragments 
required for the formation of neural intranuclear inclusions and progression of the 
disease.  Inhibition of caspase 1 slows progression of Huntington disease in a mouse 
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model.204  Caspase 1 is also implicated in stroke, ALS, and Parkinson’s disease.205  In 
Alzheimers, caspase 3 (and others) cleave the β-amyloid precursor protein (β-APP) 
giving a C-terminal fragment that is found in senile plaques and is a potent inducer of 
apoptosis.205  
For these reasons there has been a great deal of interest in small molecule inhibitors of 
caspases.197,205-207  Nonpeptide inhibitors of caspase 3 inhibit apoptosis and maintain cell 
functionality. 
Caspases 1 and 3 have a “dimer of heterodimers” quaternary structure wherein each 
heterodimer consists of a p10 and p20 fragment.  One active site is formed on each 
p10/p20 interface, hence there are two in the overall quaternary structure of each 
molecule.  Active site His237 and Cys285 residues are located on the larger, p20, 
fragments, and the substrate-binding cavity is completed by the protein-protein interface 
between this and the p10 fragment.  Consequently, caspase 1 is a dimer of obligatory 
heterodimers, wherein dissociation of the p10 and p20 fragments will negate the activity 
of the enzyme.208  A natural inhibitor of caspase 1, the serpin “crmA” acts by opening 
the p10/p20 interface, and possibly that between p10 and p20 too.209  Consequently, we 
propose small molecule disruptors of PPIs in caspases 1 and 3 can be used to modulate 
their activities. 
Caspases 1 and 3 have a “dimer of heterodimers” quaternary structure wherein each 
heterodimer consists of a p10 and p20 fragment.  One active site is formed on each 
p10/p20 interface, hence there are two in the overall quaternary structure of each 
molecule.  Active site His237 and Cys285 residues are located on the larger, p20, 
fragments, and the substrate-binding cavity is completed by the protein-protein interface 
between this and the p10 fragment.  Consequently, caspases 1 and 3 are a dimer of 
obligatory heterodimers, wherein dissociation of the p10 and p20 fragments will negate 
the activity of the enzyme.208  A natural inhibitor of caspase 1, the serpin “crmA” acts by 
opening the p10/p20 interface, and possibly that between p10 and p20 too.209  
Wells and co-workers used their tethering strategy to identify an allosteric site that is 
found in caspases.210,211  This is about 15 Å from the substrate-binding cavity, and it 
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impacts both the p10/p10 and the p10/p20 interfaces without causing dissociation.  
Binding of that inhibitor traps the enzyme in an inactive conformation.  In human 
caspase 1 that allosteric site is Arg286, Cys331 (used for tethering), and Glu390.50  This is 
particularly relevant here because the compounds that we find may disrupt interfaces in 
caspase 1.    
 
Data From EKO and eKO 
Caspase 1 
Several small molecules were found that impact the p10/p20 interface.  In fact, all the 8 
stereomers of 1 considered gave good overlays (RMSD < 0.22 – 0.46 Å) with slightly 
different, but overlapping, amino acid tracts in this region.  The fact that several parts of 
this sheet are involved enhances the scope for small molecule interface mimic design.  
For instance, using the 1 (LDL) framework, residues Asn337-Ser339-Arg341 overlaid on 
a loop region of the p10 units (N -> C; one, shown in Figure S8b, was identified in 4 
different structures: 1rwk, 1rwn, 1rww, 1bmq).210  This region is near the active site of 
the p20 unit, but not directly impacting it.  Two matches at slightly higher RMSD were 
also found (Figure S8c and d); these overlaid with overlapping sheet regions of the p10 
unit, Thr388-Phe330-Ile328 (C-to-N) and Ile328-Phe330-Ser332 (N-to-C) that interacts 
with a sheet on the p20 fragment (Figure S8c and d).  One of these matches alternates 
residues (Thr388-Phe330-Ile328) bridging two strands, whereas the other (Ile328-
Phe330-Ser332) is aligned with only one.  This type of variance validates our concept of 
“universal mimic” design. 
All the stereomers of 1 also gave good overlays for the p10/p10 interface (RMSD 0.27 – 
0.42 Å).  Thus, 1 (LDL) overlaid with Glu390-Thr388-Met386 (C-to-N; central region of 
Figure 8a, and in e) close to the glutamate residue identified by Wells as binding their 
allosteric inhibitor. 
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Figure S8. (a) structure of caspase 1 showing p10/p10 and p10/p20 interface; (b) – (d) overlays of 1 (LDL) on the 
p10/p20 interface; and, (e) – (f) 1 (LDL) on the p10/p10 interface.  
 
Table S4. Interface Mimics Identified using EKO for Overlay on Caspase 1. 
 conformer RMSD (Å) score residues direction 
chains 
interface 
       
1 LLL 0.46 25.5 N337-S339-R341 N -> C p20-p10 
2 DLL 0.35 15.3 I328-F330-S332 C -> N p20-p10 
3 LDL 0.22 12.1 N337-S339-R341 N -> C p20-p10 
4 LLD 0.33 21.8 D326-I328-T389 N -> C p20-p10 
5 LDD 0.38 23.5 E390-I328-D326 C -> N p20-p10 
6 DLD 0.29 13.1 I328-F330-S332 N -> C p20-p10 
7 DDL 0.28 19.1 R391-A329-C331 C -> N ->C p20-p10 
8 DDD 0.32 17.3 E390-I328-D326 C -> N p20-p10 
       
9 LLL 0.28 16.8 N337-T334-M386 C -> N ->C p10-p10 
10 DLL 0.41 17.3 T395-K325-I323 C -> N p10-p10 
11 LDL 0.36 18.9 E390-T388-M386 C -> N p10-p10 
12 LLD 0.35 21.4 E378-M386-T334 N -> C ->N p10-p10 
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13 LDD 0.36 21.1 T334-M386-F377 N -> C ->N p10-p10 
14 DLD 0.33 20.3 P380-E378-R376 C -> N p10-p10 
15 DDL 0.27 15.5 P380-E378-R376 C -> N p10-p10 
16 DDD 0.42 19.8 R376-T388-E390 N -> C p10-p10 
 
Caspase 3 
EKO indicated a good overlay of 1 (DDL) on the Ala227-Tyr274-Glu272 sequence in a 
N-to-C-to-N orientation at the p17/p12 interface.212  Again, remarkably, all the 
stereoisomers of 1 gave good overlays with caspase 3 at this interface (RMSD 0.29 – 
0.42 Å).  Similarly, matches could be found for the p12/p12 interface but the RMSD 
values were higher (0.33 – 0.50) indicating slightly inferior correspondence (not shown).  
Interface mimics corresponding to this region will be prepared, but priority will be given 
to p17/p12 (which is more interesting anyway because it forms the active site). 
 
Table S5. Interface Mimics Identified using EKO for Overlay on Caspase 3. 
 conformer RMSD (Å) score residues direction 
chains 
interface 
       
1 LLL 0.39 18.9 W206-I216-S213 N -> C ->N p17-p12 
2 DLL 0.37 17.2 Y195-F193-E190 C -> N p17-p12 
3 LDL 0.37 15.4 R207-F215-L219 N -> C p17-p12 
4 LLD 0.42 23.1 L271-L269-L194 C -> N p17-p12 
5 LDD 0.31 10.2 C264-A196-L194 C -> N p17-p12 
6 DLD 0.30 19.2 F193-Y195-C264 N -> C p17-p12 
7 DDL 0.29 12.0 A227-Y274-E272 N -> C ->N p17-p12 
8 DDD 0.33 14.8 A196-L194-L269 C -> N ->C p17-p12 
       
9 LLL 0.35 20.7 Y203-I262-A200 N -> C ->N p12-p12 
10 DLL 0.39 19.8 A244-K260-A258 N -> C ->N p12-p12 
11 LDL 0.39 20.9 K260-I262-N240 N -> C ->N p12-p12 
12 LLD 0.50 26.8 K260-I262-C264 N -> C p12-p12 
13 LDD 0.42 23.4 V266-M268-T270 N -> C p12-p12 
14 DLD 0.33 15.3 C264-V266-M268 N -> C p12-p12 
15 DDL 0.45 21.1 C264-I262-K260 C -> N p12-p12 
16 DDD 0.39 15.1 N240- I262-K260 N -> C ->N p12-p12 
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E. α-Antithrombin as Targets for Pyrrolinone-pyrrolidine Oligomers 1 
Structure and Function of α-Antithrombin 
Serpins are a fascinating group of serine protease inhibitors that are active in their 
monomeric forms, but can revert to inactive fibril-like oligomers.  Formation of these 
fibrils is an undesirable characteristic associated with a series of diseases collectively 
known as “serpinopathies”.213  Serpinopathies are driven by conformational changes to 
proteins that lead to fibrils, in ways that parallel, but are different to, amyloid formation 
in Alzheimer’s disease.   Overall, interaction of one serpin unit with another, a PPI, 
governs these events.   
A key feature of serpin oligomerizations is that the monomeric proteins are 
metastable;214 they revert to thermodynamically more favorable (ca 32 kcal/mol)215 
dimeric, then oligomeric forms via a domain swapping process.  This involves opening 
of the proteins via release of a loop region that is intimately associated with a β-strand 
arrangement in the monomeric form.  There is apparently a significant kinetic barrier to 
formation of the dimeric form, but once this is reached, it opens a gateway to 
oligomerization.  Thus, dimer formation in serpinopathies has been described to impart 
“infectivity”.216-218  Discovery of a small molecule that can modulate such processes for 
one serpin would have ramifications for all serpinopathies.214  
Intriguingly, like Alzheimer’s, several serpinopathies are associated with neurological 
diseases.  These include, for instance, involvement of neuroserpin in the formation of 
“Collins bodies”, a characteristic of familial encephalopathy.  However, probably the 
most studied of the serpins is α-antitrypsin; mutated forms (the “Z-mutant”) of this 
protein are associated with liver cirrohosis and emphysema.  Of particular interest here is 
another serpin called antithrombin.  Mutations of antithrombin are associated with 
thrombosis, and blood-clotting events in thrombosis are related to stroke.  
Various groups have investigated how peptides corresponding to the loop region 
involved in domain swapping can be used to inhibit oligomer formation in 
serpinopathies.  For instance, this approach has been proven for α-antitrypsin,216-220 and 
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α-antithrombin.221  In vitro assays used to identify the active peptides in these studies 
involve differentiation between serpins in monomeric and oligomeric forms.  This can be 
done by gel-electrophoresis and by methods that rely on intrinsic Trp fluorescence. 
Ultimately, peptides that are active in vitro are unlikely to be useful in vivo due to the 
usual reasons associated with bioavailability (cellular and stability to proteases; oral is 
not required since intravenous injection of therapeutics for life threatening disease is 
standard and acceptable).  Consequently, the awaits for small molecules to be discovered 
that exert similar inhibition of dimerization properties.  This is analogous to the stage of 
development of Alzheimer’s therapies when peptide leads were shown to inhibit amyloid 
formation.222  
Data From EKO and eKO 
Domain swapping processes leading to antithrombin oligomers involves a loop-sheet 
interaction in the monomeric closed form being transformed into a similar one between 
one or more protein monomers.  Data mining experiments for this study were performed 
using the only available structural information (human antithrombin, 2znh), and that 
involves the wild type antithromin and not the mutated one that most inclined to form 
firbils.215  Hit PPI regions where EKO predicts compounds 1 could bind (see below) 
correspond to the sheet region where that the loop interacts with in the closed form.  
Antithrombin mutations that lead to fibril formation are not associated with this loop-
sheet interaction and, because of this, the inhibitors that are designed here should be 
appropriate for mutated serpin. 
Table S6 summarizes the interface mimics 1 found after data mining all the 
stereoisomers; all but one overlaid on the sheet region that is either side of the key loop 
(Figure S9); the exception (Table S6, entry 5) overlaid on an ill-defined helix-loop motif.  
Figure S9b shows how 1 (LLL) (small letters correspond to codes for parent amino acids 
with the same side-chains) overlays with the C-terminus of the mimic on the C-terminal 
end of the featured interface; in other words, the two chains that are overlaid run in the 
same direction, so we call this an N -> C mimic (natural orientation).  Overlays for the 
 341 
other mimics listed in Table S6 are superior to this in terms of RMSD; the worst match 
is shown here (Figure S9b) but, even so, the correspondence looks fine. 
 
 
 
Figure S9. (a) Crystal structure of antithrombin wild-type stable dimer that illustrates how chain swapping can lead 
to oligomerization and fibril formation, deactivating the serpin; (b) overlay of 1 (LLL) on Ala382-
Ala384-Thr386 wherein the sheet and interface mimic orient site the same N -> C polarity. 
 
Table S6 shows that some interface mimics 1 may “align” the protein strand and others 
“oppose” it (N -> C, and C -> N respectively) but both can give good side-chain fitting.  
One compound, 1 (DLL) (entry 2; primed small letters indicate D-stereochemistry) 
overlays with discontiguous amino acids that reverse relative to the mimic (C -> N -> C). 
 
Table S6. Interface Mimics Identified using EKO for Overlay on Antithrombin. 
 
 
 
 
 
 
  
A382
A384
T386most interface
mimics
other
interface
mimic
a
b
N-terminus
C-terminus
of sheet
 conformer RMSD (Å) score residues direction 
      
1 LLL 0.37  15.2 A382-A384-T386 N -> C 
2 DLL 0.28 17.6 E374-F372-A384 C -> N -> C 
3 LDL 0.25 15.1 S385-H369-A367 C -> N 
4 LLD 0.34 21.8 L373-A383-S385 N -> C 
5 DDL 0.36 19.5 D97-C95-A20 C -> N 
6 DLD 0.33 17.0 V388-T386-K370 C -> N 
7 LDD 0.23 12.6 A384- A382- E374 C -> N 
8 DDD 0.34 14.5 H369-A387-V389 C -> N 
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